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 Pregnancy and adolescence are both periods of elevated calcium (Ca) demand.  
Pregnancy during adolescence places both mother and fetus at risk for adverse skeletal outcomes.  
The overall goal of this research was to address how maternal Ca intake and vitamin D status 
impact calcitropic hormones and fetal bone development during pregnancy, and investigate how 
effects may be mediated at the level of the placental in a skeletally immature population.   
 Maternal Ca intake,25(OH)D status calcitropic hormones (PTH and 1,25(OH)2D) and 
fetal biometry measures (fetal femur and humerus length and birth length) were monitored across 
pregnancy in 171 pregnant adolescents (≤18 yrs).  Neonatal hormonal status and placental tissue 
were obtained at delivery.  Stable Ca isotopes were administered to twelve adolescents early in 
labor (
44
Ca orally and 
42
Ca intravenously) to obtain a dynamic measure of maternal-to-fetal Ca 
transfer.   
Among these adolescents, 25(OH)D insufficiency (≤20 ng/mL) was prevalent (~50%) 
and PTH was inversely related to 25(OH)D status throughout pregnancy, and was elevated (≥60 
pg/mL) in 24% of teens at term.  Maternal 25(OH)D was also negatively associated with 
1,25(OH)2D concentrations. Associations with Ca intake were less evident, indicating that 
maternal vitamin D status is a key determinant of the calcitropic hormone response to pregnancy.  
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Maternal Ca intake and 25(OH)D status interacted to influence fetal femur and humerus Z-
scores; sufficient status of one nutrient was associated with improved long bone Z-score when 
the other nutrient was limited.  This interaction remained evident at delivery, and was associated 
with neonatal birth length.   
At the level of the placenta, VDR expression was positively related to neonatal 
1,25(OH)2D, and was higher in neonates with low 25(OH)D status.  Placental VDR was also 
positively related to fetal femur length.  Of note, placental VDR expression was a significant 
predictor of maternal-to-fetal 
42
Ca transport which was itself significant in a model of fetal femur 
Z-score.  Placental VDR expression was responsive to fetal endocrine signals and appeared to 
impact fetal skeletal growth via modulation of placental Ca transport.  In a skeletally immature 
pregnant adolescent, achieving adequate 25(OH)D status and Ca intake may improve calcitropic 
hormone levels and optimize fetal skeletal accretion.  
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INTRODUCTION 
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Specific Aims 
Calcium (Ca) dynamics are dramatically altered during pregnancy to meet the Ca 
demands of the developing fetus.  Maternal vitamin D status has also been increasingly linked to 
a variety of maternal and offspring health outcomes.  This pregnancy-induced increase in Ca 
demand, and the importance of maintaining adequate vitamin D status is especially profound in 
the context of adolescent pregnancy when fetal skeletal development coincides with the demands 
and physiological stresses of adolescent growth.  Additionally, adolescents often consume 
suboptimal Ca intakes and have insufficient vitamin D status, which may increase the risk of 
adverse maternal and fetal outcomes.  Despite the number of studies linking maternal Ca intake 
and vitamin D status across gestation with maternal and offspring outcomes, the response of the 
calcitropic hormones, parathyroid hormone (PTH) and 1,25-dyhydroxyvitamin D (1,25(OH)2D) 
during pregnancy, and how this response may be impacted by nutritional status are not well 
understood in at-risk populations.  There is also a lack of data addressing regulation of Ca 
partitioning during pregnancy at the level of the placenta.  Further research is needed to 
characterize how calcitropic hormone and nutritional status impact placental gene expression, 
nutrient partitioning to the fetus, and fetal development.     
The goals of this research were fourfold:  1) To characterize the temporal trends and 
determinants of the two calcitropic hormones across pregnancy in an adolescent population, and 
to describe relationships between these hormones and the impact of nutritional (Ca and vitamin 
D) status on these relationships; 2) To determine how maternal Ca intake and vitamin D status 
during pregnancy are associated with measures of fetal and neonatal skeletal outcomes;  3) To 
determine if vitamin D status or Ca intake is associated with placental vitamin D receptor (VDR) 
expression, and if variation in expression is correlated with fetal long bone length; and 4) To 
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obtain in-vivo measures of maternal-to-fetal Ca transfer, to describe determinants of this transfer 
in-utero, and determine if increased transfer is associated with improved fetal skeletal health, as 
assessed by long bone length. 
 
The specific aims and hypotheses are: 
I.  To characterize the temporal trends in calcitropic hormones, PTH and 1,25(OH)2D 
during pregnancy and elucidate relationships between these hormones and Ca intake 
and 25-hydroxyvitamin D (25(OH)D) status in the pregnant adolescent and her 
neonate. 
Hypotheses:  1) PTH will increase across pregnancy as a compensatory response to 
improve Ca availability in order to satisfy fetal Ca demands.  2) Maternal vitamin D 
status will be associated with PTH and 1,25(OH)2D in pregnant adolescents.   
 
II.  To determine if maternal Ca intake and vitamin D status during pregnancy are related 
to measures of fetal and neonatal bone health obtained in-utero and at birth, and to 
investigate potential interactions between maternal Ca intake and vitamin D status on 
fetal and neonatal outcomes. 
Hypothesis:  Maternal Ca intake and vitamin D status will both be positively correlated 
with fetal femur and humerus length Z-scores and birth length.  An interaction between 
these nutrients will be relevant, such that achieving sufficiency of one nutrient has the 
most significant impact when the other nutrient is suboptimal. 
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III.  To determine if vitamin D status and Ca intake are associated with placental VDR 
expression and investigate relationships between placental VDR expression and fetal 
femur length Z-scores. 
Hypotheses:  1) Placental VDR expression will be increased when 25(OH)D is low as a 
compensatory response to increase placental capacity for vitamin D activity.  2) Placental 
VDR expression will be positively associated with fetal femur Z-scores. 
 
IV. To obtain in-vivo measures of placental Ca transfer in-utero using stable Ca isotopes 
and to characterize determinants of this transfer and investigate if increased transfer is 
associated with longer fetal femur and humerus lengths. 
Hypothesis:  Placental Ca transfer will be positively associated with placental VDR 
expression, with maternal 25(OH)D, and with fetal long bone (femur and humerus) 
length. 
 
Together these data will improve our understanding of the calcitropic response to pregnancy in 
pregnant adolescents and the impact of inadequate vitamin D and Ca intake on fetal and neonatal 
bone outcomes.  The data provided will inform dietary recommendations provided to this group. 
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Background and Significance 
The United States has the highest adolescent pregnancy rate of any industrialized nation 
(1); approximately 410,000 adolescents (≤ 19 years) gave birth in 2009 (2).  During pregnancy, 
maternal Ca intake must meet both maternal demands and those of the developing fetus.  Over 
the course of gestation, approximately 30 g of Ca are transported across the placenta and 
incorporated into the fetal skeleton (3).  Placental Ca flux markedly increases in the third 
trimester, when ~80% of net Ca transfer occurs (4).  Peak rates of fetal Ca deposition occur at 35 
weeks gestation and are thought to approximate 330 mg/d (5).  This pregnancy associated 
increase in Ca demand is especially profound in the context of adolescent pregnancy, when fetal 
development occurs in an environment that is already physiologically stressed due to the 
additional Ca demands of adolescent growth.   
Maternal physiology does respond to the Ca demands of pregnancy by increasing 
intestinal Ca absorption and metabolic bone activity (6).  In spite of these adaptations, many 
studies of bone turnover during pregnancy have detected a net loss of maternal bone across 
gestation (7-9).  This loss has been reported to be more severe among pregnant adolescents than 
adult women (10;11).  As the majority of Ca that crosses the placenta is incorporated into the 
developing fetal skeleton, insufficient Ca intakes and/or an insufficient physiological adaptations 
during pregnancy may result in adverse fetal outcomes including decreased fetal skeletal growth 
and bone mineralization (11-15). 
Vitamin D status plays an equally important role in the maintenance of Ca homeostasis 
during pregnancy due to its role in the regulation of Ca homeostasis.  Vitamin D status has been 
linked to a variety of both maternal and fetal outcomes (16).  The current Ca intake 
recommendations for pregnant adolescents (≤ 18 years) do not differ from their non-pregnant 
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peers (EAR = 1100 mg/d) (17).  However, the adolescent EAR/RDA is 300 mg higher than the 
EAR/RDA for pregnant and non pregnant adult women ≥ 19 years of age (17).  Table 1.1 
presents the 2011 DRI’s for Ca and vitamin D for pregnant and non-pregnant adolescents and 
adult women.   
 
Table 1.1.  
Calcium and Vitamin D DRI Recommendations for Pregnant and Non-pregnant Adolescents and 
Adult Women (17) 
Ca (mg/day) Vitamin D (IU/day) 
Stage Age (years) EAR RDA UL EAR RDA UL 
Non-pregnant 9 - 18 1100 1300 3000 400 600 4000 
Pregnant 14 - 18 1100 1300 3000 400 600 4000 
Non-pregnant 19 - 30 800 1000 2500 400 600 4000 
Pregnant 19 - 50 800 1000 2500 400 600 4000 
EAR – Estimated Average Requirement 
RDA = Reference Daily Allowance 
UL = Upper Limit 
 
The 2010 IOM committee on Ca and vitamin D intake recommendations identified gaps in 
knowledge when data were lacking.  The committee reported that research is needed to provide 
data regarding the physiology of the metabolism of Ca and vitamin D as well as data detailing 
the interactive and independent effects of Ca and vitamin D (17).  Data from this dissertation 
research will contribute to these research needs to fill current knowledge gaps and inform future 
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studies and interventions designed to reduce adverse maternal and fetal health outcomes in 
adolescent pregnancy. 
 
I.  Calcium Metabolism and Vitamin D Endocrinology 
Regulation of Ca Homeostasis 
Calcium homeostasis is tightly regulated in the body at the level of the intestine, bone, 
and kidney.   In the intestines, Ca is absorbed paracellularly via concentration gradient-driven 
diffusion (18).  Calcium can also be actively absorbed by several Ca-transport proteins, including 
transient receptor potential vanilloid 6 (TRPV6), which imports Ca from the gut lumen across 
the brush border membrane of enterocytes.  Once in the enterocyte, Ca is shuttled across the cell 
by Ca-chaperone proteins such as calbindin 9DK and 28K, and actively exported into circulation 
by Ca export proteins, such as the plasma membrane Ca ATPase’s (PMCA’s), located on the 
basolateral membrane (19).  A more detailed discussion of these proteins is located in Section V.  
Active absorption increases the fractional absorption of dietary Ca above that which results from 
passive diffusion alone.  It is this active absorption mechanism that is hormonally regulated by 
vitamin D.  Active absorption is commonly observed to be inversely related to Ca intake.  Active 
Ca absorption is upregulated when Ca intake is low (< 400 mg/day), and can account for up to 
80% of total absorbed Ca (20).  Conversely, active Ca absorption plays a diminished role when 
Ca intake is high.  In the context of high habitual Ca intake (~ 2000 mg/day), paracellular 
absorption is adequate to meet Ca demands and  active absorption contributes less than 10% of 
net Ca absorption (18).     
Calcium homeostasis is tightly regulated by three main hormones: 1,25(OH)2D (also 
known as calcitriol), PTH, and calcitonin.  In humans, vitamin D is a unique micronutrient in that 
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it is both obtained from the diet and endogenously produced.  Both vitamin D3 (cholcalciferol) 
and vitamin D2 (ergocalciferol: from plant sources) can be obtained from the diet (21).  The 
majority of daily vitamin D requirements are thought to be met by endogenous production of 
vitamin D3, which is produced in the skin from 7-dehydrocholesterol upon exposure to UVB 
light (22).  Once released into circulation from the skin or via the lymphatic system after 
digestion, the vitamin D binding protein (DBP) transports vitamin D2 and vitamin D3, as well as 
their downstream metabolites (23).   
Calcitriol is produced by successive hydroxylations of vitamin D2/D3 first in the liver and 
then in the kidneys (18).  In the liver, vitamin D2 and D3 are hydroxylated by the 25-hydroxylase 
enzyme (CYP2R1) to become 25(OH)D (24).  Because production of 25(OH)D (calcidiol) in the 
liver is not regulated, circulating concentrations of 25(OH)D reflect both dietary intake and 
endogenous production.  As such, circulating concentrations of 25(OH)D serve as an acceptable 
biomarker of vitamin D status (25).  In the kidneys, the 1α-hydroxylase (CYP27B1) further 
hydroxylates 25(OH)D generating 1,25(OH)2D (24).  Serum 1,25(OH)2D is the active hormonal 
form of vitamin D.  As such, the activity of the 1α-hydroxylase and net production of 
1,25(OH)2D remains tightly regulated.  The inactive metabolite, 24,25(OH)2D, can also be 
produced from 25(OH)D  in the kidney, by the 24-hydroxylase (CYP24A1) (18).  Increased 
concentrations of 1,25(OH)2D serve as negative feedback for its own production, by decreasing 
1,25(OH)2D production and increasing 24,25(OH)2D production.   
The majority of circulating 1,25(OH)2D is bound to DBP which has a higher affinity for 
25(OH)D, and thus leaves a small fraction of 1,25(OH)2D free while the majority is bound (26).  
It is this free 1,25(OH)2D that is hormonally active.  Once released into the circulation, free-
1,25(OH)2D can bind cell surface receptors and initiate various non-genomic rapid responses 
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within the cell that have many downstream effects including increased cellular Ca
2+
 
concentrations and pH (27).  Calcitriol also elicits genomic responses by binding to its receptor, 
the vitamin D receptor (VDR) and migrating to the nucleus.  This complex (1,25(OH)2D / VDR) 
forms a heterodimer with the retinoid X receptor (RXR) and then binds to specific DNA 
sequences referred to as vitamin D response elements (VDRE’s) (27).  Upon binding VDRE 
sequences, this complex initiates the co-localization of additional regulatory elements, ultimately 
resulting in increased or decreased transcription of VDRE-containing genes.  This is the 
mechanism whereby 1,25(OH)2D increases the transcription of many Ca-transport proteins in the 
gut, thus increasing active Ca absorption (3;18).   
This mechanism of 1,25(OH)2D mediated regulation of VDRE containing genes is also 
vital to bone growth, mineralization, and maintenance of bone health (28).  Additional roles of 
vitamin D activity, outside of the classically described role in Ca homeostasis, have been 
extensively explored in recent years.  In addition to bone and small intestine, VDR has been 
detected in over 30 tissues in the human body, including placenta (21).  Recently, the role of 
1,25(OH)2D in the induction of the innate immune system has been described in detail (29;30).  
Vitamin D may also play a role in the regulation and function of the adaptive immune system, 
minimizing inflammation and autoimmune disease (31;32).  Calcitriol also regulates genes that 
are responsible for cell proliferation, differentiation, and apoptosis (24).  Epidemiological studies 
have documented several relationships between low vitamin D status and chronic diseases and 
infections/inflammatory states including type I and II diabetes, bacterial vaginosis, preeclampsia, 
breast, prostate, and colorectal cancers, and all-cancer mortality (33-41).  Thus, 1,25(OH)2D 
plays a role in the regulation of hundreds of genes and many physiological processes, beyond 
those simply related to Ca metabolism and bone health.  However, it should be noted that the 
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recent (2010) IOM committee for establishing the vitamin D and Ca DRI’s found that there was 
insufficient evidence to conclude a causal relationship or dose response for any other health 
outcome related to vitamin D other than bone health (17).  More research is clearly needed to 
detail these relationships and increase our understanding of all physiological consequences of 
vitamin D deficiency.   
In light of the far-reaching effects of 1,25(OH)2D, it becomes clear why circulating 
concentrations are so tightly regulated.  Parathyroid hormone is one of primary endocrine 
controls regulating production of 1,25(OH)2D.  In the parathyroid gland, PTH secretion is 
coupled to membrane Ca
2+
 sensing receptors, which ensure PTH is secreted only under 
conditions of low serum ionoized Ca
2+
 (18).  Upon secretion, PTH exerts direct effects on bone 
and kidneys, increasing resorption of bone and decreasing urinary Ca excretion.  Both of these 
short term effects increase serum Ca concentrations to maintain homeostatic serum Ca levels (3).  
In the kidneys, PTH also acts to increase 1α-hydroxylase activity which increases net renal 
conversion of 25(OH)D to 1,25(OH)2D when Ca and/or phosphorus status is low (42).  Thus, in 
non-pregnant adults, PTH and 1,25(OH)2D concentrations are inversely related when Ca 
economy is strained (potentially resulting from inadequate Ca intake or low vitamin D status) 
(42).  Due to its stimulation of 1,25(OH)2D, PTH is also indirectly associated with intestinal Ca 
absorption.  In serum, PTH has both short term and chronic effects on whole body Ca 
homeostasis.  As part of a negative feedback loop, increased 1,25(OH)2D concentrations inhibit 
PTH secretion, assuring that Ca balance is maintained.  Under conditions of chronic vitamin D or 
Ca insufficiency, PTH levels can remain elevated to maintain continued synthesis of 
1,25(OH)2D.  This persistent elevation in PTH as a result of low vitamin D or Ca status is 
referred to as secondary hyperparathyroidism, and may have detrimental long-term effects on 
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bone health (43).  Figure 1.1 below diagrams the integrated roles of 25(OH)D, PTH, and 
1,25(OH)2D in the regulation of Ca homeostasis.     
 
 
Figure 1.1. Diagram of 25(OH)D, PTH, and 1,25(OH)2D Regulation of Serum Calcium     
Serum Ca is tightly regulated by PTH and vitamin D.  Black arrows indicate stimulatory or 
activating pathways, and red lines indicate inhibitory pathways.  Calcitriol (1,25(OH)2D) 
stimulates active Ca absorption and bone resorption and PTH stimulates bone resorption and 
renal Ca conservation.  Calcitriol synthesis is tightly regulated and 1,25(OH)2D serves as 
negative feedback inhibitor of its own production in the kidney and also decreases PTH 
secretion.    
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Not detailed in Figure 1.1 are the integrative effects of phosphorus (P) on Ca 
homeostasis, and vice versa.  Phosphorus is the second largest mineral component of bone, as a 
major component of the crystal hydroxyapatite (Ca10(PO4)6(OH)2) which is laid down in the 
inorganic matrix of bone during the mineralization process.  Calcitriol synthesis is stimulated by 
low P concentrations, and serves to increase intestinal absorption of both Ca and P, and also 
increases release of both Ca and P from bone (44).  Parathyroid hormone inhibits P reabsorption 
in the renal proximal tubules (45).  Fibroblast growth factor 23 (FGF23) is a key regulator of P 
homeostasis discovered in 2000 (45).  FGF23 is released into serum by osteocytes and 
osteoblasts when P is high.  While FGF’s normally exert local paracrine or autocrine effects, 
FGF23 regulates P homeostasis using systemic endocrine mechanisms.  FGF23 has a similar 
impact on renal P reabsorption as PTH.  FGF23 also inhibits the production of 1,25(OH)2D in the 
kidneys (44) which decreases P absorption in the gut.  In a negative feedback loop, increases in 
1,25(OH)2D cause an increase in circulating FGF23 (44), which contains a VDRE in its promoter 
(45).  FGF23 also decreases secretion of PTH from the parathyroid gland (44).  In this manner, P 
and Ca homeostasis are inter-connected.  The role of FGF23 in calcitropic hormone status is a 
developing area of research.   
Calcitonin is a hormone produced in the parafollicular cells of the thyroid and serves to 
oppose the actions of PTH when serum Ca is high.  Thus, when serum Ca is high, calcitonin 
causes an increase in bone deposition, which reduces serum Ca levels to normal (46).  Calcitonin 
is thought to play a very limited role in the physiological response to pregnancy (3;6)  
Vitamin D Economy: Racial and Environmental Disparities 
Endogenous vitamin D3 production is influenced by many factors.  Because cutaneous 
production can only occur when the skin is exposed to UVB between 290 – 315 nm, geographic 
 13 
 
location, season of the year, pollution, and cloud cover all impact the amount and/or quality of 
UVB that reaches the ground-surface, thereby effecting capacity for vitamin D production 
(22;24;47;48).  In northern latitudes > 42
0
 (Boston, MA), no endogenous vitamin D3 production 
occurs between the months of November through February due to the angle of the earth during 
this season (49).  It should be noted that the study location of this research, Rochester, NY lies at 
42
0 
N.
  
 
Individual variation in skin pigmentation also affects dermal production of vitamin D.  
The concentration of melanin in the skin is responsible for the degree of skin pigmentation.  
Melanin absorbs UVB light of the same wavelength that is necessary to convert 7-
dehydrocholesterol into cholcalciferol (22).  In effect, melanin limits the amount of UVB 
available to produce vitamin D.  As a result of this competition, dark skinned individuals may 
need upwards of six times more sun exposure to produce equivalent increases in circulating 
25(OH)D observed in light skinned counterparts (50).  For this reason, dark-skinned populations 
are at increased risk for lower circulating 25(OH)D and a higher risk of vitamin D deficiency 
than Caucasians residing in the same environment (43;47;48).  Additionally, African Americans 
have higher average circulating concentrations of PTH, and a higher prevalence of secondary 
hyperparathyroidism compared to Caucasians (43;47;48;50).  As a result, the inverse relationship 
between PTH and 25(OH)D (indicative of suboptimal 25(OH)D status) is more commonly 
detected in African American compared to Caucasian populations (22;47;51).  Whether these 
differences in vitamin D status translate into differences in circulating levels of 1,25(OH)2D 
remains controversial.  It has been reported that 1,25(OH)2D concentrations in African 
Americans are both comparable to (22;47) and higher than Caucasians (43;52-54).  Few data 
exist regarding these possible differences during pregnancy.          
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Paradoxically, even though African Americans have lower vitamin D status and higher 
PTH, they have significantly higher skeletal bone mineral density (BMD) than Caucasians at 
every age, averaging between 11-17% higher BMD and bone mass (43;55).  African American 
women (<50 years) display similar BMD to that of Caucasian men of the same age (55).  African 
Americans also have a lower risk of osteoporosis than Caucasians, despite elevated PTH and 
lower 25(OH)D (43;55;56).  When dietary Ca intake is changed from high to low Ca content, 
PTH, 1,25(OH)2D, and fractional Ca retention increase similarly in both African American and 
Caucasian women, indicating that the PTH/vitamin D axis regulates Ca homeostasis similarly in 
both races (53).  However, when given 1,25(OH)2D extraneously, the increase in fractional Ca 
absorption is blunted in African American women compared to Caucasian women, indicating a 
decreased “gut-sensitivity” to the PTH/1,25(OH)2D regulation of Ca absorption (52).  In a cohort 
of younger girls (5-16 years) fractional absorption of Ca was more closely related to Ca intake in 
Caucasians than African American girls, confirming that the PTH and 1,25(OH)2D axis may 
have a more prominent effect on the gut in Caucasians (57).  Another source of the racial skeletal 
differences observed in adults may be that African Americans also seem to exhibit a decreased 
skeletal sensitivity to PTH, as bone mass and BMD are higher, and markers of bone resorption 
are lower in this racial group despite elevated PTH (43;58).  However, African Americans 
exhibit an increased renal response to PTH to conserve Ca, as urinary excretion of Ca is lower in 
African Americans than Caucasians.  This is observed in children and adults (43;53;57;59).  
Thus, while the same endocrinology regulates Ca homeostasis in both African Americans and 
Caucasians, the subtleties of this regulation may differ by race, potentially resulting from an 
evolutionary adaptation to dark skin’s limited ability to endogenously produce vitamin D.  When 
racial differences are observed in a vitamin D or Ca related outcome, it is difficult to assess 
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whether genetic differences or differences in nutritional status (namely 25(OH)D and related 
metabolites) are driving the  results observed.   
In addition to physical environment, skin pigmentation and diet, other factors also impact 
individual vitamin D status.  Cultural and personal practices such as limited outdoor activity, 
extensive skin covering (such as veiling) or extensive sunscreen usage can place certain groups 
at elevated risk for inadequate vitamin D.  Additionally, increased adiposity is a risk factor for 
insufficient vitamin D status (60).  Various measures of adiposity including BMI, fat mass, 
leptin, percent body fat, visceral adiposity, and hip circumference are commonly found to be 
negatively associated with circulating 25(OH)D in pediatric, adolescent, and adult populations, 
regardless of race (61-66).  As vitamin D is a fat soluble vitamin, it is postulated that vitamin D 
sequestration in fat compartments results in decreased bioavailability of vitamin D from dietary 
and endogenous sources in overweight and obese individuals (60).  In all of these ways, vitamin 
D is a unique micronutrient as it is impacted by multiple modifiable and non-modifiable factors 
in addition to diet. 
Diagnostic values for vitamin D deficiency and insufficiency vary in the literature and 
range from ≤ 10 to ≤ 30 ng/mL.  In this research, vitamin D deficiency is defined as serum 
25(OH)D ≤ 10 ng/mL.  Many have argued for a more liberal cutoff, suggesting that 25(OH)D ≤ 
20 ng/mL should be considered deficient (67).  However, as the DRI defined 25(OH)D > 20 
ng/mL as “adequate”, the cutoff of  ≤ 20 ng/mL will be used herein as vitamin D insufficiency 
(17).   
In American children (≤ 21 years), older age, winter season, high BMI, and African 
American race are all associated with low 25(OH)D (61).  Even in southern states, studies have 
reported an 18% prevalence of vitamin D insufficiency amongst girls; this prevalence was higher 
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in African American girls (48).  A study of African American girls age 12-14 years (n = 21) in 
New York City in the winter found 100% of participants to be vitamin D insufficient, and 43% 
of the population sampled to be severely deficient (25(OH)D ≤ 8 ng/mL) (51).  From the 
NHANES III data, 14% of the American adolescent population had insufficient levels of vitamin 
D, and African American teens had a 20 times higher risk of deficiency (68).  The 2011 DRI’s 
for vitamin D derived an EAR of 400 IU/day and an RDA of 600 IU/day for all age groups 
between 1 and 70 years in order to maintain serum 25(OH)D at a minimum of 16 ng/mL (for the 
EAR) and 20 ng/mL (for the RDA), assuming no endogenous production (17) (Table 1.1).  
Despite these recommendations, vitamin D insufficiency remains a public health concern both in 
the United States and globally.   
Ca Homeostasis in the Adolescent 
Adolescence is a time of physiological strain.  Nutritional demands increase to 
accommodate the physical growth that occurs at this time.  Non-pregnant adolescent females 
have increased PTH, fractional Ca absorption, rates of bone turnover, and decreased urinary Ca 
excretion compared to adult women (69;70).  These alterations in Ca homeostasis result in 
greater Ca retention by ~240 mg/day, an amount needed to meet the Ca demands for bone 
mineralization associated with adolescent growth (69).  Peak bone acquisition occurs by ~17 
years in females (71), but small increases in bone mass continue to accrue for several years after 
linear growth is complete (72;73).   
During adolescence and this period of elevated bone acquisition, girls exhibit higher rates 
of fractional Ca absorption, decreased urinary and fecal Ca loss, and higher net Ca retention than 
young adult women, despite similar 25(OH)D, 1,25(OH)2D, and PTH concentrations (69;74).  
Serum PTH increases during adolescence to accommodate the elevated Ca demand and rates of 
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bone formation (75).  Racial differences in calcitropic hormones and bone acquisition also 
become evident by adolescence, as African American teens exhibit higher 1,25(OH)2D 
concentrations, fractional Ca absorption, and rates of bone deposition than Caucasian 
counterparts (57;59).  These racial differences are consistent with the higher BMD, and lower 
osteoporosis risk that have been documented in African American adults (43;71).  Pregnancy is 
also a physiological state of increased nutritional demands.  Pregnancy during adolescence may 
place both the mother and her developing fetus at risk for inadequate nutrition and adverse 
outcomes. 
Fetal Bone Development  
There are two main types of bone development that occur in-utero.  Intramembranous 
ossification is less common and involves direct ossification of membranous sheaths that derive 
from mesenchymal cells.  This type of bone formation results in flat bones, such as those of the 
skull.  The limb bones result from ossification of cartilaginous models in a process referred to as 
endochondral bone formation (76).  This more complex process begins with the differentiation of 
embryonic mesoderm cells into mesenchyme, or embryonic connective tissue.  Mesenchymal 
cells will condense at skeletal sites and differentiate into chondrocytes and form chondrification 
centers that form bone models (76;77).  Cartilage first appears in the embryo by the fifth week of 
gestation (76).  In long bone formation, chondrocytes at the center of the condensation halt 
proliferation and become hypertrophic.  These hypertrophic cells direct adjacent cells to become 
osteoblasts, direct mineralization of the cartilaginous matrix, and attract blood vessels.   The 
osteoblasts mineralize the cartilaginous matrix by laying down hydroxyapatite crystals, which 
provide bone strength and also serve as a reserve for Ca and P.  The majority of fetal skeletal 
mineralization and Ca accretion (~80%) occurs in the third trimester of pregnancy when rates of 
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Ca transfer to the fetus peak (78).  The central region of bone formation in the diaphyses (or 
shaft) of the developing long bone is called the primary ossification center, from which 
chondrocytes continue to proliferate, lengthening the bone.  Near the time of birth, secondary 
ossification centers form at the ends of the long bone through similar cycles of chondrocyte 
proliferation and hypertrophy, vascularization and mineralization (77).  These secondary 
ossification centers are the epiphysial growth plates, which remain active to facilitate the skeletal 
growth of childhood and finally fuse when adult height is achieved, by ~age 17 in females and 
later in males (79).  Each of the individual steps of bone development are facilitated by a 
complex series of transcription factors and endocrine signals that regulate cell differentiation and 
recruitment of additional necessary cell types, bone formation, growth, and mineralization.  
Vitamin D, the calcitropic hormones, and serum Ca concentrations all contribute to the 
regulation of bone development and growth (80-82).    
 
II.  Ca Metabolism and Vitamin D Endocrinology During Pregnancy  
Physiological Adaptations to Ca homeostasis during Pregnancy 
Over the course of pregnancy, approximately 30 g of Ca is transferred from maternal 
circulation to the fetus (5).  During pregnancy, maternal Ca homeostatic mechanisms are altered 
and others are introduced in order to accommodate the increased Ca demand.  There are two 
main physiological alterations that occur during pregnancy to increase Ca availability to the 
fetus.  Fractional Ca absorption from the gut increases early in pregnancy and is elevated 
upwards of two-fold at term (83-86).  This increase in absorption, combined with plasma volume 
expansion increases maternal total exchangeable Ca pool size by 20% over the last five weeks of 
gestation (83).  The large Ca transfer to the fetus occurs despite increased urinary Ca losses 
 19 
 
which result from an increased plasma volume and glomerular filtration rate during pregnancy 
(13).   
The second major adaptation that occurs to maintain Ca homeostasis during pregnancy is 
increased metabolic bone activity.  Biochemical markers of bone turnover increase early in 
gestation and continue to rise throughout pregnancy, and are elevated upwards of 200% at term 
(8;9;84;87).  Biochemical markers of bone resorption often increase earlier in gestation than 
markers of formation (8;9;13;84;88), and many studies have detected decreases in bone mineral 
density (BMD) and other indexes of bone quality at certain sites across pregnancy, especially in 
trabecular-rich bone (8;9;11;15;87;89).  These losses of BMD observed in pregnancy are often 
recovered post-partum with the resumption of menses (13;15;87).  However, no firm consensus 
exists regarding the skeletal site and permanence of pregnancy-induced bone loss.   
Some studies postulate that the increases in Ca absorption are the primary source of fetal 
Ca supply, which is later supplemented by increases in bone Ca resorption (85).  This is because 
the increase in fractional Ca absorption is offset by an increase in urinary Ca loss, and increases 
in absorption alone are insufficient to meet the demands of fetal development (8;83).  In reality, 
the actual source of Ca supplied to the fetus is likely to vary by degree to which Ca absorption 
and bone turnover are modified during pregnancy.  Factors that may impact Ca homeostasis 
include: maternal age, parity, diet, and nutrient and endocrine status (87).  
Because of the physiological adaptations that occur during pregnancy, including 
increased fractional Ca absorption, and because studies have documented a lack of association 
(or even a protective effect) between parity and bone health in women, the Ca DRI for pregnant 
women does not differ from that of non-pregnant women (EAR: 800 mg/d; RDA: 1000 mg/d).  
Similarly, the Ca DRI for pregnant adolescents does not differ from that of their non-pregnant 
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peers (EAR: 1100 mg/d; RDA: 1300 mg/day) (Table 1.1) (17).  While recommendation for 
pregnant vs. non-pregnant teens do not differ, pregnant adolescents were identified as a 
population in need of more research by the IOM 2010 Ca and vitamin D DRI committee (17).     
 
Vitamin D and Calcitropic Hormones During Pregnancy 
Like Ca, vitamin D plays an important role in fetal bone development and maternal bone 
Ca retention and regulates hundreds of genes containing vitamin D response elements (VDRE’s).  
Thus, maintenance of adequate levels of vitamin D during pregnancy may be critical to maternal 
and fetal health.  Recently, the IOM released new recommendations for vitamin D intake for all 
populations including pregnant women.  The new vitamin D DRI is the same for all population 
groups between the ages of 1 and 70 years (EAR: 400 IU; RDA: 600 IU) (Table 1.1) (17).  This 
recommendation represents an increase of up to 3-fold from the previous vitamin D DRI which 
was set at an AI of 200 IU/day (25).  However, as previously mentioned the NIH roundtable 
addressing vitamin D research needs highlighted both pregnant women and adolescents as high 
priority populations in whom more research is needed (90).  Maternal 25(OH)D concentrations 
remain relatively stable across pregnancy in spite of marked increases in plasma volume (84;91).  
However, many pregnant women do not receive adequate dietary vitamin D or sufficient sun 
exposure given that the prevalence of vitamin D insufficiency in pregnant women and in 
newborns is high across the globe, ranging from ~30 - 90 percent (92-98).  Table 1.2 below 
shows the global prevalence of vitamin D insufficiency (25(OH)D ≤ 20 ng/mL) and deficiency 
(as defined by the authors) in pregnant women. 
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Table 1.2. 
Global Prevalence of Vitamin D Deficiency and Insufficiency in Pregnant Women  
Location n Time of 
Assessment 
Insufficient 
(%) 
Deficient 
(%) 
Assessment 
Method 
France
2
  (99) 80 Term  46% In-house RIA 
with rat serum 
Turkey
1
 (100) 100 Term  82% IDS RIA  
Ireland
1
 (92) 43 Mean of three 
trimesters 
48 – 77% 14 – 23% IDS ELISA 
Melbourne, 
Australia
2
 (101) 
374 28-32 weeks  7.2% 
 
IDS RIA 
Pittsburgh, 
USA
c
 (93) 
400 Term  17.1% IDS ELISA  
Sydney, 
Australia
1
 (98) 
971 23-32 weeks 48.8% 
 
15% Nichols 
Advantage Assay 
Finland
1
 (94) 98 Mean: 1
st
 
trimester and 2 
days post-partum 
98.0% 70.7% IDS ELISA  
Southampton, 
UK
1
 (95) 
424 34 weeks 36.6% 5.9% Diasorin RIA 
Southampton, 
UK
1
 (96) 
198 34 ± 2 weeks 31% 18%  IDS RIA 
Baltimore, 
USA
3
 (97) 
80 Third trimester 46.3% 21.5% Diasorin RIA 
Boston, USA
2 
(102) 
40 Term  50% In-house RIA 
Winnipeg, 
Canada
3
 (103) 
50 Term  46% Diasorin RIA 
Amsterdam, 
Netherlands
2
 
(104)  
3730 12-14 weeks 44.4% 23.1% IDS ELISA  
1
 Deficiency defined by authors as: 25(OH)D ≤ 10 ng/mL. 
2
 Deficiency defined by authors as: 25(OH)D ≤ 12 ng/mL. 
3
 Deficiency defined by authors as: 25(OH)D ≤ 15 ng/mL. 
IDS = Immunodiagnostic systems 
 
The fetus is incapable of dermal 25(OH)D production, and is completely dependent on 
maternal supply of 25(OH)D.  As such, maternal and fetal levels of 25(OH)D are highly 
correlated (23;98-100;102;103;105-108).  However there are inconsistent reports as to whether 
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neonatal 25(OH)D concentrations are similar to (93;99;100;102), or significantly lower (by 
~25%) than maternal concentrations (23;103;105-108).  Serum 25(OH)D freely crosses the 
placenta both free and bound to DBP, but is more efficiently transferred when unbound (26;109). 
PTH 
The role of PTH during pregnancy is more controversial.  Studies report that PTH is 
either unchanged, remains low, or even decreases throughout the course of pregnancy in healthy 
women (3;6;8;9;88;91;110).  Two studies (n = 16 and n = 14) identified a trend for increased 
PTH across gestation in adult women, but this trend did not reach statistical significance (9;111).  
Additionally, some studies have observed an increase in PTH late in pregnancy, especially in 
women with low Ca intakes (13;91;112;113).  Furthermore, elevated PTH (≥ 46 pg/mL) was 
detected among 13% of a cohort of 971 pregnant women in Australia, and this prevalence was 
higher amongst women with poor vitamin D status (98).  Because of such observations, it has 
been postulated that PTH may increase as a compensatory response to cause an increase in renal 
Ca retention and bone resorption in women with inadequate Ca intakes, poor vitamin D status 
and/or excess Ca demand (6;87;114).  This hypothesis is supported by the finding that PTH is 
higher in pregnant adolescents compared to adult counterparts (70), as pregnant adolescents may 
have a higher Ca demand compared to adult women due to the combination of the Ca demands 
of the fetus and of a biologically immature maternal skeleton.  These observations together 
support the postulation that, when whole-body Ca economy is strained during pregnancy, 
increased PTH may serve as a compensatory response to meet fetal Ca needs (6).  The 
determinants of PTH secretion (i.e. maternal age, race, vitamin D status and Ca intake, etc.) and 
role of PTH in Ca homeostasis during pregnancy still remain poorly characterized, especially in 
at-risk populations.   
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Unlike 25(OH)D, the fetus is capable of endogenous PTH synthesis, and is not dependent 
on maternal transfer of this hormone.  Neonatal concentrations of PTH are much lower than 
maternal concentrations at parturition (106;107;115-117).  Thus, the fetus is less impacted by 
maternal changes in PTH. 
 1,25(OH)2D 
In contrast to the reported lack of change in 25(OH)D and PTH concentrations across 
pregnancy, circulating concentrations of 1,25(OH)2D as well as vitamin D binding protein (DBP) 
increase during pregnancy (16;23;118;119).  However, the increase in 1,25(OH)2D is more 
substantial than that of DBP resulting in a 37 – 69%  increase in free-1,25(OH)2D (23;118-120).  
Other studies that have assessed only total 1,25(OH)2D all report increases in circulation during 
early pregnancy (84-86;91;111;112;121-126).  Whether circulating 1,25(OH)2D increases 
steadily across gestation (84;85;123), or increases early in pregnancy and then plateaus later in 
gestation remains controversial (91;111;121;122).   
The increase in 1,25(OH)2D is due to increases in renal and extra-renal (ie: placental) 
synthesis of 1,25(OH)2D (21;117;127).  The relative contributions of each of these tissues are 
uncertain (13;87).  The limited change in PTH commonly observed across normal pregnancy 
indicates that an alternative stimulation of 1,25(OH)2D production must exist during pregnancy.  
A prime candidate for this role is PTHrP (parathyroid hormone related peptide) (3;6;87).  
Parathyroid hormone related peptide is secreted by the placenta and a number of other maternal 
tissues, and circulating levels increase throughout the course of pregnancy (3;6;13;128).  The 
amino terminus of PTHrP and PTH are homologous, and both bind one of the three PTH 
receptors (PTH1R) (3).  Administration of PTHrP has been shown to cause an increase in plasma 
1,25(OH)2D, analogous to PTH (129).  Serum PTHrP levels also correlate with markers of bone 
 24 
 
turnover during pregnancy further suggesting a role in regulation of Ca homeostasis (128).  In 
addition to PTHrP, several other hormones, mainly of placental origin, are increased during 
pregnancy - all of which may potentially play a role in the regulation of 1,25(OH)2D synthesis.  
These include insulin-like growth factor-1 (IGF-1), estrogen, placental lactogen, placental 
growth hormone, and prolactin (6;13;87).  Details of the specific roles of each of these hormones 
in 1,25(OH)2D synthesis during pregnancy remains unknown.  It has recently been highlighted 
that research is needed to determine how 1,25(OH)2D is increased in maternal circulation during 
pregnancy, and the relative contributions of the kidney and placenta (16). 
Regardless of the source, increased 1,25(OH)2D is thought to be responsible for the 
increased intestinal Ca absorption that occurs during pregnancy from 1,25(OH)2D-mediated 
regulation of Ca transport in the intestine (13).  However, reports of relationships between 
1,25(OH)2D and Ca absorption during pregnancy are inconsistent (85;126).  Calcitriol has a 
stimulatory effect on bone resorption (24) and increases in 1,25(OH)2D parallel the increases in 
bone turnover observed during pregnancy (6).  In summary, the increase in 1,25(OH)2D that 
occurs early in pregnancy is well-documented, but the stimulus for the increased 1,25(OH)2D 
production, and the role of elevated 1,25(OH)2D during pregnancy is not fully understood.   
It is universally found that neonatal concentrations of 1,25(OH)2D are lower than 
maternal concentrations at birth, and the two are often unrelated (106;107;115-117).  Some 
studies have reported a positive relationship between maternal and neonatal 1,25(OH)2D 
(107;116) while others report a lack of association (115).   
The fetus it is not dependent on maternal supply of 1,25(OH)2D, as it is capable of 
synthesizing 1,25(OH)2D (130) and fetally produced 1,25(OH)2D regulates fetal Ca homeostasis 
independent of maternal 1,25(OH)2D  concentrations in animal models (131).  Whether maternal 
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1,25(OH)2D even crosses the placenta is controversial.  Calcitriol does not cross the rat placenta, 
but does cross the sheep and primate placenta (132).  Studies in perfused human placenta have 
indicated that 1,25(OH)2D is capable of crossing the placenta, and is more efficiently transferred 
when unbound to DBP (26).  The placenta is also capable of synthesizing 1,25(OH)2D (133), yet 
whether placental 1,25(OH)2D contributes to circulating fetal levels remains unknown (134).  In 
summary, while the fetus is solely dependent on maternal supply of 25(OH)D, it is capable of a 
certain degree of self-regulation of Ca homeostasis because neonatal PTH and 1,25(OH)2D are 
largely independent of maternal concentrations.   
Relationships among 25(OH)D, PTH, and 1,25(OH)2D  
Relationships among 25(OH)D, PTH and 1,25(OH)2D are well characterized in non-
pregnant populations, but these relationships are less clear during pregnancy even though several 
large studies addressing these relationships during pregnancy have been published within the last 
month (135;136).   
Whereas it has been reported that 1,25(OH)2D is positively associated with 25(OH)D in a 
study of 40 pregnant women (123), a recent meta-analyses (2010) of data from 26 studies of 
pregnant women found no correlation between maternal 25(OH)D and 1,25(OH)2D 
concentrations (125).  A recent large study (n = 530) by Hollis et al. documented a significant 
biphasic relationship between 25(OH)D and 1,25(OH)2D, with 1,25(OH)2D increasing as 
25(OH)D increased up to 40 ng/mL, at which point 1,25(OH)2D plateaued (135).  The authors 
concluded that a 25(OH)D concentration of at least 40 ng/mL was necessary to support 
maximum 1,25(OH)2D  production in pregnant woman (135).  This study was a large 
randomized control trial providing pregnant women with either 400, 2,000, or 4,000 IU vitamin 
D/day from ~13 weeks gestation to term.  However the relationship between 25(OH)D and 
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1,25(OH)2D was observed among all treatment groups combined, and was thus observational in 
nature.  It is still unclear how 25(OH)D may impact 1,25(OH)2D when 25(OH)D remains low 
across gestation.    
Both a positive (137) and negative (123) relationship between 1,25(OH)2D and PTH have 
been reported during pregnancy in ethnic populations.  There are also inconsistencies regarding 
the relationship between 25(OH)D and PTH during pregnancy.  Many studies assessing the two 
fail to report a relationship (84-86;112;138).  In the large randomized control trial referenced 
above (providing women with either 400, 2,000, or 4,000 IU vitamin D/day), no differences in 
PTH were observed between treatment groups despite significant differences in 25(OH)D (135).  
However, the intent-to-treat analyses of this study should be interpreted with care because the 
randomization process was compromised due to study design changes that were made in 
response to IRB concerns with the high dose supplementation arms (135).  The authors did 
observe that PTH decreased as 25(OH)D increased in African American women (in all treatment 
groups) (135).  A negative relationship between 25(OH)D and PTH has been reported in other 
smaller studies of pregnant women (113;123).  Finally, a recent cross-sectional study of pregnant 
women between 11 and 13 weeks gestation (n = 1,016) found that PTH was lowest in the 
summer season, and was inversely associated with 25(OH)D in African American women with 
insufficient 25(OH)D (136).  Variation in maternal Ca intake, vitamin D status, race, and age and 
interactions among these characteristics likely contributed to the variable findings between 
studies.  Failure to account for these differences may by a source of the lack of consensus in the 
relationships reported.   
The pregnancy induced physiological changes in Ca homeostasis are controlled by 
hormonal adjustments that accompany pregnancy.  The calcitropic hormones are impacted by 
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vitamin D status and Ca intake during pregnancy, and increasing data link these two nutrients 
with maternal and neonatal health outcomes.  However, details regarding temporal changes in 
calcitropic hormones and how Ca intake and 25(OH)D status may impact these changes during 
pregnancy remain relatively elusive.   
  
III. Adolescent Pregnancy  
Peak bone mass is established during adolescence and in females, this narrow window of 
bone consolidation is largely completed by the age of 17 years (71).  A pregnancy during this 
period of bone acquisition represents nine months of lost opportunity to increase maternal bone 
mass, if fetal skeletal needs are prioritized over those required for maternal skeletal growth.  The 
elevated rates of bone turnover during pregnancy, combined with a lower maternal total body 
bone mineral content (BMC) reserve may place pregnant teens at an elevated risk of bone loss 
during pregnancy.  This may also impact her peak bone mass potential and increase her risk of 
osteoporosis later in life.  These elevated Ca demands also place the developing fetus at risk for 
suboptimal Ca supply and skeletal development. 
Adolescent Pregnancy - the Competition for Nutrients 
Rates of adolescent childbearing in the United States are the highest of any industrialized 
nation; approximately 30% of American girls will become pregnant at least once before the age 
of 20 (1).  Pregnant adolescents are at increased risk for multiple adverse birth outcomes.  
Pregnant teens are more than twice as likely to deliver a low birth weight (LBW) or preterm 
infant (139;140).  Adolescents also exhibit rates of neonatal mortality three times higher than 
adult woman (> 19 yrs); approximately 14% of adolescent pregnancies end in miscarriage or 
stillbirth (139).   Pregnant adolescents are also more likely to experience maternal morbitities, 
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and exhibit twice the maternal mortality rate of adult pregnant women in the United States 
(139;141).   
Associations between adolescent pregnancy and adverse birth outcomes are confounded 
by the fact that pregnant adolescents often possess many biological and social factors that are 
independently associated with adverse birth outcomes such as low pre-pregnancy weight, poor 
pregnancy weight gain, low education, smoking, drug use, and poverty (139;142;143).  
Furthermore, adolescents are more likely to have inadequate access to prenatal care (142), to 
consume diets of poor quality (high in fat and sugar and low in micronutrients) (17;144-146), 
and to have a high prevalence of infections (sexually transmitted and bacterial) (142).  
Additionally, adolescent pregnancy disproportionately impacts minorities, who are already at 
increased risk for poor birth outcomes (139;147).  African American neonates have a higher 
preterm and mortality rate compared to Caucasian neonates regardless of maternal age (148-
150).
 
 African American pregnant adolescents have been shown to have high rates of anemia 
(upwards of 66%), with one third of adolescents exhibiting depletion of body iron by the third 
trimester in approximately (142;151).  Together these factors further compromise maternal and 
fetal health and likely contribute additional risk to adolescent pregnancy in addition to maternal 
physiological immaturity.      
Animal models of adolescent pregnancy have indicated differential nutrient partitioning 
between mother and fetus in biologically immature females, favoring growth of maternal body at 
the expense of placental (and thus fetal) growth.  This partitioning is dependent on maternal 
nutritional and growth status, as opposed to chronological age (152-154).  A model of adolescent 
pregnancy in rapidly growing ewes is characterized by excessive maternal weight gain, but 
shorter gestation, reduced numbers of placental cotyledons (a measure of placentation and 
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placental efficiency), smaller placentas and smaller fetuses (152;153).  It has been postulated that 
in “still-growing mothers” maternal growth is prioritized over fetal needs, limiting placental 
growth and placental capacity to supply adequate nutrition for fetal growth and development, 
resulting in small placentas and fetuses and decreased gestation (153;155). 
 
 
Studies in humans are lacking, but analogous trends and outcomes have been observed in 
human adolescent pregnancies.  Nutritional and growth status of the adolescent, rather than age, 
seems to have the most dramatic impact on pregnancy outcome.  Studies that have assessed 
maternal growth across pregnancy (via knee height and percent parental height achieved) in 
adolescents have established that still-growing adolescents gain more weight but deliver infants 
of lower birth weight than non-growing counterparts, indicating that weight gain was due to 
maternal verses fetal growth (156-160). 
 
Under these conditions when maternal tissue is 
prioritized, the placenta may not develop or function normally.  This is supported by decreased 
placental blood flow (by Doppler ultrasound) and decreased micronutrient concentration in cord 
blood from still-growing pregnant adolescents (147;161).  Diet and nutritional status also plays a 
role; high sugar diets have been associated with an increased risk of a small for gestational age 
(SGA) infant and reduced gestation in teen pregnancies (144;147).  Inadequate supply of 
nutrients may occur in adolescent pregnancy when demand of maternal plus fetal growth is not 
met by a nutrient-dense diet.  The resulting competition for nutrients between mother and fetus 
places both members of the maternal/fetal dyad at risk for adverse outcomes (141). 
Ca Homeostasis in the Pregnant Adolescent 
If an adolescent becomes pregnant before achieving skeletal maturity, and is not 
consuming a Ca replete diet, she may increase bone resorption to meet fetal needs, which places 
herself and her fetus at risk for adverse bone health outcomes.  Even though non-pregnant 
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adolescents have higher rates of fractional Ca absorption than non-pregnant adult women (69), 
pregnant adolescents are able to further increase fractional Ca absorption (162) to achieve the 
same fractional absorption observed in adult pregnant women.  However, adolescents do not 
increase their fractional Ca absorption beyond that observed among pregnant adult women 
(84;86;162).  Pregnancy does seem to have a more severe impact on the Ca homeostasis of teens 
versus adult women.  Among women with low Ca intake, pregnancy in teens resulted in a larger 
increase in PTH and larger decrease in urinary Ca than was seen in adult counterparts (70).  
These teens also exhibited smaller increases in markers of bone resorption, and decreases 
(compared to increases) in markers of deposition compared to mature women (70).  Together 
these data suggest that adolescents may have higher Ca demands and be at increased risk of 
pregnancy-induced bone loss.  This is supported by data from a longitudinal study assessing 
bone density across pregnancy (as measured by calcaneus ultrasound) that detected greater bone 
loss in pregnant adolescents compared to adult women (11).  Bone loss was most pronounced in 
the still-growing adolescents in this cohort (11).  A cross sectional study of white women age 20-
35 found that age at first pregnancy < 20 years was significantly negatively associated with mid-
distal radial bone mass (10).  A study of African American adolescent mothers (n = 15) detected 
“low bone mass for chronological age” (z-scores < -2) in 29% of the cohort early post-partum, 
which may indicate that significant bone loss had occurred across gestation (162;163).  
Furthermore, adolescent females are also likely to consume suboptimal Ca intakes, and have 
insufficient 25(OH)D status, which further places them at risk for a strained Ca economy during 
pregnancy (17;97). 
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In summary, it appears that adolescents’ calcitropic and physiological response to 
pregnancy is similar to that of adult women, and this may not be sufficient to maintain maternal 
skeletal accretion while fully supporting fetal skeletal mineralization and growth.   
 
IV.  Vitamin D and Ca Fetal Programming  
It is now well known that the in-utero nutritional environment may “program” the fetal 
metabolic profile and gene expression, impacting long term risk of developing subsequent 
chronic diseases in adult life.  The in-utero supply of both 25(OH)D and Ca have been linked to 
a variety of neonatal and adult outcomes.   
Vitamin D insufficiency has been associated with suboptimal skeletal development which 
may be sustained into adult life (164).  In Australia, maternal vitamin D deficiency during 
pregnancy was linked with shorter gestation and reduced knee-to-heel length in fetuses.  This 
reduction in long-bone length remained significant when accounting for reduced gestation (101).  
Vitamin D deficiency was also shown to affect bone density, as vitamin D-deficient infants had 
lower bone mass/body weight ratios than replete neonates in a Canadian study (103).  In Korea, 
neonatal 25(OH)D was found to correlate positively with total body BMC.  Infants born in 
winter months had lower 25(OH)D and 8% lower total BMC than summer born infants (165).  In 
Great Britain, 3D ultrasound was utilized to show that decreasing maternal 25(OH)D status 
during pregnancy was associated with increased fetal femoral splaying indices (commonly seen 
in childhood rickets), as early as 19 weeks gestation (95).  Infants born to Finnish mothers with 
mean 25(OH)D > 17.0 ng/mL (the median for the cohort) exhibited larger tibial BMC and cross 
sectional area  than those born to mothers with 25(OH)D below 17.0 ng/mL (94).  In summary, 
maternal vitamin D deficiency has been identified as a driving factor of the BMC of the fetal 
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skeleton (165).  This effect of vitamin D status on fetal skeletal growth and mineralization 
suggests that vitamin D status in-utero may “program” that fetus for less-than-optimal peak 
BMD, and subsequent adverse bone health outcomes into adulthood.   
In the same Finnish cohort mentioned above, 87 of the original 124 infants (70%) were 
assessed at 14 months.  Despite 25(OH)D repletion and similar 25(OH)D observed in all infants 
by 14 months, the bone differences observed at birth were only partially ameliorated, suggesting 
that fetal 25(OH)D exposure in-utero had lasting impact on offspring bone cross-sectional area 
(166).  Similarly, guinea pig pups born to vitamin D deficient mothers exhibit reduced body 
weight, length, and whole body and tibial BMC compared to pups born to sufficient sows (167).  
Moreover, after 28 days of supplemental vitamin D, this deficit remained (167).  This suggests 
modulation of bone accrual in-utero may persist, affecting adult risk of osteoporosis (168).  
Research on an epidemiological scale has supported this theory.  Offspring of women with low 
25(OH)D late in pregnancy exhibit reduced whole body and lumbar spine BMC at nine years 
compared to offspring born to women with adequate levels of 25(OH)D during pregnancy (96).  
Similar results were found when using UVB exposure in the third trimester as a proxy for 
vitamin D status (96).  Estimated ultraviolet exposure of women during their third trimester of 
pregnancy (based on historical meteorological data) has also been associated with the lean body 
mass, BMC, bone area, and BMD of offspring at nine years.  From this data, it was estimated 
that every standard deviation increase in maternal UVB exposure of a white pregnant woman, 
was associated with a 5% decrease in lifetime fracture risk of that child (169).  These data 
suggest that vitamin D status has the potential to effect fetal health long after the perinatal 
period, into childhood and adulthood.  
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More recently, deficient maternal vitamin D status and/or intake during pregnancy has 
also been linked to numerous other adverse neonatal and child health outcomes, in addition to 
bone health.  These include reduced birth weight, SGA, asthma, respiratory problems, 
autoimmune disorders, and schizophrenia (170-178).  These associations are controversial, and 
the recent IOM committee on Ca and vitamin D intake concluded that there was insufficient 
evidence to establish causality in these proposed programming effects of vitamin D (17).  The 
need for more research in this area has been highlighted (16). 
An insufficient Ca intake during pregnancy may result in reduced supply of Ca to the 
fetus and may also potentially “program” that fetus for suboptimal bone health later in life.  In a 
controlled trial of disadvantaged Indian women (n = 87), those supplemented with Ca (300 or 
600 mg/day) from week 20 of gestation through parturition, gave birth to neonates with 
significantly higher bone density than neonates born to women receiving placebo (179).  In a 
supplementation trial of healthy American mothers (n = 256) randomized to receive 2 g/day Ca, 
or placebo from ≤ 22 weeks through delivery, supplementation in women with low initial Ca 
intake (< 600 mg/day ) resulted in neonates with significantly higher total body, and lumbar 
spine BMC (180).  After adjusting for maternal age and BMI, maternal Ca intake (diet plus 
supplement, accounting for adherence) was significantly associated with higher infant total body 
BMC (180).
 
 Dairy intake seems to have a similar impact (in countries that fortify milk with 
vitamin D, such as the United States) due to its high Ca and vitamin D content.  In a 
supplementation trial of pregnant Caucasian adolescents, teens randomized to consume four 
servings of dairy per day gave birth to infants with higher 25(OH)D status and larger birth 
weights (by ~230 g) than observed in the Ca-only supplement group or the control group (181).  
Infants in the “dairy” group had 17% higher total body Ca than those in the control group (181).  
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Dairy intake has also been found to impact fetal bone growth as well; low dairy intake (< 2 
servings per day) was associated with shorter fetal femur length in pregnant adolescents (12).  
These effects of maternal dietary intake may have a lasting impact on offspring bone health as 
maternal milk intake during pregnancy has been positively associated with offspring spinal BMD 
at 16 years (182).  The high Ca demand of adolescence and pregnancy combined with the poor 
dietary quality documented in teens place their offspring at increased risk for these adverse bone 
and long term health outcomes.  
 
V.  Placental Expression of Ca-Related Proteins & VDR 
Fetomaternal Interface - the Placenta 
Humans have a hemochorial placenta; placental invasion of the uterine wall is extensive 
and maternal blood is separated from fetal circulation only by the fetal endothelium lining the 
allontoic capillaries, the fetal chorioallantoic mesoderm and the fetal chorionic epithelium. The 
syncytiotrophoblast forms a single multinucleated cell layer that surrounds the chorionic villi so 
that all nutrients must traverse the syncytiotrophoblast when crossing from maternal to fetal 
circulation. The apical membrane of the syncytiotrophoblast is microvillus, to increase the 
surface area for absorption – very similar to the intestinal enterocyte.  The apical membrane is in 
contact with maternal blood, and the basal membrane directly faces the endothelial wall of the 
fetal capillary.   
Throughout the course of pregnancy, the fetus is hypercalcemic reletive to maternal 
circulation; thus the transfer of Ca occurs against a concentration gradient (183).  Ca flux to the 
fetus consists of three distinct processes within the placenta, each of which are regulated: 1) 
apical Ca entry from maternal circulation into the syncytiotrophoblast; 2) cytoplasmic transfer 
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across the syncytiotrophoblast to the basal membrane; and 3) basal efflux out of the 
syncytiotrophoblast into fetal circulation.  Specific Ca-transport proteins identified in the 
placenta contribute to each of these processes, and 1,25(OH)2D regulates expression of many of 
these transporters.  Figure 1.2 below shows the cellular layers and proteins involved in this 
transport.    
 
 
Figure 1.2 Placental Transport of Calcium from Maternal to Fetal Circulation 
The fetus is maintained hyercalcemic to the mother and Ca is transported against a concentration 
gradient across the syncytiotrophoblast by three distinct regulated steps: 1) apical entry, 2) 
cytoplasmic transfer, and 3) basal efflux.  Several Ca transport proteins play a role in each of 
these steps.  The transient receptor potential vanilloid 6 (TRPV6) imports Ca from maternal 
circulation.  Calbindin 9DK and 28K shuttle Ca across the syncytiotrophoblast, and plasma 
membrane Ca ATPase 1-4 export Ca into fetal circulation. 
 
The TRPV6 channel is a voltage-gated Ca channel expressed on the apical membrane of 
the enterocyte and the syncytiotrophoblast, where it plays a pivotal role in facilitated Ca entry 
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into the cell (183).  Interestingly, the TRPV6 gene contains multiple VDRE’s, and thus 
expression of the Ca channel is regulated by availability of 1,25(OH)2D (27;184).  In Caco-2 
cells (intestinal cell line) treatment with 1,25(OH)2D for eight hours results in a 60 fold increase 
in TRPV6 mRNA (185).  Treatment with 25(OH)D also results in an increase in TRPV6 
expression in cells that express the 1-hydroxylase (which includes the placenta (186)) 
indicating the capacity for both intracrine and endocrine regulation of TRPV6 expression by 
1,25(OH)2D (185).   
Calbindin D9K (CaBP9K) and Calbindin D28K (CaBP28K) are two Ca transport proteins 
that shuttle Ca across the cytoplasm of the enterocyte (18).  Both of these proteins are detected in 
the human placenta and expression is high in the cytosol of the syncytiotrophoblast (110;187).  
These proteins are believed to play similar roles in placental Ca transport, as expression of these 
proteins increases in late gestation (188) when rapid fetal bone growth occurs (183).  
Furthermore, human syncytiotrophoblasts in culture exhibit an time-dependent increase in 
CaBP28K RNA that parallels rates of Ca uptake (187).  Both the CaBP9K and CaBP28K genes 
contain VDRE’s, and their expression is increased by 1,25(OH)2D in placental cells via the 
VDR-mediated pathway (18;183;189-191).  At the basal membrane, Ca is transported out of the 
syncytiotrophoblast in an energy dependent manner.  Four plasma membrane Ca ATPases 
(PMCA 1-4) all export Ca (183).  Expression of these proteins increases late in gestation when 
Ca flux increases (183;192).   The PMCA1 and 4 are expressed at higher levels than PMCA2/3, 
and it is thought that PMCA1/4 are the main modulators of Ca efflux to fetal circulation.   
Both 25(OH)D and 1,25(OH)2D contribute to regulation of each step of placental Ca 
transport.  As such, vitamin D status and placental VDR expression may regulate placental Ca 
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transport, which provides a potential mechanism for the programming effects attributed to 
deficient vitamin D status in-utero. 
VDR and other Vitamin D Machinery in the Placenta 
The placenta expresses both the 1α-hydroxylase enzyme and the VDR (186).  Both of 
these proteins are expressed in the syncytiotrophoblast and are co-localized in placental tissue 
(193-195).  This indicates the potential for paracrine and intracrine vitamin D activity within the 
placenta.  Indeed, endogenous placental production of 1,25(OH)2D has been demonstrated in-
vitro (133;196).  Furthermore, 1,25(OH)2D increases both the expression of VDR (189) and the 
vitamin D 24-hydroxylase enzyme, and down-regulates the expression of the 1α-hydroxylase 
gene in the placenta (197).  These observations indicate a tightly controlled regulation of 
paracrine vitamin D activity at the level of the placenta.  Additionally, it was recently discovered 
that the vitamin D 24-hydroxylase gene is fully methylated in the placenta, resulting in decreased 
placental CYP24A1 expression (198).  In contrast, the 1α-hydroxylase and VDR genes are 
completely unmethylated (198).  These results indicate that that the placenta is capable, and even 
“primed” for initiating significant endocrine and paracrine vitamin D response. 
In mice, VDR plays a significant role in placental Ca flux.  Heterozygote fetuses of VDR 
knockout (KO) mothers exhibit defective skeletal mineralization, increased numbers of 
osteoclastic cells, hypercalcemia and a five-fold increase in 1,25(OH)2D (199).  However, the 
role of vitamin D and VDR in regulation of Ca flux and fetal skeletal development may only be 
critical when maternal Ca intake is low enough that Ca demand cannot be met by passive 
absorption in the gut.  This is exhibited in the VDR KO mouse; when fed a high Ca/P/lactose 
diet, all of the disturbed Ca phenotypes of heterozygote pups were restored to normal (199).  
Furthermore, heterozygote, homozygous KO, and wild type (WT) littermates of heterozygote 
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dams have equivalent serum Ca, P, Mg, and PTH, and neither heterozygote or KO pups exhibit 
alterations in placental 
45
Ca flux, skeletal morphology or skeletal Ca and Mg content (200).  
However, homozygous KO pups of heterozygous dams are smaller at birth and exhibit endocrine 
disturbances including serum 1,25(OH)2D concentrations three times higher than WT littermates 
(200).  The lack of dramatic fetal phenotype in KO pups of heterozygous dams, combined with 
the rescue of fetal phenotypes from KO dams with high Ca diets has led some to propose that 
VDR plays a less significant role in placental Ca transfer or fetal bone mineralization in humans 
as well as mice (127;200).  However, extrapolating data from genomic murine knockout models 
to human pregnancy has limitations.  Data regarding placental VDR expression in humans is 
limited and it may be that the VDR plays a role in regulating placental Ca flux and fetal skeletal 
development, especially in adolescent pregnancies.   
 
VI.  Stable Ca Isotopes 
Current understanding of placental Ca flux is limited by a lack of in-vivo human data, as 
extrapolation of results from animal studies must be made with caution.  Dynamic measures of 
in-vivo Ca flux can be safely obtained in humans using stable Ca isotopes.  In nature, Ca is 
comprised of six stable isotopes; 
40
Ca is the most abundant, but five minor abundance isotopes 
are found at fractional abundances under 2.1% (
42
Ca, 
43
Ca, 
44
Ca, 
46
Ca, and 
48
Ca).  The 
44
Ca 
isotope (found in nature at 2.06%) is commonly administered orally in human metabolic studies; 
42
Ca (found in nature at 0.647%) and 
46
Ca (found in nature at 0.004%) are often administered 
intravenously.  Because these stable isotopes exist naturally and are present in the body and food 
supply, they pose no risk to mother or fetus at the doses administered.  Two of these minor 
abundance isotopes (
42
Ca and 
44
Ca) are used in this research.    
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Pregnancy is characterized by an expansion of blood volume and increased bone turnover 
both of which impact the size of the miscible Ca pool.  Thus use of an intravenous (i.v.) dose of 
Ca isotope is necessary in order to provide an estimate of this pool.  The intravenous dose can be 
viewed as a proxy for 100% absorption and will give an estimate of the miscible Ca pool in each 
individual which will differ depending on individual variation in: body size, dietary intake, 
intestinal Ca absorption, endogenous fecal losses of Ca, urinary excretion of Ca, bone turnover 
(resorption verses deposition), and Ca transfer to the fetus.  Thus, the ratio of oral:i.v. 
(
44
Ca:
42
Ca) enrichment of maternal blood post-dosing will provide a relative estimate of 
fractional absorption from the gut.  Figure 1.3 below demonstrates the relative sources of loss 
and entry into the miscible Ca pool that vary on an individual basis.    
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Figure 1.3 Model of Calcium Dynamics that Impact Calcium Balance During Pregnancy    
Rates of entry into and excretion from the miscible Ca pool are altered during pregnancy and 
vary on an individual basis. Calcium enters the miscible Ca pool from absorption of dietary Ca 
intake (VA) and resorption from bone (VO-).  Calcium is lost to endogenous fecal losses (Vendo), 
renal losses in the urine (Vu), bone Ca deposition (VO+), and Ca transfer to the fetoplacental unit 
(VFetal).  In this study 
44
Ca was administered orally (green arrow), and then assessed in maternal 
circulation and neonatal circulation (cord blood).  Intravenous 
42
Ca was administered directly 
into the miscible Ca pool, (purple arrow).  Enrichment of 
42
Ca in maternal circulation is a 
function of the size of the miscible Ca pool and rates of exit from this compartment.  Enrichment 
of 
42
Ca and 
44
Ca in neonatal circulation will provide insight into the degree of Ca transferred 
from maternal to fetal circulation. 
 
 
The ratio of fetal to maternal enrichment provides a measure of the fraction of Ca 
administered that was partitioned to the fetus.  The 
42
Ca fetal :
42
Ca maternal  ratio provides a measure 
of the fraction of Ca administered intravenously that was transferred to the fetus; the              
44
Ca fetal :
44
Ca maternal  ratio provides a measure of the fraction of dietary Ca absorbed from the gut 
that was then partitioned to the fetus.  These measures obtained can be examined in relation to 
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variation in Ca intake and vitamin D status and VDR expression in the placenta.  To our 
knowledge, such in-vivo data do not currently exist in humans using either radio- or stable Ca 
isotopes.   
 
VII.  The Teen Bone Study 
 This research was undertaken in the context of the “Teen Bone Study” – a study designed 
to investigate the impact of maternal Ca intake and vitamin D status on rates of maternal bone 
loss and fetal bone growth in pregnant adolescents.   The study employed a longitudinal cohort 
design and was funded by a grant from the USDA.  Inclusion criteria included: maternal age ≤ 18 
years, gestational age between 12 and 30 weeks at entry into the study, carrying a singleton fetus, 
and otherwise healthy.  Participants attended up to three study visits across pregnancy.  At each 
visit, dietary intake, supplement usage, maternal anthropometrics, and physical activity were 
recorded.  Maternal bone quality was monitored by calcaneous heel ultrasounds and fetal bone 
growth was monitored by fetal sonogram at each visit.  Maternal blood was collected at the mid-
gestation visit and at parturition.  Cord blood and placental tissue were obtained at birth.  Figure 
1.4 below represents a schematic of the study design and summarizes the main categories of data 
obtained from each participant.     
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Figure 1.4 Timeline of the “Teen Bone Study”   
The Teen Bone study was a longitudinal cohort study designed to characterize maternal bone 
loss and fetal bone growth in adolescent pregnancy, in relation to maternal Ca intake and vitamin 
D status.  Participant data was collected using standardized, computerized data collection forms 
(teleforms) that are included as appendices (indicated by individual superscripts).  
 
The study was initiated in Baltimore, MD in 2005.  Thirteen participants completed the 
study in Baltimore before the study was moved to Rochester, NY.  In 2006, study recruitment 
began at the Rochester Adolescent Maternity Program (RAMP), Rochester, NY.  Adolescents 
who attended RAMP received prenatal care from the Strong Midwifery Group at a clinic located 
in the inner-city of Rochester.  Adolescents delivered their infants with the same midwifery 
group at Highland Hospital, which is affiliated with the University of Rochester School of 
Medicine.  The study was active in Rochester between December, 2006 and June, 2010 when the 
last participant delivered her infant.  In the state of New York, pregnant adolescents (< 18 years) 
 43 
 
are treated as emancipated minors for the duration of their pregnancy.  All participants who were 
≥ 15 years of age signed a study-consent form (presented in Appendix 9).  Adolescents who 
were between 15 and 17 years were assigned a patient advocate.  Adolescents who were between 
12 and 14 years of age signed a different version of this consent that contained more age-
appropriate language.  For these younger participants, parental approval was also required by the 
University of Rochester IRB.       
All data were collected on standardized computerized data collection forms (teleforms) 
that were organized in the following categories: maternal demographics (collected at 
recruitment); 24-hour dietary recall and Ca food frequency questionnaire (FFQ), supplement 
usage, maternal anthropometrics, fetal sonogram, and physical activity recall (all administered at 
each study visit); and infant data and placenta characteristics (collected at delivery).  These eight 
teleforms are presented as Appendices 1 – 8.  The initial study design included assessment of the 
following biochemical measures in all three blood samples obtained from each maternal/neonatal 
dyad: 25(OH)D, PTH, 1,25(OH)2D, leptin, estradiol, osteocalcin (OC: a biochemical marker of 
bone formation), N-telopeptide (NTX: a biochemical marker of bone resorption), and 
osteoprotegerin (OPG: a decoy receptor that facilitates osteoblast/osteoclast communication and 
plays a role in regulation of rates of bone turnover). 
A total of 171 adolescents participated in this study.  This study represents a wealth of 
data which can be used to investigate a multitude of research questions in addition to the original 
study aims.  My doctoral research focuses on a sub-section of the initial aims of the grant; 1) 
investigations of calcitropic hormone status across pregnancy, 2) the impact of maternal Ca 
intake and vitamin D status on fetal bone length and length at birth, 3) the determinants of 
placental VDR expression, and associations with fetal bone length, and 4) in-vivo 
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characterization of maternal-to-fetal Ca transfer, and associations with fetal bone length.  My 
research has a “fetal focus”, and thus will not present data regarding maternal bone loss.  I have 
also completed a manuscript detailing concentrations of OPG, OC, and NTX, and relationships 
between these variables and infant birth outcomes (Appendix 11). 
 
Impact 
The prevalence of teenage pregnancy, and the high maternal and fetal risks associated 
with early childbearing give this research significant public health relevance.  The information 
obtained from this project will improve our understanding of Ca and vitamin D physiology 
during pregnancy, will have clinical relevance for pregnant adolescents, and will inform 
recommendations for adequate Ca intake in this age group to support optimal maternal and fetal 
bone health. 
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CHAPTER 2 
 
VITAMIN D INSUFFICIENCY IS PREVALENT AND VITAMIN D STATUS IS 
INVERSELY ASSOCIATED WITH PTH AND CALCITRIOL IN PREGNANT 
ADOLESCENTS* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Bridget V Essley, Thomas J McNanley, Elizabeth M Cooper, Allison W McIntyre, Frank 
Witter, Z Leah Harris, Kimberly O O’Brien. Vitamin D Insufficiency is Prevalent and Vitamin D 
is Associated with PTH and Calcitriol in Pregnant Adolescents.  
Revisions are currently under review at the Journal of Bone and Mineral Research, July 2011. 
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ABSTRACT 
Few large studies have assessed changes in calcitropic hormones and maternal 25(OH)D 
status across pregnancy and how this may impact neonatal hormone status.  We aimed to identify 
determinants of 25(OH)D, PTH, and calcitriol across pregnancy in a longitudinal study of 168 
pregnant adolescents (≤ 18y of age).  Maternal 25(OH)D, PTH, and calcitriol were assessed at 
mid-gestation (~26 weeks), delivery, and in cord blood.  Data were related to maternal 
anthropometric, dietary, and physical activity information. Insufficient 25(OH)D (≤ 20 ng/mL) 
was prevalent (~50%) in these adolescents and their infants; 25(OH)D was lower in African 
Americans versus Caucasians (p <0.001).  PTH increased across gestation (p <0.001), and 
elevated PTH was detected in 40% of adolescents at delivery.  Calcitriol decreased significantly 
by 5% across the final 13 weeks of pregnancy (p <0.001), and was lower in Caucasians versus 
African Americans at delivery (p < 0.040).  PTH and calcitriol did not significantly differ across 
the range of Ca intakes observed (257-3220 mg/day).  In the group as a whole, PTH was 
inversely associated with 25(OH)D in maternal circulation at mid-gestation (p = 0.023) and at 
delivery (p = 0.019).  However, when the cohort was partitioned by 25(OH)D sufficiency, this 
relationship was only present in those with 25(OH)D ≤ 20 ng/mL, suggestive of a threshold 
below which 25(OH)D impacts PTH during pregnancy.  Mid-gestation 25(OH)D was also 
inversely associated with calcitriol at delivery (p = 0.023), irrespective of Ca intake.  
Concentrations of PTH and calcitriol in neonatal circulation were significantly lower than          
(p <0.001), but unrelated to concentrations in maternal circulation.  These findings indicate that 
maternal 25(OH)D status plays a role in calcitropic hormone regulation in pregnant adolescents.   
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INTRODUCTION     
Calcitropic hormones such as parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D 
(1,25(OH)2D, calcitriol) regulate serum calcium (Ca) concentrations and maintain whole body 
Ca homeostasis.  Metabolic regulation of these hormones is particularly important during 
pregnancy to accommodate the 30 g of Ca necessary to mineralize the fetal skeleton.  To help 
meet this physiological demand, intestinal Ca absorption increases early in pregnancy and 
remains elevated upwards of two-fold until term (1-3).  Biochemical markers of bone resorption 
and bone formation increase significantly across gestation, suggesting that metabolic activity of 
bone is stimulated to accommodate fetal skeletal mineralization (4).  While these pregnancy-
associated adaptations are likely impacted by Ca intake, 25-hydroxyvitamin D (25(OH)D), PTH 
and 1,25(OH)2D, little has been published regarding determinants and interrelationships between 
these measures across pregnancy.   
The best biomarker of vitamin D status is serum 25(OH)D, as circulating concentrations 
of this pro-hormone are derived from both dietary intake and endogenous dermal synthesis of 
vitamin D.  During pregnancy, circulating 25(OH)D concentrations remain fairly constant in 
spite of marked increases in plasma volume (2;4).  Numerous studies have documented vitamin 
D insufficiency (≤ 20 ng/mL) during pregnancy (5),  yet little is known about relationships 
between this pro-hormone and circulating concentrations of 1,25(OH)2D and/or PTH across 
pregnancy, especially in racially diverse populations.  
Serum 1,25(OH)2D is consistently elevated during pregnancy and increases are seen as 
early as 8-10 weeks of gestation (3).  While concentrations are typically elevated, interpretation 
of existing data on 1,25(OH)2D concentrations in pregnant women is constrained by the limited 
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number of studies addressing this topic and the relatively small samples sizes (n = 10 - 40) and 
variety of different methodologies used to characterize status of this hormone (2-4;6-8).   
In contrast to the consistent elevations typically reported for calcitriol, circulating PTH 
concentrations are reported to remain unchanged, decrease, or increase across gestation (4;9;10). 
These variable findings may be impacted by differences in 25(OH)D (11), habitual Ca intake 
and/or maternal age (10) between studies.  Similar to existing calcitriol data, the normative data 
regarding PTH during pregnancy have been largely obtained from small cohorts of well-
nourished, Caucasian, adult women.  Few studies have examined associations among racially or 
ethnically diverse populations, in spite of well-described racial differences in calcitropic 
hormones (12).   
Data regarding possible interrelationships among 1,25(OH)2D, PTH and 25(OH)D across 
pregnancy are conflicting (6;7).  In non-pregnant populations, 25(OH)D has been found to be 
inversely associated with serum PTH, especially in the context of suboptimal 25(OH)D status 
(13).  The recent IOM report on Ca and vitamin D requirements found “fair evidence that this 
relationship may exist during pregnancy” (14), but additional data are clearly needed.  
Variability in dietary Ca intake likely contributes to the differences observed between studies, 
yet few studies control for the impact of habitual Ca intake on the observations noted.  
The developing fetus is solely dependent on maternal supply of 25(OH)D, and neonatal 
25(OH)D concentrations are strongly correlated with maternal concentrations.  In contrast, fetal 
1,25(OH)2D is influenced by maternal (15), placental (16), and fetal synthesis (17) of this 
hormone.
 
 
 
 At present the relative contributions of each source are unknown (18).  Data 
addressing relationships between maternal and neonatal 1,25(OH)2D have found that neonatal 
concentrations are approximately 46% lower than those observed in maternal circulation (19-21).  
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Similarly, neonatal PTH concentrations are approximately 26% lower than, but not correlated 
with, maternal PTH concentrations at birth (19).   
In an attempt to address gaps in knowledge in this area, we undertook a longitudinal 
study to assess temporal changes and interrelationships among 25(OH)D, 1,25(OH)2D, PTH and 
Ca intake across pregnancy. This study was undertaken in a large cohort of racially and 
ethnically diverse pregnant adolescents; a group that may have additional Ca demands of 
maternal growth superimposed upon those of fetal skeletal mineralization.  The impact of 
maternal hormonal status on neonatal calcitropic hormone status at birth was also explored.   
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MATERIALS AND METHODS     
Participants and Study Procedures 
A cohort of 171 pregnant adolescents (≤ 18 y) was recruited to participate in this 
prospective longitudinal study.  Thirteen participants were recruited from the Maternity Center 
East Clinic in Baltimore, MD, and followed until delivery at Johns Hopkins Hospital (Baltimore, 
MD).  All other study volunteers (n = 158) were recruited from the Rochester Adolescent 
Maternity Program (RAMP) clinic in Rochester, NY.  Pregnant adolescents were eligible to 
participate if they were between 12 and 30 weeks gestation at entry into the study, were 
otherwise healthy, and were carrying a single fetus.  Exclusion criteria included known medical 
complications such as: HIV infection, diabetes, diagnosed eating disorders, or malabsorption 
diseases.  Informed written consent was obtained from all participants, and study procedures 
were approved by the Institutional Review Boards of the University of Rochester, Cornell 
University, and Johns Hopkins University.  Maternal race, ethnicity, pre-pregnancy weight, and 
smoking history were self-reported.  Infant race was classified as African American if the mother 
reported both herself and the father as African American; as Caucasian if the mother reported 
both herself and the father as Caucasian; or biracial if maternal and paternal race differed.  Infant 
ethnicity was similarly classified as either: Hispanic, Non-Hispanic, or multi-ethnic.     
Each adolescent was asked to attend up to three study visits across pregnancy at early, 
mid, and late gestation.  At each study visit, maternal anthropometrics were recorded and a 24-
hour dietary recall, prenatal supplement survey, and physical activity survey administered.  At 
birth, maternal weight and infant weight and length were recorded by clinical staff using 
standard procedures.  
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Dietary and Physical Activity Assessment 
Dietary recall data were obtained at each study visit by study personnel utilizing food 
models to help estimate portion sizes.  All 24-hour recalls were analyzed by a registered dietitian 
using the Nutrition Data System for Research (NDSR: University of Minnesota, Minneapolis, 
MN, versions 2006, 2008, and 2009) in the Clinical Research Center at the University of 
Rochester (Rochester, NY).  To assess overall physical activity, the adolescent self-reported her 
previous day’s physical activity in 30-minute intervals using a previous day physical activity 
report (PDPAR) validated for students in grades 7-12 (22).  A physical activity score was 
calculated from this survey.     
Biochemical analyses 
Maternal blood (10 mL) was obtained at mid-gestation (~26 weeks) and at delivery, and a 
10 mL cord blood sample was obtained at delivery. Serum was separated and stored at -80
0 
C 
until analysis.  Season of each blood collection was classified as winter (November-February), 
spring (March-April), summer (May-August), or autumn (September-October), using similar 
seasonal classification groupings utilized in other studies undertaken in the northeastern United 
States (23).   
In each serum sample collected, serum total Ca concentration was measured using a 
Modular (P) Chemistry Automated System (Roche Diagnostics, Indianapolis, IN) and 25(OH)D 
was measured using the Diasorin RIA (Diasorin Inc, Stillwater, MN) by Quest Laboratories. This 
laboratory participates in the vitamin D External Quality Assessment Scheme (DEQAS).  
Vitamin D deficiency was defined as 25(OH)D < 10 ng/mL and vitamin D insufficiency as 
25(OH)D ≤ 20 ng/mL (14).  After a high prevalence of vitamin D insufficiency was observed in 
the first 45 participants, all subsequent adolescents found to be vitamin D insufficient at mid-
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gestation were provided a bottle of daily supplements containing 400 IU of vitamin D3 at their 
next prenatal visit, to take daily over the remainder of gestation.  Calcitriol (1,25(OH)2D) was 
analyzed at Boston University in the lab of Dr. Michael Holick (Boston, MA) using an in-house 
thymus receptor binding assay as previously described (24).  Intact PTH (iPTH) and leptin were 
analyzed using commercially available ELISAs (DSL Laboratories, Webster, TX and Millipore, 
Billerica, MA, respectively).  Elevated PTH was defined if PTH concentrations were ≥ 46 pg/mL 
(11).   
Statistical Analyses 
Analyses were performed using SAS 9.2 and JMP 8.0 (SAS Institute Inc, Cary, NC).  
Results are reported as the mean ± standard deviation (SD) unless otherwise stated.  Paired t-tests 
or non-parametric tests were used to assess changes in hormones across gestation within 
subjects.  Independent t-tests or ANOVA were used to determine if normally distributed 
variables differed by either race, season, or tertiles of Ca intake; the Wilcoxon Rank sum test was 
utilized for nonparametric data.  Differences in 25(OH)D, PTH, and 1,25(OH)2D between mid-
gestation, delivery, and cord blood within subjects were tested, controlling for participant ID as a 
fixed effect and utilizing a Tukey correction.  Simple linear regression was used to assess 
relationships among 25(OH)D, PTH, and 1,25(OH)2D at each time point.  Simple and multiple 
linear regressions were used to model statistical predictors of circulating 25(OH)D, PTH, and 
1,25(OH)2D in the adolescent and neonate.  Variables were tested for normality using the 
Shapiro Wilks test.  Non-normally distributed variables were log transformed as necessary to 
ensure normality of the residuals.  P values < 0.05 were considered significant, and P values 
between 0.05 and 0.10 were identified as trends of interest.   
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RESULTS 
Subject Characteristics 
Characteristics of the study population as a whole, and when stratified by race are 
presented below in Table 2.1.   
 
Table 2.1.  
Characteristics of Pregnant Adolescents and their Neonates at Birth
1
  
Subject Characteristics All Subjects 
 
African American 
Adolescents 
Caucasian 
Adolescents 
Total Recruitment 168 66.1% (111) 33.9% (57) 
Age at Enrollment (years) 17.1 ± 1.1 (167) 17.1 ± 1.2 (110) 17.2 ± 0.9 (57) 
Hispanic 
Non-Hispanic 
24.1 %  (39) 
75.9%  (123) 
6.6 % (7)
2
 
93.4% (99) 
57.1 % (32) 
42.9 % (24) 
Ca Intake (mg/day) 913 ± 414 (162) 886 ± 421 (106) 963 ± 400 (56) 
Vitamin D Intake (µg/d) 5.4 ± 3.4 (162) 5.3 ± 3.4 (106) 5.7 ± 3.3 (56) 
Pre-Pregnancy BMI 
(kg/m
2
) 
24.7 ± 5.3 (163) 24.4 ± 5.1 (106) 25.2 ± 5.7 (57) 
Parity ≥ 1 9.2% (167) 9.1% (110) 9.3% (57) 
Gestational Age at 
Enrollment (weeks) 
22.1 ± 5.7 (165) 22.6 ± 5.8 (110) 21.1 ± 5.5 (57) 
Gestational Age at 
Delivery (weeks) 
39.2 ± 2.9 (162) 39.2 ± 2.8 (107) 39.2 ± 3.1 (55) 
Birth Weight (g) 3236 ± 592 (159) 3207 ± 607  (105) 3293 ± 561 (54) 
Preterm 8.6% (162) 8.4% (107) 9.1% (55) 
Birth Weight > 4500 8.8% (159) 9.5% (105) 7.4% (54) 
Birth Weight < 2500 6.29% (159) 5.71 (105) 7.41% (54) 
1
Data are reported as the Mean ± SD, or percentage, with the sample size in parentheses.  
2
Significantly different than Caucasians: p<0.0001.   
 
Biochemical samples were not obtained from two Baltimore participants and one 
Rochester participant.  Because vitamin D status in these adolescents was unknown, they were 
excluded from all analyses making the final sample size 168.  Data regarding circulating 
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concentrations of osteoprotegerin and markers of bone turnover in a subset of this cohort have 
been previously reported (25).  Two of the 168 participants self-identified their race as American 
Indian.   None of the race-specific analyses differed if data were analyzed with these two 
adolescents combined with either the African American or Caucasian cohort.  In order to 
collapse maternal race into a bivariate category, data from the two American Indian adolescents 
were included within the African American cohort.  Maternal age at enrollment into the study 
ranged from 13.6 to 18.7 years.  Gestational weight gain was 16.8 ± 8.0 kg on average (ranging 
from -2.3 to 43.1 kg).  The mid-gestation blood collection was obtained at 26.3 ± 3.6 weeks 
gestation, on average.  Length of gestation ranged from 20.7 to 43.0 weeks, and birth weight 
ranged from 1,054 to 4,705 g.  Infant sex did not differ by race, and 53.1% of infants were male.  
A significantly higher percentage of Caucasian participants self-identified as Hispanic (57.1%) 
compared to African American (6.6%) participants; p<0.0001.  Other than ethnicity, there were 
no other racial differences in maternal or infant characteristics including; length of gestation, 
birth weight, or rate of preterm, low birth weight (LBW: <2500g), or large for gestational age 
infants (LGA: >4500g) (Table 2.1). 
Dietary Intake 
Daily dietary caloric, vitamin D and Ca intakes recorded at different study visits across 
gestation did not significantly differ within subjects.  Thus, the mean intake of all study visits for 
each adolescent was used.  On average, adolescents consumed 2,320 ± 740 calories, of which of 
52%, 14% and 34% were obtained from carbohydrates, protein, and fat, respectively.  Calcium 
intake ranged from 257 to 3220 mg/day.  Only 29% of adolescents met the EAR for Ca (1100 
mg/day) and only 16% met the RDA (1300 mg/day) (14).  Vitamin D and Ca intake were both 
positively associated with the amount of calories consumed (p<0.0001, n = 162), and were also 
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highly correlated with each other (p<0.0001, R
2
 = 0.462, n = 162).  Dietary caloric, vitamin D, 
and Ca intake did not significantly differ as a function of maternal race.  Supplemental vitamin D 
was provided to 25(OH)D insufficient adolescents at 30.3 ± 3.5 weeks, on average.  Self-
reported data from the prenatal supplement survey indicated that only 8.9% of teens consumed 
the provided vitamin D3 supplement on a daily basis. 
Vitamin D Supplementation 
Supplemental vitamin D3 (400 IU/day) was offered to teens whose mid-gestation 
25(OH)D concentrations were ≤ 20 ng/mL, who had enrolled in the study after the first 45 
participants had enrolled.  Adolescents who received supplements (n = 49) were more likely to 
be African American (79.6% vs. 61.0%, p = 0.016), and had a higher pre-pregnancy BMI (25.9 ± 
5.7 vs. 24.2 ± 5.1 kg/m
2
, p = 0.050), but were otherwise similar in characteristics to the 
unsupplemented group.  Supplements were provided at 30.3 ± 3.5 weeks gestation.  Those who 
were vitamin D insufficient but did not receive supplements either joined the study before the 
supplements were provided (n = 19), failed to return to the clinic to receive the supplements (n = 
15), or refused to accept them (n = 4).  Self-reported data indicated that only 26.4% of 
adolescents consumed these supplements daily.   
Longitudinal Changes and Predictors of 25(OH)D, PTH, and 1,25(OH)2D 
The biochemical measures of calcitropic hormone status in these adolescents and their 
neonates are shown for the cohort as a whole, and when separated by maternal race in Table 2.2.  
Approximately 50% of adolescents were vitamin D insufficient (25(OH)D ≤ 20 ng/mL), with 
African American participants having a significantly higher prevalence of insufficiency 
compared to Caucasians at mid-gestation (p = 0.002) (Table 2.2).   
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Table 2.2.  
Serum Vitamin D and PTH concentrations across Gestation in Pregnant Adolescents 
and in their Neonates at Birth
1
 
 All Subjects African American Caucasian 
25(OH)D (ng/mL) 
Mid-Gestation € 
% ≤ 20 
(n) 
22.1 ± 10.2
a
 
52.4% 
(166) 
20.5 ± 9.9
a
 
60.6% 
(110) 
22.5 ± 9.8
a
 
35.7% 
(56) 
Delivery
 #
 
% ≤ 20 
(n) 
21.5 ± 11.6
 a
 
50.3% 
(137) 
19.8 ± 10.1
 a
 
54.0% 
(87) 
24.4 ± 13.4
 a
 
42.0% 
(50) 
Cord Blood
  € 
% ≤ 20 
(n) 
20.8 ± 10.2
 a
 
52.8% ≤ 20 
(123) 
16.6 ± 9.4
 a
 
61.5% 
(50) 
24.6 ± 10.6
 a
 
37.8% 
(45) 
PTH (pg/mL) 
Mid-Gestation
  
% > 46 
(n) 
28.7 ± 16.0
 a
 
12.1% 
(91) 
32.2 ± 18.2
 a 
19.6% 
(56) 
23.0 ± 9.4
 a 
0% 
(35) 
Delivery 
% > 46 
(n) 
45.1 ± 29.4
 b 
40.0% 
(80) 
47.1 ± 33.2
 b 
43.1% 
(51) 
41.5 ± 21.0
b 
34.5% 
(29) 
Cord Blood 
% > 46 
(n, % detectable) 
19.0 ± 12.1
 c 
0% 
(33, 37%) 
19.3 ± 12.2
 c 
0% 
(22, 39%) 
18.2 ± 12.5
 c 
0% 
(11, 33%) 
1,25(OH)2D (pg/mL) 
Mid-Gestation 
(n) 
117 ± 30
 a 
(100) 
118 ± 30
 a 
(63) 
115 ± 31
 a 
(37) 
Delivery 
#
 
(n) 
106 ± 31
 b 
(96) 
111 ± 31
 b 
(63) 
97 ± 29
 b 
(33) 
Cord Blood 
(n) 
48 ± 19
 c 
(74) 
48 ± 17
 c 
(49) 
46 ± 23
 c 
(n = 25) 
1
Data are reported as the Mean ± SD, or percentage, with the sample size in parentheses.  
Mid-Gestation = 26.3 ± 3.6 weeks; Delivery = 39.2 ± 2.9 weeks. 
Races differ at the given time-point: 
#
: p < 0.05; 

: p < 0.01; 
€
: p < 0.001 
Different letter superscripts statistically differ within subjects, between Mid-Gestation, Delivery, and 
Cord Blood values; p < 0.05. 
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Trends in 25(OH)D, PTH, and 1,25(OH) 2D from mid-gestation to delivery as a function 
of race are depicted below in Figure 2.1.   
 
 
Figure 2.1 Temporal Trends in 25(OH)D, 1,25(OH)2D, and PTH Concentrations as a 
Function of Race in Pregnant Adolescents 
Temporal trends in 25(OH)D (ng/mL), PTH (pg/mL), and 1,25(OH)2D (pg/mL) from mid-
gestation (23.3 ± 3.6 weeks) to delivery (39.2 ± 2.9 weeks). Caucasians had higher 
concentrations of 25(OH)D at both mid-gestation and delivery (a: p <0.0001).  Serum PTH was 
higher in African American adolescents at mid-gestation (a: p <0.0001), and increased from mid-
gestation to delivery in both races (c: p <0.0001).  Serum 1,25(OH)2D decreased from mid-
gestation to delivery in both races (c: p <0.0001), and was higher in African Americans at 
delivery (b: p < 0.040).  The mean change in all three measures from mid-gestation to delivery 
did not significantly differ between the African American and Caucasian adolescents. 
 
 
Maternal race and season of blood collection were both associated with maternal 
25(OH)D at mid-gestation and at delivery.  Caucasians had higher 25(OH)D at both time-points 
(mid-gestation: p < 0.0005, delivery: p = 0.034), and 25(OH)D was higher in the summer versus 
the winter (p < 0.040).  Physical activity score at mid-gestation was positively associated with 
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maternal 25(OH)D status at mid-gestation (p = 0.005, R
2
 = 0.049), and delivery (p = 0.014, R
2
 =  
0.045).  Adolescents consuming Ca intakes within the third tertile (> 1060 mg/d) had 
significantly higher 25(OH)D at mid-gestation (p = 0.034) and at delivery (p = 0.006).  Vitamin 
D intake during pregnancy was positively associated with 25(OH)D status at delivery only (p = 
0.004, R
2
 = 0.062).  Maternal 25(OH)D concentrations were inversely related to maternal weight 
at mid-gestation (p = 0.034, R
2
 = 0.027), but not at delivery.  Maternal age, BMI, weight gain, 
and leptin concentrations were not significantly associated with 25(OH)D in maternal circulation 
at either time point.  Teens who received vitamin D supplements continued to exhibit 
significantly lower 25(OH)D concentrations at delivery (17.9 ± 7.3 ng/mL vs. 23.1 ± 13.0 
ng/mL, p = 0.001) and a higher prevalence of vitamin D insufficiency (63.3% vs. 44.4%, p = 
0.03) at delivery compared to unsupplemented teens.   
In the cohort as a whole, concentrations of 25(OH)D did not significantly differ within 
subjects between the mid-gestation and delivery measures, and the average change over the 12.9 
± 4.4 weeks study interval was -0.5 ± 11.7 ng/mL.  The change in 25(OH)D concentrations in 
those who received supplements (3.2 ng/mL, n = 45) was significantly higher than the change 
observed in unsupplemented adolescents (-2.3 ng/mL, n = 90, p = 0.0002).  Among non-
supplemented adolescents only, the change in 25(OH)D from mid-gestation to delivery was 
larger in those who delivered in the summer and autumn compared to those who delivered in the 
spring (p = 0.020, n = 90).  
PTH at mid-gestation was significantly lower in Caucasians (p = 0.012), but this 
difference was not evident at delivery.  PTH was not associated with gynecological age or Ca 
intake and did not differ between teens who received and did not receive vitamin D 
supplementation at any time point measured.  At mid-gestation, 12.1% of adolescents exhibited 
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elevated PTH (≥ 46 pg/mL) and PTH concentrations were significantly higher in African 
American adolescents compared to Caucasians, by 9.2 pg/mL (Table 2.2).  Over the average ~13 
weeks that elapsed between the mid-gestation and delivery blood draw, PTH increased 
significantly by 16.3 ± 26.6 pg/mL, (p<0.0001) in the cohort as a whole.  This increase was 
significant in both the Caucasian and African American cohorts (p<0.001), and the magnitude of 
increase did not differ by race (Figure 2.1), Ca or vitamin D intake, receipt of vitamin D 
supplementation, or season of blood draw.  By delivery, the prevalence of elevated PTH had 
more than doubled, reaching 40.0%.   
Caucasian teens had significantly lower 1,25(OH)2D than African American adolescents 
at delivery (p = 0.037) (Table  2.2).  Calcitriol at delivery was significantly higher in adolescents 
who received vitamin D supplements compared to those who did not (115.8 ± 32.3 vs. 100.9 ± 
28.6 pg/mL, p = 0.036).  Calcitriol at mid-gestation was positively associated with pre-pregnancy 
BMI (p = 0.028, R
2
 = 0.022) and maternal weight at the time of blood collection (p = 0.010, R
2
 = 
0.065).  Calcitriol at mid-gestation was also positively associated with estradiol (p = 0.010, R
2
 = 
0.065) and with gestational age over the ~17 week interval across which this blood collection 
was obtained (p < 0.001, R
2
 = 0.108).  When both estradiol and gestational age were entered as 
covariates into a model predicting 1,25(OH)2D at mid-gestation, only gestational age remained a 
significant predictor of 1,25(OH)2D.   Calcitriol was unrelated to maternal age or Ca or vitamin 
D intake at any time point measured.   
 Calcitriol decreased on average by 10.9 ± 34.9 pg/mL (5.0 ± 32%) from mid-gestation to 
delivery.  The decrease was significant (p = 0.005) in the cohort as a whole, and within each race 
individually (Table 2.2).  While 1,25(OH)2D was significantly higher in African American 
adolescents at delivery, the observed decrease in calcitriol did not significantly differ by race 
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(Figure 2.1), or as a function of average Ca or vitamin D intake, season of blood collection, or 
receipt of vitamin D supplements.  The decrease in 1,25(OH)2D was larger in adolescents with 
25(OH)D > 20 ng/mL at delivery compared to those with insufficient 25(OH)D (p = 0.033).  The 
analogous non-significant trend also existed at mid-gestation between those who were 25(OH)D 
sufficient vs.  insufficient (p = 0.057). 
Relationships among 25(OH)D, PTH, and 1,25(OH)2D in Maternal Circulation 
Possible associations between maternal 25(OH)D status and calcitropic hormone 
concentrations were explored.  A significant increase was observed across pregnancy in the 
prevalence of elevated PTH in adolescents who were 25(OH)D sufficient (Figure 2.2).   
 
 
Figure 2.2 Prevalence of Elevated PTH by Categories of 25(OH)D at Mid-Gestation and at 
Delivery  
The prevalence of elevated PTH (≥ 46 pg/mL) increased from mid-gestation (23.3 ± 3.6 weeks) 
to term (39.2 ± 2.9 weeks), and was detected in adolescents with replete 25(OH)D at delivery. 
The number of adolescents in each 25(OH)D category are indicated within each column.  At 
mid-gestation, there were 30 adolescents with 25(OH)D > 30ng/mL, none of these teens 
exhibited elevated PTH (indicated by the asterisk). 
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At mid-gestation, 9.9% of adolescents with suboptimal 25(OH)D exhibited elevated PTH, and 
2.2% of adolescents with 25(OH)D > 20 ng/mL exhibited elevated PTH.  These percentages 
increased to 22.5% and 17.5%, respectively at delivery (Figure 2.2).  At mid-gestation and at 
delivery, PTH was inversely associated with 25(OH)D in maternal circulation (mid-gestation: p 
= 0.023, R
2
 = 0.057, n = 91, and delivery: p = 0.003, R
2
 = 0.068, n = 80) (Figure 2.3a).  When 
analyzed separately by race, the negative relationship between 25(OH)D and PTH was 
significant only among African American adolescents, both at mid-gestation (p = 0.047, R
2
 = 
0.071, n = 56 vs. p = 0.340, n = 35) and at delivery (p = 0.008, R
2
 = 0.133, n = 51 vs. p = 0.573, 
n = 29).  However, this racial dichotomy appeared to be driven by vitamin D insufficiency; as the 
negative relationship between 25(OH)D and PTH was detected  in adolescents of both races who 
exhibited mid-gestation 25(OH)D insufficiency, but not among those with 25(OH)D > 20 ng/mL 
(mid-gestation: p = 0.0243, R
2
 = 0.110, n = 46 vs. p = 0.625, n = 45, and delivery: p = 0.036, R
2
 
= 0.106, n = 42 vs. p = 0.382, n = 38).  In contrast, the relationship between 25(OH)D and PTH 
did not differ when analyzed separately in adolescents above and below the median Ca intake 
(860 mg/d), nor did it differ when assessed as a function of  maternal calcitriol concentration 
above and below the mean observed at mid-gestation (117 pg/mL) or delivery (106 pg/mL) nor 
was it impacted by maternal receipt of vitamin D supplements.   
In addition to the association noted between 25(OH)D and PTH, maternal concentrations 
of 25(OH)D at mid-gestation (26.3 ± 3.6 weeks) were also inversely associated with 1,25(OH)2D 
concentrations at delivery (p = 0.032, r = -0.221, n = 95) (Figure 2.3b).  This relationship was 
not impacted by race or Ca intake and remained significant when examined separately among 
those with 25(OH)D above and below 20 ng/mL, or separately in either the African American or 
Caucasian cohort.  Paradoxically, serum PTH was not related to 1,25(OH)2D at any time point.   
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Figure 2.3 Relationships Between Maternal 25(OH)D at Mid-Gestation, PTH at Mid-
Gestation, and 1,25(OH)2D at Delivery in Pregnant Adolescents                     
A: At mid-gestation (23.3 ± 3.6 weeks) the Ln(PTH, pg/mL) was inversely associated with the 
Ln(25(OH)D, ng/mL): p = 0.023, n = 91, R
2
 = 0.057.  The untransformed relationship is 
presented for ease of interpretation.  This relationship was maintained at delivery (data not 
shown: p = 0.019, n = 80, R
2
 = 0.068).  B: Mid-gestation 25(OH)D concentrations were inversely 
associated with 1,25(OH)2D concentrations at delivery: p = 0.032, n = 95, R
2
 = 0.049.   
 
Predictors of Hormonal Status of the Neonate at Birth and Relationships with Maternal Status 
At birth, neonates born to Caucasian mothers had significantly higher cord 25(OH)D 
concentrations than those born to African American mothers (p = 0.001).  In the cohort as a 
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whole, 16.8% of neonates were vitamin D deficient (25(OH)D < 10 ng/mL), and 52.8% of 
neonates were vitamin D insufficient (25(OH)D ≤ 20 ng/mL).  Vitamin D deficiency and 
insufficiency were more prevalent in neonates born to African American adolescents than among 
those born to Caucasian teens (p = 0.007).  Neonatal 25(OH)D was highly correlated with 
(p<0.0001), and did not significantly differ from maternal concentrations of 25(OH)D at mid-
gestation or at delivery.  Similar to maternal 25(OH)D, cord 25(OH)D concentrations were 
positively related to maternal physical activity score at mid-gestation (p = 0.020, R
2
 = 0.045), 
maternal vitamin D intake (p = 0.015, R
2
 = 0.049), and maternal Ca intake (p = 0.002, R
2
 = 
0.076).   
PTH was undetectable (< 10 pg/mL) in 63.3% of cord blood samples assessed and no 
elevated values (≥ 46 pg/mL) were observed in samples that had detectable PTH.  Neonates with 
detectable concentrations of PTH in cord blood did not differ from those with undetectable 
values in terms of race, gestational age, birth weight, maternal Ca or vitamin D intake, or 
maternal 25(OH)D, PTH, or 1,25(OH)2D concentrations.  Cord blood PTH was significantly 
lower than (p<0.001), but unrelated to maternal concentrations at mid-gestation and delivery.  
Neonatal PTH concentrations did not differ by race, season of delivery, or maternal Ca or 
vitamin D intake.         
Calcitriol measures were obtained in 100 neonates at delivery.  Neonatal serum 
1,25(OH)2D averaged 58.5 ± 34.1 pg/mL and was 49.3% lower than maternal concentrations at 
delivery (p <0.0001).  Neonatal concentrations remained significantly lower than maternal 
concentrations when examined within each racial cohort individually (p <0.0001).  While 
significantly lower, cord blood concentrations of 1,25(OH)2D were unrelated to maternal 
concentrations at mid-gestation or at delivery.  Neonatal 1,25(OH)2D concentrations were  
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negatively correlated with gestational age at delivery (35.1 – 41.9 weeks) across the 6.8 week 
range observed in this cohort (p = 0.035, R
2
 = 0.061).  No other study variables were 
significantly associated with neonatal 1,25(OH)2D concentrations.   
Of the neonates with detectable PTH in cord blood (n = 33), no significant relationships 
between PTH and either maternal or neonatal 25(OH)D or 1,25(OH)2D were evident.  Neonatal 
25(OH)D was inversely associated with maternal concentrations of PTH both at mid-gestation (p 
= 0.0005, R
2
 = 0.143, n = 82) and at delivery (p = 0.004, R
2
 = 0.104, n = 76). 
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DISCUSSION   
 Vitamin D insufficiency was prevalent in this group of racially diverse pregnant 
adolescents.  Of note, PTH concentrations increased significantly across gestation in both races, 
and were inversely related to 25(OH)D at both mid-gestation and at delivery.  Maternal 
25(OH)D at mid-gestation was also significantly inversely related to 1,25(OH)2D at delivery.  
These relationships suggest that 25(OH)D status may have an impact on calcitropic hormone 
regulation during pregnancy.   
  The high prevalence of vitamin D insufficiency observed (~50%) was similar to other 
reports among pregnant women (26) and African American adolescents (27) in the northeastern 
United States.  The expected racial and seasonal differences in 25(OH)D were observed in these 
adolescents.  Both dietary intake of vitamin D and mid-gestation activity score (likely a proxy for 
sun exposure) were positively associated with maternal 25(OH)D concentrations, indicating that 
both  intake and endogenous production of vitamin D contributed to circulating 25(OH)D in this 
population as a whole.  However, the change in 25(OH)D status only differed by season in 
adolescents who did not receive vitamin D supplements, indicating that provision of daily 400 IU 
of vitamin D3 blunted the effect of season on 25(OH)D in those with suboptimal concentrations.  
However, although supplemented teens exhibited a significantly greater increase in 25(OH)D 
over the final 13 weeks of pregnancy, they still exhibited a significantly higher prevalence of 
insufficiency at delivery compared to those who did not receive supplements.  We are unable to 
assess whether the amount of total vitamin D provided from diet and supplements was 
inadequate, or if compliance with the supplements provided was poor.  
Of particular note, serum PTH concentrations and the prevalence of elevated PTH in this 
group increased from mid-gestation to delivery, an effect that was independent of race and 
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vitamin D supplementation.  Few other studies have reported an increase in PTH across gestation 
(4;9) or documented elevated PTH concentrations during pregnancy (11).  Circulating PTH may 
increase during pregnancy to stimulate renal Ca conservation in women with suboptimal Ca 
intake (28), but increases in this hormone were independent of dietary Ca intake in these 
adolescents.  It is possible that the unique Ca challenges, coupled with the suboptimal 25(OH)D 
status in this pediatric population may be partially responsible for our findings of increasing and 
elevated PTH that have not been reported in other published data from well-nourished adults.  
There are limitations to the assessment of PTH status from a single serum sample at mid-
gestation, and at delivery.  Serum used for PTH analyses must be frozen quickly after collection 
as PTH degrades quickly.  However, increased degradation would only have diluted our ability 
to detect elevated intact PTH in this population.  Parathyroid hormone does exhibit diurnal 
variation in its secretion pattern, and we did regulate the time of blood collection.  However, 
PTH secretion peaks between 1:30 and 4:10 am in pre-menopausal non-pregnant women (29) 
and we obtained all mid-gestation blood samples at prenatal care appointments.  Blood 
collections obtained at delivery were obtained at all times of day, when the adolescent was 
admitted for delivery of her infant.  However, the amplitude of PTH secretion over the course of 
24 hours is only 3.8 pg/mL (29), and thus variation in time of collection was unlikely to have 
inflated the prevalence of elevated PTH detected either at mid-gestation or at delivery.    
Although PTH was not associated with dietary Ca intake, PTH was significantly 
inversely associated with maternal 25(OH)D at both time-points.  This inverse relationship has 
been documented in other studies conducted in non-pregnant adults and adolescents (30;31).  In 
adults, some studies have noted an inverse relationship between 25(OH)D and PTH until a 
minimum threshold level of 25(OH)D is achieved (31), but the inflection point at which this 
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association is evident remains unclear (14).  In our adolescents, there did appear to be a 
threshold-type relationship, in that PTH was inversely related to 25(OH)D concentrations in 
adolescents of both races when 25(OH)D concentrations were ≤ 20 ng/mL.  It is possible that the 
negative relationship between 25(OH)D and PTH in African Americans, but not in Caucasians, 
was driven by the lower 25(OH)D status of the African American cohort given that this 
relationship was evident in all vitamin D insufficient teens, irrespective of race.  A similar 
inverse relationship between 25(OH)D and PTH has been detected in non-pregnant adolescents 
consuming Ca intakes similar to our cohort (30).  In that study it was postulated that PTH 
secretion was increased in the context of insufficient 25(OH)D to accommodate the demands of 
growth (30).  A similar mechanism may be present among our vitamin D insufficient teens in 
order to meet the combined Ca demands of both maternal and fetal growth.      
 This is the largest longitudinal study to asses 1,25(OH)2D at multiple time points across 
pregnancy in an adolescent cohort.  The 1,25(OH)2D concentrations we observed are lower than 
reported in a group of 10 pregnant Nigerian adolescents assessed during the third trimester of 
pregnancy (137 ± 31 pg/mL) and at term (130 ± 38 pg/mL) (19), and are also lower than reported 
among a cohort of 20 Gambian women at 20 weeks gestation (143 ± 48 pg/mL) (32).  However, 
the calcitriol concentrations we reported are higher than other data from healthy pregnant adult 
women (50 ± 9 pg/mL at 33 weeks gestation, n = 26 and 82 ± 31 pg/mL at 34-36 weeks 
gestation, n = 14) (3;7).  Because no standard reference materials exist for 1,25(OH)2D, it is 
difficult to interpret absolute values between studies.   
We noted a positive relationship between maternal 1,25(OH)2D concentration at mid-
gestation and the gestational age of the blood collection, across the 16.1 week window over 
which the mid-gestation measure was obtained.  This increase over mid-gestation is consistent 
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with previous studies (3).  In our adolescent cohort, 1,25(OH)2D concentrations decreased 
significantly by 5% over the last trimester of pregnancy.  This differs from some reports of no 
change in 1,25(OH)2D across the last trimester of pregnancy (2;33), but is consistent with other 
studies that have documented a trend for a decrease in this hormone late in gestation, ranging 
from 5.1 – 16.7% (8;19).  Because the average 1,25(OH)2D concentration we observed at mid-
gestation was relatively high, even with the observed 5% decrease, average delivery 
concentrations remained over 100 pg/mL.  While the observed decrease did not significantly 
differ between the races, 1,25(OH)2D concentrations in Caucasian adolescents were significantly 
lower than observed in the African American adolescents at delivery.  Pregnant African 
American women have been shown to have significantly higher 1,25(OH)2D3 and tend to have 
higher total 1,25(OH)2D than Caucasian counterparts at term (34).  Similarly, higher 1,25(OH)2D 
concentrations have been reported among African American vs. Caucasian non-pregnant 
adolescent females (35).  The physiological relevance of the observed 13.7 pg/mL difference in 
1,25(OH)2D between our African American and Caucasian adolescents is unknown.  We did not 
measure vitamin D binding protein (DBP) in this cohort, and are thus unable to assess the degree 
to which  the observed differences in total 1,25(OH)2D are related to concentrations of free 
1,25(OH)2D.  In general, pregnancy has been associated with increases in DBP, total, and free 
1,25(OH)2D concentrations (36;37).  Because it is the free form that is hormonally active and 
crosses the placenta (36), future research on changes in bound and free 1,25(OH)2D across 
pregnancy are warranted. 
 A greater decrease in 1,25(OH)2D was observed among teens with sufficient 25(OH)D at 
delivery which is consistent with the inverse relationship observed between 25(OH)D at mid-
gestation and 1,25(OH)2D at term.  This relationship may be a potential source of the observed 
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racial difference in 1,25(OH)2D detected at delivery, as the African Americans had lower 
25(OH)D concentrations than the Caucasians at mid-gestation.  The mechanisms responsible for 
this observation are not known.  Prior work in rats fed a vitamin D deficient diet found D 
deficiency to result in a time-delayed 30-fold increase in the activity of the 1α-hydroxylase 
enzyme in renal mitochondria (38).  Thus, it is possible that the chronic suboptimal 25(OH)D 
status of our population impacted 1α-hydroxylase activity and renal calcitriol secretion.  It has 
also been postulated that high serum 1,25(OH)2D during pregnancy may suppress 25(OH)D 
production via 1,25(OH)2D-mediated increased transcription of the 24-hydroxylase gene (39).  A 
recent meta-analyses designed to address this hypothesis during pregnancy found no relationship 
between 25(OH)D and 1,25(OH)2D (39), but this study contained few longitudinal data, limiting 
the ability to detect relationships between 25(OH)D and 1,25(OH)2D that may be time-delayed.  
In a recent study by Hollis et al., a positive relationship was noted between 25(OH)D and 
1,25(OH)2D, indicating that 1,25(OH)2D concentrations increased as 25(OH)D increased until a 
threshold of 40 ng/mL was achieved (40).  In that study (mean age = 27 y), 25(OH)D was 
increasing as pregnancy progressed due to the vitamin D supplementation all women received.  It 
is possible that different physiological relationships regulate 1,25(OH)2D production when 
25(OH)D is suboptimal and remains low as pregnancy progresses.  Because our study was 
observational, we are unable to establish the causal direction of the observed relationships 
between 25(OH)D and 1,25(OH)2D or between 25(OH)D and PTH.    
 It is noteworthy that serum 1,25(OH)2D concentrations were not significantly impacted 
by habitual Ca intake across the observed 257 - 3220 mg/day range in dietary intake.  Calcitriol 
concentrations were also not significantly related to PTH concentrations at any time-point 
studied.  Future research is needed to characterize the relative contribution of extra-renal tissues, 
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such as the placenta, to circulating 1,25(OH)2D.  Additionally, the role of other potential 
regulators of the 1α-hydroxylase enzyme during pregnancy (such as PTHrP (28) and FGF23 
(41)) should be examined in order to more fully explore both the regulation and role of 
1,25(OH)2D concentrations across pregnancy.     
As expected, there were no significant differences between maternal and neonatal 
25(OH)D concentrations.  Neonates born to African American adolescents had lower 
concentrations than neonates born to Caucasian adolescents, as has been previously reported 
(11;34;42).  While the fetus is solely dependent on maternal supply of 25(OH), it is capable of 
endogenous PTH and 1,25(OH)2D synthesis (43;44).  We observed no associations between 
maternal and neonatal concentrations of PTH or 1,25(OH)2D.  Infant calcitriol values were 
significantly lower than maternal values, as has been reported in other smaller studies (n = 10-25 
dyads) of this relationship (21;42;45).  In contrast to the associations noted in the pregnant 
adolescents, neonatal 1,25(OH)2D and PTH concentrations were not associated with neonatal 
25(OH)D concentrations and did not significantly differ as a function of race.  
We have demonstrated that PTH increases across gestation in pregnant adolescents, and 
is impacted by systemic 25(OH)D concentrations.  A negative relationship between 25(OH)D at 
mid-gestation and 1,25(OH)2D at delivery was also found. These data suggest that low 25(OH)D 
may impact calcitriol or PTH synthesis or conversely that calcitriol and PTH concentrations may 
impact metabolism of 25(OH)D.  These data in this group of pregnant adolescents add to our 
understanding of the calcitropic hormone responses to pregnancy, and speaks to the importance 
of maintaining optimal vitamin D status across pregnancy.  Further work addressing the impact 
of these hormones on maternal and fetal bone turnover is warranted.    
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CHAPTER 3 
 
MATERNAL VITAMIN D STATUS AND CALCIUM INTAKE INTERACT TO 
IMPACT FETAL SKELETAL GROWTH IN PREGNANT ADOLESCENTS* 
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Witter, Z Leah Harris, Kimberly O O’Brien.  Maternal Vitamin D and Calcium Interact to 
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ABSTRACT 
Background: Maternal calcium (Ca) intake and vitamin D status may impact fetal bone 
development.   
Objective:  This study was designed to examine relationships between maternal Ca intake, 
25(OH)D status and fetal bone growth across pregnancy. 
Design:  This was a prospective longitudinal design.  Maternal 25(OH)D, PTH, and 1,25(OH)2D 
were determined at mid-gestation (~26 weeks) and at delivery in 171 adolescents (≤ 18y).  
Dietary recalls and fetal sonograms were performed up to three times across gestation; fetal 
femur and humerus Z-scores were generated.  
Results:  Fetal femur and humerus Z-scores and neonatal birth length were significantly greater  
(p < 0.03) in adolescents consuming ≥1050 mg vs. those consuming <1050 mg Ca/day.  
Maternal 25(OH)D > 20 ng/mL was significantly positively associated with fetal femur and 
humerus Z-scores (p < 0.01).  When controlling for maternal smoking, height, race, weight gain, 
and gestational age, these relationships remained significant.  Interactions between Ca intake and 
25(OH)D were evident.  Calcium intake was only associated with fetal femur Z-scores and birth 
length when maternal 25(OH)D was ≤ 20 ng/mL (p < 0.05).  Similarly, maternal 25(OH)D was 
only associated with fetal femur and humerus Z-scores when maternal Ca intake was < 1050 
mg/day (p < 0.03).  
Conclusions:  Optimal Ca intake and adequate maternal vitamin D status are both needed to 
optimize fetal bone growth.  Interactions between these nutrients were evident when either Ca or 
vitamin D status was limited.  Optimizing maternal Ca intake and/or vitamin D status during 
pregnancy status may have a positive impact on fetal skeletal development in pregnant 
adolescents. 
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INTRODUCTION 
 The prevalence of vitamin D deficiency (25(OH)D ≤ 10 mg/mL) in pregnant women 
residing at northern latitudes has been reported to range between 21 to 50% (1-3);  an even larger 
number of women are vitamin D insufficient (25(OH)D ≤ 20 ng/mL) (3).  This high prevalence 
may be of concern given the number of reports linking insufficient vitamin D status during 
pregnancy with detrimental effects on fetal growth and development, and subsequent risk of 
chronic diseases (4).  Both vitamin D and Ca are needed to fully mineralize the developing 
skeleton.  Thus low Ca intake, especially when combined with insufficient vitamin D status, may 
limit fetal bone growth and mineralization (5). 
 To date, maternal 25(OH)D status during pregnancy has been linked to infant birth 
weight (6) and adverse neonatal bone outcomes, including impaired fetal femoral development 
(7), reduced bone mineral content (BMC), and reduced neonatal bone density at birth (8;9).  The 
bone alterations observed in-utero may impact subsequent pediatric bone mineralization as 
children whose mothers had low 25(OH)D status during pregnancy have reduced BMC at 9 y of 
age (10).   
 Like maternal vitamin D status, maternal Ca intake impacts fetal skeletal development.  
Supplemental Ca provided to women with low Ca intake (< 600 mg/day) resulted in increased 
bone density and total body BMC in the neonate (11;12).  In pregnant adolescents, maternal 
dairy intake has been positively associated with increased fetal femur length (13) and milk intake 
has been associated with infant total body Ca (14).  In adults, maternal milk and vitamin D intake 
have been found to be significantly associated with infant birth weight (15).  Additionally, 
maternal milk intake during pregnancy has been linked to subsequent spinal bone mineral 
density (BMD) of offspring  at 16 y of age (16).  In food-based Ca supplementation studies (i.e. 
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dairy products), it is difficult to distinguish whether it is the Ca and/or vitamin D or other 
components of dairy products that are impacting neonatal bone outcomes.  Similarly, many 
studies fail to control for possible interactions between maternal Ca intake and vitamin D status 
when investigating the impact of maternal status of these nutrients on neonatal outcomes.  These 
interactions are biologically plausible given that the active form of vitamin D, 1,25(OH)2D, is 
generated from 25(OH)D and this hormone stimulates active intestinal Ca absorption particularly 
when Ca intakes are low.  At present, few studies addressing the effects of maternal Ca intake 
and vitamin D status on fetal development have also measured circulating 1,25(OH)2D.  This is 
of concern as there is a growing awareness that local paracrine/autocrine effects of 1,25(OH)2D 
are influenced by circulating 25(OH)D (17).  
Pregnancy during adolescence may result in a competition for nutrients between the 
mother and her developing fetus, placing both at risk for adverse outcomes (18).  To address 
possible associations and interactions between maternal Ca intake and 25(OH)D status with fetal 
bone growth, we followed a large cohort of pregnant adolescents across gestation obtaining 
measures of fetal skeletal development in-utero in relation to maternal Ca intake, calcitropic 
hormones, and 25(OH)D status.    
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MATERIALS AND METHODS 
Participants and Study Procedures 
A cohort of 171 pregnant adolescents (≤ 18 y) was recruited to participate in a 
prospective longitudinal study designed to characterize changes in maternal bone quality and 
fetal bone growth across gestation.  Thirteen participants were recruited from the Maternity 
Center East Clinic in Baltimore, MD, and followed until delivery at Johns Hopkins Hospital 
(Baltimore, MD).  The remainder of the adolescents (n = 158) were recruited from the Rochester 
Adolescent Maternity Program (RAMP) in Rochester, NY.  Pregnant adolescents were eligible to 
participate if they were between 12 and 30 weeks gestation at entry into the study, were 
otherwise healthy, and were carrying a single fetus.  Exclusion criteria included known medical 
complications including: HIV infection, diabetes, diagnosed eating disorders, or malabsorption 
diseases.  Informed written consent was obtained from all participants, and study procedures 
were approved by the Institutional Review Boards of the University of Rochester, Cornell 
University, and Johns Hopkins University.  Maternal pre-pregnancy weight and smoking history 
were self-reported.  Smoking status was self-reported as never, previously, or currently smoking 
and information on the number of cigarettes smoked per day was obtained in those that were 
currently smoking.  Maternal ethnicity (Hispanic or Non-Hispanic) and race (African-American, 
Caucasian, or Other) were self reported.  Neonatal race was classified as African American if the 
mother reported both herself and the father as African American; as Caucasian if the mother 
reported both herself and the father as Caucasian; or biracial if maternal and paternal race 
differed.  Infant ethnicity was similarly classified as either: Hispanic, Non-Hispanic, or multi-
ethnic.  Data on markers of bone turnover and OPG concentrations (Appendix 11) and maternal 
calcitropic hormone concentrations (Chapter 2) in this cohort have been previously published. 
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Each adolescent attended up to three study visits across pregnancy, roughly timed to 
coincide with early, mid, and late gestation.  At each visit maternal anthropometric measures 
were recorded and a 24-hour dietary recall was administered by study personnel using food 
models to help estimate portion sizes.  All 24-hour recalls were analyzed by a registered dietitian 
using the Nutrition Data System for Research (NDSR: University of Minnesota, Minneapolis, 
MN, versions 2006, 2008, and 2009) at the University of Rochester CTRC.  Tertiles of dietary 
Ca intake were defined based on observed Ca intakes.   
Up to three times across pregnancy, both standard fetal biometry measures (femur length, 
biparietal diameter, abdominal circumference and head circumference) and humerus length were 
recorded by certified sonographers.  Fetal humerus length Z-scores were calculated from 
published curves generated by Chitty et al. in adult women (19).  Fetal femur length Z-scores 
were generated from equations previously published by our laboratory, derived from a large 
cohort (n = 929) of African-American pregnant adolescents in Baltimore, MD, USA (13).  The 
curves generated for fetal femur growth in these pregnant adolescents are comparable to similar 
curve fits generated from data obtained in adult women (13;19).  At birth, infant weight, length, 
and head circumference were recorded by clinical staff, according to standard procedures.   
Biochemical analyses 
Maternal blood (10 mL) was obtained at mid-gestation (~26 weeks) and again at delivery.  
All blood samples were allowed to clot at room temperature, before serum was separated by 
centrifugation.  An aliquot of serum was immediately sent to Quest laboratories for assessment 
of 25(OH)D using the Diasorin RIA (Diasorin Inc, Stillwater, MN).  This laboratory participates 
in the vitamin D External Quality Assessment Scheme (DEQAS) as a means of quality 
assurance.  Serum collected for other biochemical assessment was stored at -80
0
C until analysis.  
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Season of each blood collection was classified as winter (November-February), spring (March-
April), summer (May-August), or autumn (September-October) using seasonal classifications for 
the northeast United States (20).  Vitamin D insufficiency was defined as 25(OH)D ≤ 20 ng/mL  
in accordance with recent 2010 IOM guidelines (21).  After a high prevalence of vitamin D 
insufficiency was observed in the first 45 study participants, all subsequent participants found to 
be vitamin D insufficient at mid-gestation were provided with an additional 400 IU of vitamin D3 
at their next prenatal visit, and were instructed to take one pill daily over the remainder of 
gestation.  Compliance with all prenatal supplements provided was queried by self-report at each 
study visit.  Calcitriol (1,25(OH)2D) was analyzed at Boston University in the laboratory of Dr. 
Michael Holick (Boston, MA) using an in-house thymus receptor binding assay as previously 
described (22).  Due to the lack of standardized reference ranges for calcitriol concentrations 
across pregnancy, adolescents were classified as exhibiting 1,25(OH)2D concentrations above or 
below the mean 1,25(OH)2D value both at mid-gestation and at delivery.  Intact parathyroid 
hormone (PTH) was analyzed using a commercially available ELISA (DSL Laboratories, 
Webster, TX).  Elevated PTH was defined if concentrations were  ≥ 46 pg/mL (23).   
Statistical Analyses 
Analyses were performed using SAS 9.2 and JMP 8.0 (SAS Institute Inc, Cary, NC).  
Results are reported as the mean ± standard deviation (SD) unless otherwise stated.  Paired t-tests 
or non-parametric tests were used to assess changes in hormones across gestation within 
subjects.  Independent t-tests or ANOVA were used to determine if normally distributed 
variables differed by race, season, or categories of vitamin D status and Ca intake; the Wilcoxon 
Rank sum test was utilized for nonparametric data.   
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Simple linear regression was used to explore relationships among Ca intake, 25(OH)D, 
PTH, and 1,25(OH)2D and fetal skeletal growth.  Multiple linear regression was used to control 
for covariates and interactions between variables and to model statistical predictors of measures 
of fetal skeletal growth.  Previous research had identified maternal height, pre-pregnancy BMI, 
and dairy intake as predictors of fetal femur length in a group of 350 African American 
adolescents (13).  As such, we initially considered maternal height and pre-pregnancy BMI, as 
well as infant sex, season of delivery, maternal race, weight gain, smoking status, chronological 
age, and gynecological age as potential predictors of fetal femur and humerus Z-scores and 
neonatal birth length.  Using simple linear regression, maternal smoking status, race, height, 
weight gain, and gestational age at delivery (for birth length) were identified as potential 
statistical predictors (p < 0.20) of fetal femur and humerus Z-score and/or neonatal birth length.  
These variables were controlled for as covariates in the generated models of fetal bone Z-scores 
and birth length. 
Interactions between maternal Ca intake and vitamin D status on fetal and neonatal bone 
outcomes were assessed statistically.  Relationships between maternal Ca intake and bone 
outcomes were also analyzed stratified by categories of vitamin D status in order to describe the 
nature of interactions between Ca and vitamin D status (≤ 20 or > 20 ng/mL) on fetal and 
neonatal bone outcomes.  Similarly, relationships between maternal vitamin D status and fetal 
bone outcomes were analyzed when stratified by categories of Ca intake (tertiles or < 1050 vs. ≥ 
1050), in order to assess potential interactions between the two nutrients.   
Using published means and standard deviations for fetal femur length reported in 
pregnant adolescents (13), we determined that a sample size of 146 participants would provide us 
with sufficient power (0.85) to characterize the mean fetal femur lengths in this population and to 
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obtain a minimal detectable difference of 0.25 Z-scores from expected fetal bone measures, with 
an alpha level of 0.05.  We over-recruited by 14% to allow for missing data and possible subject 
loss to follow-up due to the known increased risk of fetal death in-utero and preterm birth in this 
age group.   Variables were tested for normality using the Shapiro Wilks test.  Non-normally 
distributed variables were log transformed as necessary to ensure normality of the residuals.  P 
values < 0.05 were considered significant, and P values between 0.05 and 0.10 were considered 
trends of interest.   
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RESULTS 
Subject Characteristics 
Characteristics of the adolescents are presented in Table 3.1.   
Table 3.1.  Characteristics of Pregnant Adolescents Enrolled  
Maternal Characteristics Mean ± SD (n) 
Total Recruitment 171 
Age at Enrollment (years) 17.1 ± 1.1 (170) 
Racial Group:  African American  
                        Caucasians  
66.7% (114) 
33.3% (57) 
Ethnicity:  Hispanic  
                  Non-Hispanic  
23.7% (39) 
76.2% (125) 
Parity ≥ 1 8.2% (14/170) 
Smoking at Entry into study 10.0% (17/170) 
Pre-Pregnancy BMI (kg/m
2
) 24.7 ± 5.5 (165) 
Weight Gain (lbs) 37.1 ± 1.5 (150) 
Dietary Ca Intake (mg/day)
1
 917 ± 416 (163) 
Dietary Vitamin D intake (IU/day)
1
 216 ± 135 (163) 
Gestational Age at Delivery (weeks) 39.2 ± 2.9 (165) 
Maternal 25(OH)D at Delivery (ng/mL) 21.9 ± 11.0 (168) 
Maternal 1,25(OH)2D at Delivery (pg/mL) 106.2 ± 30.6 (96) 
Maternal PTH at Delivery (pg/mL) 45.1 ± 29.4 (80) 
1 
Intakes presented are the mean of all 24-hour recalls administered over pregnancy (up to 
three for each participant) 
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Birth data was missing or unavailable in nine adolescents: of these three (1.8%) suffered a fetal 
death in-utero, while six adolescents either dropped out of the study prior to delivery or delivered 
at another hospital, so birth data was not obtained.  Among neonates assessed at delivery, birth 
length was recorded in the medial chart of 153 (94.4%) infants.  In 163 adolescents (95.3%), at 
least one dietary assessment was obtained during pregnancy, and 25(OH)D was assessed at least 
once across gestation in 168 (98.2%) study participants.  Gestational age at delivery ranged from 
20.7 to 43.0 weeks; 8.5% of births were premature (< 37 weeks gestation).  Two of the 171 
adolescents self-identified their race as American Indian.  None of the study results differed if 
these two adolescents were excluded from analyses or combined with either the African 
American or Caucasian cohort.  To avoid eliminating data from these two adolescents, they were 
grouped with the African American cohort in order to collapse maternal race into a bivariate 
variable. 
In adolescents with multiple 24-hour recall data, reported Ca, vitamin D, and caloric 
intake did not significantly differ between study visits, so the mean of all visits for each 
participant was used for all subsequent analyses.  Dietary Ca intake ranged from 257 to 3220 mg 
(Table 3.1), with only 29.4% of adolescents meeting the EAR (1100 mg/day) (21), and 15.3% of 
adolescents meeting the RDA (1300 mg/day).  Maternal vitamin D intake was highly correlated 
with Ca intake (p <0.0001, R
2
 = 0.40).  Because maternal 25(OH)D concentrations at mid-
gestation did not significantly differ from concentrations at delivery (p = 0.64), when 25(OH)D 
was not assessed at delivery (n = 31 out of 168), the 25(OH)D concentration obtained at mid-
gestation was substituted for this measure in order to have a measure of vitamin D status from 
each participant (Table 3.1).  Maternal vitamin D and Ca intake were both positively correlated 
with maternal 25(OH)D (p = 0.002, R
2
 = 0.06 and p = 0.004, R
2
 = 0.05, respectively, n = 162).  
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Vitamin D insufficiency (25(OH)D ≤ 20 ng/mL), was present in 47.6% of adolescents and 52.8% 
of neonates at birth.  Supplemental vitamin D3 (400 IU/day) was provided to 56% of teens whose 
mid-gestation 25(OH)D concentration was ≤ 20 ng/mL.  Those who were vitamin D insufficient 
and did not receive supplements either joined the study before the supplements were provided (n 
= 19), failed to return to the clinic to receive the supplements (n = 15), or refused to accept them 
(n = 4).  Vitamin D insufficient adolescents who received supplements began supplementation on 
average at 30.3 ± 3.5 weeks gestation.  Self-reported data indicated that 35.8% of these 
adolescents consumed the vitamin D supplement at least two times per week, and only 26.4% of 
adolescents self-reported that they consumed these supplements daily.  The change in 25(OH)D 
concentrations from mid-gestation to delivery observed in those who received supplements (3.2 
ng/mL, n = 45) was significantly different than the change observed in those who were not 
supplemented (-2.3 ng/mL, n = 90, p = 0.0002).  Despite this increase in 25(OH)D, teens who 
received vitamin D supplements still had significantly lower 25(OH)D concentrations (17.4 
ng/mL vs. 23.6 ng/mL, p = 0.001) and a higher prevalence of vitamin D insufficiency (63.3% vs. 
44.4%, p = 0.03) at delivery compared with teens who did not receive supplements.   When 
considered as a potential covariate, maternal receipt of vitamin D supplements was not 
significant in any models of fetal and neonatal skeletal outcomes. 
 Birth weight and length did not differ by maternal or infant race, infant sex, season of 
delivery, or receipt of vitamin D supplements.  Data from at least one sonogram was available in 
all but two adolescents.  The femur and humerus lengths from the last sonogram measure 
obtained (at 33.8 ± 4.0 weeks gestation) were used to generate gestational age-specific fetal bone 
Z-scores.  Humerus measures were not obtained from two adolescents due to position of the fetus 
at the time of measurement.  Fetal femur and humerus length Z-scores were both significantly 
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below zero (p <0.0001, n = 169 and p = 0.009, n = 167) and did not differ by maternal race 
(Table 3.2), infant race, infant sex, season of delivery, or receipt of vitamin D supplements, 
although there was a trend for higher fetal femur Z-scores in African American verses Caucasian 
adolescents (p = 0.054).  Fetal femur length Z-score in non-smoking adolescents was 
significantly more positive, by 0.424 SD, than in adolescents who were smoking (p = 0.030). 
 
Table 3.2.  Fetal and Neonatal Outcomes as a Function of Maternal Race
1
 
Neonatal 
Characteristics 
All 
Adolescents 
African 
American 
Caucasian p  
Birth Weight (g) 3238 ± 586  
(162) 
3210 ± 599 
(108) 
3293 ± 561 
(54) 
0.300 
Birth Length (cm) 51.0 ± 2.6  
(153) 
51.0 ± 2.6 
(102) 
51.2 ± 2.2 
(51) 
0.932 
Fetal Femur 
Length Z-Score 
-0.540 ± 0.918 
(169) 
-0.446 ± 0.917 
(114) 
-0.734 ± 0.897 
(55) 
0.054 
Fetal Humerus 
Length Z-Score 
-0.201 ± 0.971 
(167) 
-0.197 ± 1.024 
(112) 
-0.207 ± 0.865 
(55) 
0.950 
1
 Data presented as mean ± SD with sample size in parentheses 
p –values are for comparison between neonates born to African American vs. Caucasian 
adolescents. 
 
Maternal 1,25(OH)2D and PTH concentrations at mid-gestation and delivery were not 
significantly related to fetal femur, or humerus length Z-scores, or neonatal birth length.  
Furthermore, fetal femur and humerus Z-scores and neonatal birth length did not differ between 
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adolescents with elevated PTH vs. those with PTH < 46 pg/mL at either time point, or between 
adolescents with 1,25(OH)2D concentrations above vs. below the mean concentration observed 
at mid-gestation (116.9 pg/mL) or delivery (106.2 pg/mL). 
Maternal Ca Intake and Fetal Bone Outcomes    
Maternal Ca intake, as a linear variable, was not associated with fetal femur or humerus 
Z-score.  When the cohort was divided into tertiles of Ca intake (< 653; < 1066; ≥ 1066 mg/day), 
those in the highest tertile had a significantly more positive fetal femur length Z-score                
(p < 0.040), when compared to those in the lower two tertiles (Figure 3.1A).  The same trend 
was present for fetal humerus length Z-score but this difference only approached significance    
(p <0.070).  A marked difference in fetal bone Z-scores was evident between the second and 
third tertile of Ca intake (653 to 1066 mg/day).  To further define the Ca intake at which 
significant increases in fetal bone Z-scores became evident, possible differences in fetal bone Z-
scores were evaluated at 50 mg intervals across the Ca intake range of 653-1066 mg/day.  Using 
this approach, a Ca intake of ≥ 1050 mg/day was identified as the intake at which differences in 
both fetal femur length Z-score (-0.319 vs. -0.680, p = 0.020, n = 161) and fetal humerus length 
Z-score (0.003 vs. -0.337; p = 0.024, n = 159) became evident (Figure 3.1B).  The raw 
difference in fetal femur Z-score observed in those consuming < 1050 mg/day was equivalent to 
a 0.98 mm shorter femur at 33.8 weeks, which represents 1.5% of the mean predicted femur 
length at that week gestation.  The raw difference in fetal humerus Z-score observed in those 
consuming < 1050 mg/d was equivalent to a 0.92 mm shorter humerus at 33.8 weeks, which 
represents 1.6% of predicted humerus length at that week gestation.   
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Figure 3.1 Fetal Femur and Humerus Z-scores Differ by Maternal Calcium Intake  
Fetal femur and humerus length were evaluated by sonogram at 33.8 ± 4.0 weeks gestation in 
169 pregnant adolescents and Z-scores were calculated for each measure.  Ca intake was 
categorized into tertiles: 1
st
 < 653 mg/day; 2
nd
 = 653 - 1066 mg/day; 3
rd
 > 1066 mg/day.  A: 
Adolescents consuming within the third tertile of Ca intake had better fetal femur length Z-scores 
(p < 0.039) and tended to have better fetal humerus length Z-scores (# p < 0.070) compared to 
those in the first and second Ca tertile.  B: Between the second and third tertile of Ca intakes, the 
Ca intake of ≥ 1050 mg/day was identified as the intake at which significant differences in fetal 
femur (p = 0.020) and humerus (p = 0.024) Z-scores became evident.   
 
 
Multiple regression models of fetal femur and humerus Z-scores were generated to test 
the main effect of maternal Ca intake after controlling for the identified covariates: maternal 
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smoking status, race, height, and weight gain.  After controlling for these maternal 
characteristics, maternal Ca intake ≥ 1050 mg/day remained a significant predictor of fetal femur 
Z-score (parameter estimate = 0.009) and was associated with a 0.196 increase in fetal femur Z-
score.  Maternal Ca intake ≥ 1050 mg/day explained an additional 4% of the variation in femur 
Z-score (i.e, increased the R
2
 of the model from 0.031 to 0.068).  Similarly, when controlling for 
the identified covariates, maternal Ca intake ≥ 1050 mg/day also remained a significant predictor 
of fetal humerus length Z-scores (parameter estimate = 0.026).  In step-wise regression, all other 
covariates dropped out of the model of fetal humerus Z-score, and maternal Ca intake ≥ 1050 
mg/day was associated with a 0.180 increase in fetal humerus Z-score and predicted 3.2% of the 
variation in this measure. 
Maternal 25(OH)D status and Fetal Bone Outcomes    
 When analyzed as a continuous variable, maternal dietary vitamin D intake was 
significantly positively associated with fetal humerus Z-score (p = 0.015, R
2
 = 0.037, n = 158), 
but not with any other fetal/neonatal outcomes.  Maternal 25(OH)D is a biomarker for vitamin D 
status, and when analyzed as a categorical variable, pregnant adolescents with sufficient 
25(OH)D status (> 20 ng/mL) had significantly higher fetal femur and fetal humerus length Z-
scores compared to measures obtained in vitamin D insufficient adolescents (-0.321 vs. -0.746, p 
= 0.003, n = 166 and 0.012 vs. -0.403, p = 0.006, n = 164).  After controlling for maternal 
smoking status, race, height, and weight gain, maternal 25(OH)D sufficiency remained a 
significant predictor of fetal femur length Z-score (parameter estimate = 0.001) and was 
associated with a 0.225 increase in fetal femur Z-score.  Maternal 25(OH)D > 20 ng/mL 
explained an additional 6% of the variation in femur Z-score (i.e. increased the R
2
 of the model 
from 0.031 to 0.089).  Maternal 25(OH)D sufficiency also remained a significant predictor of 
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fetal humerus length Z-scores when controlling for identified covariates (parameter estimate = 
0.006).  In step-wise regression, all other covariates dropped out of the model of fetal humerus 
Z-score, and maternal 25(OH)D sufficiency was associated with a 0.208 increase in fetal 
humerus Z-score and predicted 4.5% of the variation in this measure.   
Interaction between Maternal Ca intake and 25(OH)D status on Fetal Bone Outcomes    
Because both maternal Ca intake ≥ 1050 mg/day and maternal 25(OH)D > 20 ng/mL 
were individually associated with fetal femur and humerus Z-scores, both of these variables, 
along with an interaction term were entered into a model to test for possible interactions between 
the effects of maternal 25(OH)D > 20 ng/mL and maternal Ca intake ≥ 1050 mg/day on fetal 
bone length.  In this combined model of fetal femur length Z-score, the main effect of Ca ≥ 1050 
mg/day,  the main effect of 25(OH)D sufficiency, and the interaction term between Ca intake and 
25(OH)D all remained significant (p < 0.05) (Table 3.3).  In the best model identified for 
humerus length Z-score, the main effect of maternal Ca intake ≥ 1050 was borderline significant 
(p < 0.10), the main effect of 25(OH)D sufficiency remained significant, and the interaction term 
was not significant.  These models are summarized in Table 3.3.  
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Table 3.3. Maternal Ca Intake and Vitamin D Sufficiency are Determinants of Fetal Femur and 
Humerus Z-scores in Pregnant Adolescents 
Covariate
1
 Fetal Femur Z-Score Fetal Humerus Z-score 
 β ± SE2 p β ± SE2 p 
25(OH)D < 20 ng/mL -0.1462 ± 0.0738 0.049 -0.1753 ± 0.0784 0.027 
Ca intake < 1050 mg/day - 0.1655 ± 0.0738 0.026 -0.1341 ± 0.0808 0.099 
25(OH)D X Ca intake
3
 -0.1628 ± 0.0739 0.029 - - 
Maternal Race (AA) 0.1744 ± 0.0741 0.020 - - 
Maternal Height (m) 0.0203 ± 0.0100 0.042 0.0166 ± 0.0109 0.130 
p < 0.0001 0.007 
R
2
 0.125 0.057 
n 160 158 
AA = African American 
1 
In step-wise regression, maternal weight gain and smoking status were not significant in models 
of either bone Z-score.  In step-wise selection, the interaction term and race were dropped from 
the model of fetal humerus Z-score. 
2 β ± Standard Error 
3 
Interaction term between maternal Ca intake and 25(OH)D status 
 
To further investigate the nature of the interaction between maternal Ca intake ≥ 1050 
mg/day and 25(OH)D sufficiency, the initial models of fetal femur and humerus length Z-scores 
that included Ca intake as a bivariate variable ≥ 1050 mg/day were run separately in adolescents 
with maternal 25(OH)D ≤ 20 ng/mL, and in adolescents with 25(OH)D > 20 ng/mL.  In both the 
models of fetal femur and humerus Z-score, Ca intake remained a significant covariate only in 
adolescents with 25(OH)D ≤ 20 ng/mL.  Figure 3.2 presents the effect of maternal Ca intake ≥ 
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1050 mg/day on fetal femur and humerus Z-scores separately in adolescents who were 25(OH)D 
sufficient and 25(OH)D insufficient.   
 
 
Figure 3.2 Fetal Femur and Humerus Z-scores are Higher in Adolescents with Ca Intakes ≥ 
1050 mg/day when Maternal 25(OH)D is Insufficient 
Third trimester (33.8 ± 4.0 weeks gestation) fetal femur and humerus lengths were measured and 
converted into Z-scores. Maternal dietary Ca intake and 25(OH)D status interacted to impact 
bone length outcomes.  In adolescents with 25(OH)D ≤ 20 ng/mL, those who consumed ≥ 1050 
mg Ca/day had significantly higher fetal femur Z-Score (* p = 0.019) and higher fetal humerus 
Z-score (# p = 0.116).  Among adolescents who were 25(OH)D sufficient, there was no 
significant difference in fetal Z-scores between adolescents who consumed above or below 1050 
mg Ca/day. 
 
Similarly, when the initial models of fetal femur and humerus length Z-scores that 
included 25(OH)D sufficiency were run separately in adolescents consuming above and below 
1050 mg Ca/day, 25(OH)D sufficiency remained a significant predictor only in adolescents 
consuming < 1050 mg Ca/day.  Figure 3.3 presents the effect of maternal 25(OH)D sufficiency 
on fetal bone Z-scores separately in adolescents consuming Ca intakes above and below 1050 
mg/day.   
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Figure 3.3 Fetal Femur and Humerus Z-scores are Higher in Adolescents with Sufficient 
25(OH)D when Maternal Ca Intakes < 1050 mg/day  
An interaction between maternal 25(OH)D and maternal Ca intake was observed such that, in 
adolescents consuming < 1050 mg/day Ca, those with 25(OH)D > 20 ng/mL had significantly 
higher fetal femur (** p = 0.001) and humerus Z-scores (* p = 0.030).  Among adolescents who 
consumed ≥ 1050 mg Ca/day, there were no significant differences in fetal long bone Z-scores 
between adolescents who were 25(OH)D sufficient vs. insufficient. 
 
The combined effect of 25(OH)D status and Ca intake on Fetal Bone Outcomes 
 The above interactions suggested that both adequate maternal Ca intake (≥ 1050 mg/day) 
or sufficient 25(OH)D status were capable of compensating when intake or status of the other 
nutrient was limited.  To further explore this possibility, we classified teens into two groupings 
according to Ca intake and vitamin D status as “Ca/D insufficient” if  both maternal 25(OH)D ≤ 
20 ng/mL and Ca intake < 1050 mg/day, and all others were classified as “Ca/D sufficient”.  
Adolescents classified as Ca/D sufficient had significantly more positive fetal femur (p < 0.001, 
n = 160) and humerus (p = 0.002, n = 158) Z-scores in comparison to measures obtained in the 
Ca/D insufficient group (Figure 3.4).  When controlling for maternal smoking, height, race, and 
weight gain, Ca/D sufficiency remained a significant determinant of both fetal femur (parameter 
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estimate p < 0.0001) and humerus (parameter estimate p = 0.002) Z-scores explained an 
additional 10.5% of the variation in fetal femur Z-score and an additional 5.3% of the variation 
in fetal humerus Z-score.  The improvement associated with moving from the Ca/D insufficient 
to Ca/D sufficient group, by improving either Ca intake or 25(OH)D status, was 0.314 SD in 
fetal femur Z-score and 0.249 SD in fetal humerus Z-score.   
 
 
Figure 3.4 Fetal Femur and Humerus Z-scores are Higher in Adolescents with 25(OH)D >   
20 ng/mL and/or Ca Intakes ≥ 1050 mg/day Compared to those with Insufficient Ca 
Intakes and Insufficient 25(OH)D 
Adolescents consuming Ca intakes < 1050 mg/day who also had 25(OH)D ≤ 20 ng/mL (Ca/D 
insufficient) were compared to adolescents with Ca intake ≥ 1050 mg/day and/or 25(OH)D > 20 
ng/mL (Ca/D sufficient).  Adolescents within the “Ca/D sufficient” category (n = 102) had 
higher fetal femur and humerus Z-scores (* p <0.0001 and p = 0.003, respectively) when 
compared to those in the “Ca/D insufficient” category (n = 60).  
 
There were no differences in either bone Z-score value between adolescents with either an 
adequate maternal Ca intake (≥ 1050 mg/day) or a sufficient 25(OH)D value vs. adolescents who 
were adequate/sufficient in both Ca and 25(OH)D. 
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The combined effect of 25(OH)D status and Ca intake on Neonatal Birth Length  
The observed effects of maternal Ca intake on fetal bone length in-utero were also 
evident at birth using recorded measures of neonatal birth length.  Adolescents in the highest 
tertile of Ca intake delivered neonates with a significantly longer mean birth length (p < 0.020) 
in comparison to the mean observed in adolescents consuming in the lower two tertiles (Figure 
3.5A).  Similarly, adolescents consuming ≥ 1050 mg Ca/day delivered neonates that were 1.03 
cm longer at birth than infants delivered to adolescents consuming < 1050 mg Ca/day (p = 0.028, 
n = 147; Figure 3.5B).  In a multiple regression model of neonatal birth length (that controlled 
for gestational age at delivery, maternal smoking status, race, height and weight gain), maternal 
Ca intake (as a linear variable) remained a significant predictor of neonatal birth length 
(parameter estimate p = 0.041), and explained an additional 3% of the variation in birth length.  
In this model, every 100 mg increase in Ca intake was associated with a 0.12 cm (95% CI: 0.02 – 
0.21 cm) increase in birth length.   
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Figure 3.5 Neonatal Birth Length Differs by Maternal Ca Intake  
Birth length was measured in 153 neonates born to adolescents (≤ 18 y of age).  Maternal Ca 
intake was categorized into tertiles: 1
st
 < 653 mg/day; 2
nd
 = 653 - 1066 mg/day; 3
rd
 > 1066 
mg/day, and also categorized as above or below the identified Ca intake at which differences in 
fetal long bone Z-scores were evident (1050 mg/day).  A: Adolescents consuming within the 
third tertile of Ca intake delivered infants that were significantly longer at birth (* p < 0.015).  B: 
Adolescents consuming ≥ 1050 mg of Ca/day delivered infants that were significantly longer at 
birth (* p = 0.035). 
 
 
In contrast to the significant associations found between neonatal birth length and 
maternal Ca intake, maternal 25(OH)D status was not significantly correlated with birth length.  
While a main effect of maternal 25(OH)D status was not evident, an interaction between 
maternal Ca intake and maternal 25(OH)D sufficiency was observed.  When the initial model of 
birth length that included Ca intake as a linear variable was run separately in adolescents with 
maternal 25(OH)D ≤ 20 ng/mL, and in adolescents with 25(OH)D > 20 ng/mL, Ca intake 
remained a significant covariate only in adolescents with 25(OH)D ≤ 20 ng/mL.  Furthermore, 
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when maternal Ca intake and 25(OH)D status were combined and grouped as Ca/D insufficient 
or  Ca/D sufficient (as described above), this Ca/D sufficiency variable remained borderline 
significant (parameter estimate p = 0.074) in the model of birth length, increased the R
2
 of the 
model from 0.035 to 0.038, and was associated with a 0.34 cm increase in birth length.  
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DISCUSSION 
 In these pregnant adolescents, both maternal 25(OH)D status and dietary Ca intake 
influenced fetal bone growth.  A significant interaction was evident between these two nutrients 
with higher Ca intakes compensating for suboptimal vitamin D status and vice versa.  These 
interactions are biologically feasible given the known role of vitamin D on active Ca absorption.  
The relationships and interactions detected in-utero remained evident at delivery, as evidenced 
by significant differences in neonatal birth length. 
Dietary Ca intake had a significant effect on fetal bone.  Significantly longer fetal femur 
and humerus lengths were evident in adolescents consuming Ca intakes ≥ 1050 mg/day.  The 
1050 mg/d Ca intake at which these significant differences in bone outcomes became apparent is 
similar to the 2010 EAR (1100 mg/day) set for this age group by the IOM (21).  The DRI 
recommendations for Ca intake for pregnant adolescents do not differ from recommendations set 
for non-pregnant adolescent females.  The recommended intakes are based on achieving 
maximum Ca retention during adolescent years (21).  When undertaking analyses stratified by 
vitamin D status, we chose to use the concentration identified by the IOM that corresponds with 
the RDA for vitamin D sufficiency (25(OH)D ≤ 20 ng/mL).  For Ca intake, we chose to use the 
Ca intake cut-point identified in our data (1050 mg/day) for stratified analyses, as opposed to the 
RDA of 1300 mg for two reasons. Firstly, this intake was identified based on its association with 
functional fetal and neonatal skeletal outcomes (fetal femur and humerus Z-scores and birth 
length), which the DRI does not assess.  Secondly, use of the RDA for Ca intake (1300 mg/day) 
was impractical for making statistically sound comparisons between groups as only 15.3% of 
adolescents in this study actually consumed ≥ 1300 mg Ca/day.         
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The raw difference in fetal femur Z-score observed in those consuming < 1050 mg/d was 
0.36 Z-scores.  Other in-vivo studies have found that maternal dairy intake is significantly related 
to fetal femur length in pregnant adolescents (13).  Similar nutrient driven gains in fetal femur 
length (0.24 Z-scores at 38 weeks) have also been documented in disadvantaged Peruvian 
women provided daily 25 mg zinc supplements (24).  Our observed deficit in fetal humerus (0.34 
Z-scores) was similar to that observed for the femur.  Biological plausibility for a role of Ca in 
long bone elongation is supported by several in-vitro studies in animal cells that have shown that 
extracellular Ca
2+
 concentrations and Ca
2+
-sensing receptor activation in developing fetal bone 
induces type X collagen synthesis, increases rates of development and differentiation of growth 
plate chondrocytes, and increases the height of the growth plate hypertrophic zone (25-27). 
Similar to the findings evident for Ca intake, pregnant adolescents with sufficient 
25(OH)D exhibited more positive fetal femur and humerus Z-scores (by 0.42 SD).  These results 
substantiate findings in adult pregnant women that have also found low maternal 25(OH)D to be 
associated with adverse fetal and neonatal bone outcomes (7;9;28).  While many mechanistic 
studies have focused on the role of 1,25(OH)2D on regulation of endochondral bone development 
(29), it is interesting to note that we found no significant relationships between 1,25(OH)2D and 
fetal bone Z-scores.  Increasing attention has been paid to the importance of local production and 
action of 1,25(OH)2D on bone growth (30), where availability of the 25(OH)D substrate may 
impact rates of 1,25(OH)2D synthesis.  Thus, if systemic circulating 1,25(OH)2D concentrations 
are not reflective of local production, we may not expect to see on overall association between 
circulating 1,25(OH)2D and fetal bone.  The high prevalence of vitamin D insufficiency observed 
in these adolescents (48%) is similar to that reported among pregnant adult women in the United 
States (31).  
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 A significant interaction between dietary Ca intake and 25(OH)D status was evident, 
such that maternal Ca intake ≥ 1050 mg/day and maternal 25(OH)D ≤ 20 ng/mL were only 
significantly associated with fetal femur and humerus Z-scores when the other nutrient was 
inadequate.  This suggests that increases in dietary Ca intake and/or improvements in maternal 
vitamin D status can offset deficits when the other nutrient is limited.  Similar interactions have 
been described in non-pregnant adolescent females (age 11-16 years, n = 211) in whom reduced 
areal bone mineral density Z-scores were observed in girls that had both low dietary Ca intake  
(< 600 mg/day) and low 25(OH)D status (≤ 16 ng/mL) when compared to girls who exhibited 
either higher dietary Ca intakes and/or vitamin D status (32).  Figure 3.6 below represents a 
conceptual diagram of the interaction between maternal Ca intake and 25(OH)D status on fetal 
bone development (adapted from (33)).  Ideally all adolescents would achieve both Ca intakes ≥ 
1050 mg Ca/day and sufficient vitamin D status (“ideal”, shown in green).  However, only 
24.7% of teens met these criteria.  The clinical relevance of the interaction we identified lies in 
the implication  that significant improvements in fetal and neonatal bone outcomes can be 
achieved when adolescents move from the “inadequate” red area to either the “A” or “B” 
location; ie by achieving adequacy in just one of the two nutrients.    
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Figure 3.6 Conceptual Diagram of the Interaction between Maternal Ca Intakes ≥ 1050 
mg/day and 25(OH)D > 20 ng/mL on Fetal and Neonatal Bone Outcomes in Pregnant 
Adolescents 
In this cohort of pregnant adolescents, the interaction identified between maternal Ca intakes ≥ 
1050 mg/day and achievement of 25(OH)D > 20 ng/mL implied a compensation between the two 
nutrients.  Significant improvements in fetal femur and humerus Z-scores and birth length were 
observed when adolescents moved from the red “Insufficient” area to either the “A” or the “B” 
area.  Furthermore, no differences in fetal femur or humerus Z-scores or birth length were 
observed between adolescents in the “A” or “B” compared to adolescents in the “Ideal” location.  
Adapted from DeLucia et al (33).  
 
Sufficient 25(OH)D concentrations may be necessary to  support renal and extra-renal 
production of 1,25(OH)2D which is known to regulate efficiency of intestinal Ca absorption (34).  
Additionally, increased systemic concentrations or local production of 1,25(OH)2D in the 
placenta may result in increased placental flux of Ca to the fetus (35;36).  The clinical relevance 
of the observed increase in fetal long bone Z-scores with achievement of either 25(OH)D > 20 
ng/mL or Ca intake ≥ 1050 mg/day is underscored by the number of teens (37%) that failed to 
meet either criteria. 
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In our adolescent population, the observed differences in long bone growth in-utero were 
associated with similar differences in birth length as a function of Ca intake.  In the generated 
models of neonatal birth length, increasing maternal Ca to ≥ 1050 mg Ca/day was associated 
with a 0.54 cm increase in birth length.  Data from Ca replete, skeletally mature populations may 
differ from that observed in adolescents, and prior data linking maternal Ca intake with infant 
birth length has been inconsistent.  A study of 222 Caucasian women (>30 y of age, consuming 
average intakes of ~1300 mg Ca/day) found no relationship between that maternal Ca intake 
during pregnancy and infant birth length (37) but a randomized control trial in 256 healthy adult 
pregnant women showed that providing 2 g daily Ca supplementation from < 22 weeks gestation 
to term resulted in a non-significant 0.5 cm increase in birth length (11).  These studies’ results 
may have been impacted by a limited potential to benefit since they were undertaken in relatively 
well-nourished adult women.     
In these adolescents the effect of maternal Ca intake on birth length was mediated by 
maternal vitamin D status, and only remained significant when maternal 25(OH)D was 
insufficient (≤ 20 ng/mL).  A study of women in Iran reported that infants born to women who 
consumed adequate amounts of both Ca (> 1000 mg/day) and vitamin D (> 200 IU/day) were 
significantly longer at birth by 0.87 cm (38), compared to the 0.4 cm longer birth length we 
detected in our “Ca/D sufficient” pregnant adolescents.  In our study, birth length was measured 
by clinical staff upon delivery using standard hospital practices which likely increased 
measurement error and variability.  Our lack of standardization of neonatal birth length measures 
likely increased variability and only diluted our ability to detect significant associations.   
A strength of our study design was the biochemical assessment of vitamin D status 
combined with dietary assessment of Ca intake, as no analogous biomarker for Ca exists.  In this 
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population, vitamin D intake only explained 6% of the variation in 25(OH)D, emphasizing the 
need to use a biomarker for vitamin D status.  As expected, dietary intake of vitamin D and Ca 
intake in this group were highly correlated, which necessitates that effects attributed to Ca intake 
be interpreted with caution.  The collinearity of Ca and vitamin D intake is likely due to 
consumption of dairy/vitamin D fortified foods, and thus counseling pregnant adolescents to 
increase their consumption of Ca and vitamin D rich foods would be appropriate to ensure the 
gains in fetal skeletal outcomes attributed to Ca in these models.  The wide range in Ca intakes 
and 25(OH)D concentrations observed, and the skeletal immaturity of this age group may have 
increased our ability to detect the associations noted.  We assessed the impact of maternal 
nutritional status on fetal long bones in both the upper and lower limb.  Presumably, both these 
bones are subject to the same regulatory processes in-utero (39), yet possible racial differences in 
these bone lengths may not be analogous as fetal femur, but not humerus lengths, may differ by 
maternal race (40;41).  A similar trend for racial differences in long bone length approached 
significance in our data.  At present, fetal biometry standard curves are not race-specific, but 
maternal race was controlled for in our models of fetal bone length to account for potential 
differences.  It is noteworthy that, although physiological differences between the femur and 
humerus may exist, the nature of the interactions observed, and size of the effect of maternal Ca 
intake and vitamin D status on each of these two bones was similar. 
The significant interaction between maternal Ca intake and 25(OH)D status that we 
observed in these teens suggests that consuming either an adequate Ca intake or achieving 
sufficient 25(OH)D status may partially attenuate the deficits in fetal long bone growth and 
neonatal birth length observed in pregnant adolescents who were Ca/D insufficient.  Whether or 
not the findings in this group of adolescents are generalizable to skeletally mature women 
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remains unknown, yet the possibility merits investigation as nearly 50% of American women of 
child-bearing age consume < 1050 mg Ca/day (21), and vitamin D insufficiency is prevalent.  
These findings underscore the need for pregnant adolescents to ingest recommended Ca intakes 
and maintain optimal vitamin D status throughout gestation to ensure optimal fetal skeletal 
growth.   
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ABSTRACT 
Vitamin D status may impact placental gene expression.  To assess this possibility, relationships 
among placental vitamin D receptor (VDR) expression, fetal bone length, maternal Ca intake and 
maternal and neonatal vitamin D status were examined.  The study was undertaken in 94 
pregnant adolescents (≤ 18 y of age) who delivered at 39.9 ± 1.2 weeks of gestation.  Serum 
25(OH)D, 1,25(OH)2D, and PTH were measured in maternal circulation at delivery and in cord 
blood obtained at birth.  Maternal Ca intake was assessed via 24-hour recall.  Fetal femur length 
Z-scores were generated from sonogram measures obtained at 34.3 ± 3.2 weeks gestation.  
Placental VDR expression (via Western blot) was significantly and inversely associated with 
neonatal 25(OH)D (p = 0.012); and a similar but non-significant trend was evident between 
placental VDR and maternal 25(OH)D (p = 0.080).  The hormonal form of vitamin D in the 
neonate, 1,25(OH)2D, was highly significantly positively associated with placental VDR 
expression (p = 0.006).  Neonatal 1,25(OH)2D and 25(OH)D concentrations were not 
significantly related.  Adolescents with high placental VDR expression had a significantly more 
positive fetal femur length Z-score at late gestation (p = 0.029).  Placental VDR expression 
remained a significant predictor of fetal femur length Z-score (p = 0.018) after controlling for 
maternal smoking, race, weight gain, height, Ca intake, 25(OH)D status, and placental weight.  
Insufficient neonatal 25(OH)D status and high neonatal 1,25(OH)2D concentrations may impact 
VDR expression in the placenta to impact skeletal growth in-utero.  The effects of placental 
VDR expression on placental function and transport of nutrients to the fetus warrant further 
investigation. 
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INTRODUCTION 
All nutrients necessary for fetal growth and development are transported across the 
placenta over only 266 days in the human.  Increasing attention has been focused on the 
placenta’s ability to respond to signals of fetal demand and optimize transport of nutrients to the 
fetus within the context of maternal supply (1;2).  The mechanisms and proteins involved in the 
regulation of placental nutrient transport is an evolving area of research.   
Maternal vitamin D status, as measured by circulating 25(OH)D concentrations, has been  
linked to pregnancy outcomes and offspring risk of chronic disease (3).  Increasing data have 
also found significant associations between maternal vitamin D status and both placental 
function and fetal growth (4).  Low 25(OH)D has been linked with impaired fetal femoral 
development (5), reduced bone mineral content (BMC) and bone density in the neonate at birth 
(6;7), and persistent reductions in BMC in offspring at  9 years of age (8).  The mechanisms 
responsible for these associations remain unknown.   
Vitamin D-mediated regulation of gene expression at the level of the placenta may 
influence transport of Ca and other essential nutrients to the fetus.  The 1α–hydroxylase enzyme 
(1α-OHase) is expressed in the kidney and in the placenta (9) and converts 25(OH)D  into the 
hormonal form of vitamin D, 1,25(OH)2D.  This hormone binds to the vitamin D receptor (VDR) 
and regulates expression of genes containing vitamin D response elements (VDRE).  The 
presence of both the 1α-OHase and the VDR in the placenta suggests that this organ has the 
capacity for endocrine as well as local paracrine and autocrine vitamin D activity (9;10).   
There are limited data investigating the determinants and effects of VDR expression in 
the placenta, but other studies have established that VDR likely plays an important role in 
placental function.  The VDR gene is completely unmethylated in the placenta (11).  This lack of 
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epigenetic inhibition of transcription suggests that the placenta as an organ is “primed” for 
optimal vitamin D activity.  These data, suggest that VDR likely plays a role in the modulation 
placental gene expression and as over 150 genes have been found to contain VDRE’s (12), 
modulation of VDR expression in the placenta has the potential for significant downstream 
impact on placental function.   
In-vitro studies using human cell lines have found that placental VDR expression is 
regulated by vitamin D metabolites (13).  Data from animal models suggest that VDR plays a 
role in fetal growth and that this effect is mediated by maternal Ca intake (14) but in-vivo human 
data are lacking.  To address this issue, we explored determinants of placental VDR expression 
in relation to maternal and neonatal vitamin D status in a group of pregnant adolescents.  
Possible associations between placental VDR and in-utero measures of fetal bone length were 
explored.   
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MATERIALS AND METHODS 
Study Participants: 
Placental tissue from 94 adolescents was obtained at birth.  These 94 adolescents were 
part of a larger cohort (n = 157) of pregnant adolescents enrolled in a prospective study designed 
to assess maternal and fetal bone health and vitamin D homeostasis across gestation.  All 
adolescents were recruited from the Rochester Adolescent Maternity Program (RAMP) clinic in 
Rochester, NY.  Healthy pregnant adolescents were eligible to participate if they were  ≤ 18 y of 
age, between 12 and 30 weeks gestation at entry into the study, were otherwise healthy, and were 
carrying a single fetus.  Adolescents with known medical complications (such as HIV infection, 
diabetes, gestational hypertension, diagnosed eating disorders or malabsorption diseases) were 
ineligible to participate.  At entry into the study data on race, ethnicity, pre-pregnancy weight, 
and smoking history were self-reported.  Informed written consent was obtained from all 
participants, and the study was approved by the Institutional Review Boards of the University of 
Rochester and Cornell University.  Data from this study population detailing vitamin D status 
(Chapter 2), bone turnover markers, serum and placental osteoprotegerin (Appendix 11) and fetal 
long bone growth (Chapter 3) are currently under review. 
  Up to three times during pregnancy, maternal dietary intake was assessed by 24-hour 
dietary recall and fetal biometry measures were obtained by sonogram.  Fetal femur length Z-
scores were generated using previously published equations derived from a large cohort (n = 
929) of pregnant African American adolescents in Baltimore, MD, USA (15).  At birth, infant 
weight and length were recorded by clinical staff using standard procedures.  Sex and gestational 
age-specific infant birth weight Z-scores were generated from published equations (16).  
Immediately after delivery, the placenta was collected and weighed to the nearest 0.1 g.   
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Biochemical Analyses: 
At delivery, a maternal and cord blood sample (10 mL) was obtained.  Serum was 
separated from all blood samples and aliquots were immediately sent to a Quest Laboratory 
(participating in DEQAS) for assessment of 25(OH)D using the Diasorin RIA (Diasorin Inc, 
Stillwater, MN).  According to the 2010 DRI, vitamin D insufficiency was defined as 25(OH)D 
≤ 20 ng/mL (17).   Intact parathyroid hormone (PTH) was analyzed in maternal samples using a 
commercially available ELISA (DSL Laboratories, Webster, TX).   Calcitriol (1,25(OH)2D) was 
analyzed in 60 of the 94 maternal samples and 51 of the 94 neonatal samples at Boston 
University in the lab of Dr. Michael Holick (Boston, MA), as previously described (18).  Missing 
calcitriol data was due to insufficient serum volume for this analysis. 
Placental Sample collection: 
Placentas were processed shortly after delivery as previously described (19;20;Appendix 
11).  Placentas were weighed to the nearest 0.1 g and dimensions and shape recorded.  The sac 
was trimmed, and five tissue sections (approximately one-square-inch each) were collected from 
representative sites.  The maternal and fetal membranes were removed from each section.  
Samples were then pooled, homogenized, and frozen in small aliquots at -80
0
C until analysis.  
Protein lysates were generated by homogenizing thawed placental tissue using a Polytron 
PT3100 tissue homogenizer (Kinematica, Lucerne, Switzerland) at 5,000 rpm in a hypertonic 
lysis buffer containing protease inhibitor.  Homogenized tissue was centrifuged at 13,000 rpm 
for 20 minutes at 4
0
C.  Protein concentration in the supernatant was determined with the Bio-Rad 
assay (Bio-Rad, Hercules, CA).  Lysates were diluted in SDS sample buffer and stored at -80
0
C 
until analyses. 
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Western Blot: 
Relative placental expression of VDR was determined by Western blot.  Lysates were 
separated on a 10% SDS-PAGE gel and transferred to a PVDF membrane (Millipore, Billerica, 
MA).  Membranes were blocked in Odyssey Blocking Buffer (Li-Cor BioSciences, Lincoln, NB) 
for one hour at room temperature and then probed with anti-human VDR, raised in rat 
(ab8756:AbCam, Cambridge, MA) at a dilution of 2µg/mL and anti-human β-actin, raised in 
rabbit (AbCam, Cambridge, MA) at 10.1 ng/mL overnight at 4
0
C.  Fluorescent secondary 
antibodies were used (Li-Cor BioSciences): anti-rat 800, raised in goat at a concentration of 0.2 
µg/mL, and anti-rabbit 680, raised in goat at 0.1 µg/mL.  All antibodies were made up in a 
solution of Odyssey blocking buffer diluted 1:1 in a phospho-buffered saline (PBS) solution.  All 
antibodies were tested for cross-reactivity before collection of data.  The VDR and β-actin bands 
were quantified using the Odyssey infrared imaging system (Li-Cor Biosciences), and the ratio 
of VDR to β-actin calculated.  HeLa nuclear lysate (ab14655:AbCam, Cambridge, MA) was used 
as a positive control for VDR.  Thirteen placental samples and a standard control placental 
sample were run on every gel.  This standard control placenta sample originated from a single 
lysate that was generated from an adult placenta (from an individual not participating in this 
study) collected at term, as previously described.  If the VDR: β-actin ratio of the control 
placenta sample on any given gel was over two SD from the mean observed for this control 
sample on all gels run, data from that gel was not used, and all study placentas on that gel were 
re-analyzed.  Thus, the control placental samples’ VDR: β-actin ratios from every gel were 
normally distributed and all within two SD from the mean.  Intra-membrane variation was 
controlled for by normalizing the VDR: β-actin ratio of each study sample to the standard control 
placental sample that was run on that gel.  
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Statistical Methods: 
Analyses were performed using SAS 9.2 and JMP 8.0 (SAS Institute Inc, Cary, NC).  
Results are reported as the mean ± standard deviation (SD) unless otherwise stated.  Independent 
t-tests or ANOVA were used to determine if normally distributed variables differed by categories 
of vitamin D status or placental VDR expression, and the Wilcoxon Rank sum test was utilized 
for nonparametric data.  Simple linear regression was used to assess relationships between 
25(OH)D or 1,25(OH)2D and placental VDR expression, and between placental VDR expression 
and fetal femur Z-scores.  Multiple linear regression was used to model the relationship between 
placental VDR expression and fetal femur Z-scores, while controlling for covariates including 
placental weight (to control for placental size).  An interaction term between placental VDR 
expression and placental weight was included in all models but was not significant in any model, 
and thus will not be discussed herein.  Normality was tested using the Shapiro-Wilks test, and 
non-normally distributed variables were log transformed as necessary to ensure normality of the 
residuals.  P values < 0.05 were considered significant, and P values between 0.05 and 0.10 were 
considered trends.   
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RESULTS 
Subject Characteristics 
Characteristics of the 94 adolescents and their neonates are presented below in Table 4.1. 
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Table 4.1. Characteristics of 94 Pregnant Adolescents from whom Placental Tissue was 
Obtained, and their Neonates at Birth 
Characteristic Mean ± SD (n) 
Maternal Age Enrollment (y) 17.1 ± 1.1 (94) 
African American 
Caucasian 
62.8% (59) 
37.2%  (35) 
Hispanic 
Non-Hispanic 
26.6% (25)
1
 
73.4% (69) 
Parity ≥ 1 10.6% (10) 
Pre-pregnancy BMI (kg/m
2
) 25.1 ± 5.9 (93) 
Weight Gain (Lbs) 39.5 ± 17.7 (93) 
Ca Intake (mg/d) 904 ± 358 (93) 
Infant Sex (Male) 51.1% (48) 
Birth Weight (g) 3287 ± 472 (94) 
Birth Weight Z-Score -0.382 ± 0.890 (94) 
Placental Weight (g) 601.4 ± 121.7 (91) 
Fetal Femur Length Z-Score
2
 -0.606 ± 0.934 (94) 
Maternal 25(OH)D at delivery (ng/mL) 21.5 ± 12.9 (91) 
Maternal 1,25(OH)2D at delivery (pg/mL) 104.2 ± 33.3 (60) 
Neonatal 25(OH)D (ng/mL) 21.2 ± 10.7 (89)
 
 
Neonatal 1,25(OH)2D (pg/mL) 47.9 ± 17.7 (51) 
1
 60.0% of Caucasians self-identified as Hispanic vs. 6.8% of African Americans, p<0.0001. 
2
 Measured at 34.3 ± 3.2 weeks gestation   
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Maternal age ranged from 13.6 to 18.7 years.  Approximately 38% of adolescents were 
overweight (BMI ≥ 25.0 kg/m2) pre-pregnancy, with pre-pregnancy BMI ranging from 15.0 to 
42.1 kg/m
2
.  One adolescent reported her race as American Indian.  Study results did not differ if 
this adolescent was excluded or grouped with either the Caucasian or African American cohorts.  
In order to collapse maternal race into a bivariate variable, the American Indian adolescent was 
grouped with the African American cohort.  A larger percentage of Caucasians reported their 
ethnicity as Hispanic (60.0%) than did African American participants (6.8%; p < 0.0001).   
Approximately 12% of adolescents were currently smoking during pregnancy (an average of 0.5 
packs of cigarettes/day).   
Fetal femur length measures were obtained in the third trimester of pregnancy at week 
34.3 ± 3.2 of gestation.  Fetal femur Z-scores were highly variable ranging from -2.70 to 2.20.  
All but one of the 94 adolescents delivered at term (39.9 ± 1.2 weeks); one infant was premature 
(36.9 weeks gestation).  This is an underestimate of the rate of preterm delivery normally 
reported in this age group and evident in the larger cohort, and is due to the decreased likelihood 
of obtaining placental tissue from a preterm delivery.  Birth weight Z-scores were variable, 
ranging from -2.58 to 2.09.  As evident in the larger cohort (Chapter 2), neonates born to 
Caucasian adolescents had significantly higher 25(OH)D concentrations at birth when compared 
to neonates born to African American adolescents (p = 0.004).  Neonatal 25(OH)D was highly 
correlated with maternal 25(OH)D (p < 0.0001, n = 86, R
2
 = 0.63).  Neonatal circulating 
1,25(OH)2D was not correlated with 25(OH)D in the mother or the neonate.  
Maternal Determinants of Placental VDR Expression 
VDR was detected in all placental homogenates analyzed (Figure 4.1).  Placental VDR 
was not significantly related to maternal 25(OH)D, although a negative association approached 
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significance (p = 0.080, R
2
 = 0.03, n = 91).  Placental VDR was not significantly related to 
maternal 1,25(OH)2D or PTH.  VDR expression was not related to maternal pre-pregnancy BMI, 
weight gain, gestational age, placental weight, smoking status, Ca intake, or maternal race or 
ethnicity.   
 
 
Figure 4.1 VDR Expression is Detectable via Western Blot in all Placental Tissue Collected 
from 94 Pregnant Adolescents  
VDR expression was assessed via Western blot in protein lysates generated from placental tissue 
obtained at delivery from 94 pregnant adolescents (age 17.1 ± 1.1 years) at delivery.  Shown is a 
representative blot with individual placental lysate samples in lanes 1 - 10.     
 
 
 
Neonatal Determinants of Placental VDR Expression 
Placental VDR was significantly negatively associated with neonatal 25(OH)D (P = 
0.012, n = 89, R
2
 = 0.06; Figure 4.2A), and significantly positively associated with neonatal 
1,25(OH)2D (P = 0.006, n = 54, R
2
 = 0.14; Figure 4.2B).  Placental VDR did not differ by 
neonatal race or ethnicity or infant sex.   
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Figure 4.2 Placental VDR Expression is Negatively Associated with Neonatal 25(OH)D and 
is Positively Associated with Neonatal 1,25(OH)2D  
A: Relative placental VDR expression via western blot (a unit-less measure) was inversely 
related to Ln (neonatal 25(OH)D concentrations) (p = 0.018, R
2
 = 0.06, n = 89).  B: Placental 
VDR expression was positively related to neonatal 1,25(OH)2D concentrations  (p = 0.006, R
2
 = 
0.14, n = 51).  
 
 
 
Figure 4.3 below summarizes the inter-relationships between maternal and neonatal 
vitamin D status and placental VDR expression.    
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Figure 4.3.  Summary of Inter-Relationships Between Maternal and Neonatal Vitamin D 
Status and Placental VDR Expression 
Maternal and neonatal determinants of placental VDR expression were explored.  Shown are the 
inter-relationships and corresponding P values between maternal and neonatal vitamin D status 
and placental VDR expression.  Solid black lines represent significant positive relationships.  
Dashed lines represent significant inverse relationships.  Gray lines indicate variables are not 
significantly (NS) associated.  Neonatal calcitriol was the most significant predictor of placental 
VDR expression. 
 
 
Relationships between Placental VDR Expression and Neonatal Outcomes 
Placental VDR was not linearly related to neonatal birth weight, birth weight Z-score, or 
fetal femur length Z-score at 34.3 ± 3.2 weeks.  However, when placental VDR expression was 
categorized as either above and below the median expression observed, adolescents with 
placental VDR expression above the median had significantly longer fetal femur lengths (higher 
femur length Z-score) than those with placental VDR expression below the median value (P = 
0.029, n = 94) (Figure 4.4).  The difference in mean femur length Z-score between those with 
placental VDR above and below the median expression amounted to 0.420 SD.  At 34.3 weeks 
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gestation, a 0.420 difference in femur length Z-score is equivalent to a 1.15 mm difference in 
femur length, a value that represents 1.7% of total bone length at this stage of development.   
 
Figure 4.4 Fetal Femur Z-Score is Higher in Adolescents with Placental VDR Expression 
Above verses Below the Median Expression Observed 
Fetal biometry was assessed at 34.3 ± 3.2 weeks gestation and age-specific fetal femur Z-score 
generated using published equations (15).  Placental vitamin D receptor (VDR) expression was 
assessed by Western blot (n = 91).  Fetal femur Z-scores were significantly more positive by 
0.420 SD in adolescents with VDR expression above the median when compared to Z-scores 
evident in those with placental VDR expression below the median (*p = 0.030, n = 91). 
 
 
After controlling for maternal smoking, race, weight gain, height, Ca intake, 25(OH)D 
sufficiency, and placental weight, placental VDR expression remained a significant predictor of 
fetal femur length Z-score (parameter estimate = 0.018, n = 90) (Figure 4.5).  Controlling for 
25(OH)D sufficiency as opposed to 25(OH)D as a linear variable improved the model’s 
predictability.  Adding placental VDR expression to the model of fetal femur Z-score, increased 
the R
2
 from 0.17 to 0.21.  Adjusted fetal femur Z-score was 0.409 SD higher in placentas with 
VDR expression above the median than in those below the median (p = 0.020).  
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Figure 4.5 Placental VDR Expression is Positively Associated with Adjusted Fetal Femur 
Z-Score 
Fetal biometry femur length Z-scores were generated using published equations (15).  In a 
multivariate model controlling for significant covariates, placental vitamin D receptor (VDR) 
expression (via western blot) was significantly positively associated with adjusted femur length 
Z-score (p = 0.018, R
2
 = 0.06, n = 90).   
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DISCUSSION  
 In this cohort of racially diverse pregnant adolescents, a significant positive relationship 
between neonatal 1,25(OH)2D and placental VDR expression was observed.  Placental VDR 
expression was also significantly negatively associated with neonatal 25(OH)D.  The significant 
differences in VDR expression were associated with a biologically relevant outcome as 
evidenced by the significant relationship between VDR expression and fetal femur length in-
vivo.  
Newborns with low vitamin D status (25(OH)D) had significantly higher placental VDR 
expression.  To our knowledge this association has not previously been reported in human or 
animal studies.  In these adolescents, the negative association between maternal 25(OH)D and 
placental VDR did not reach significance, even though the fetus is completely dependent on 
maternal supply of 25(OH)D in-utero, and neonatal 25(OH)D concentrations are highly 
correlated with 25(OH)D status (21;22).  Whereas maternal and neonatal 25(OH)D were 
significantly correlated in these adolescents, neonatal 25(OH)D explained twice as much 
variation in VDR expression compared to maternal 25(OH)D.   The mechanism for this 
association is unknown, but VDR expression may be increased as a compensatory response to 
low neonatal 25(OH)D status, which may limit substrate availability for local placental 
1,25(OH)2D production.    
Of the variables measured, the strongest determinant of placental VDR expression was 
neonatal 1,25(OH)2D concentration.  Unlike the negative association seen for 25(OH)D, higher 
concentrations of neonatal 1,25(OH)2D were associated with greater placental VDR expression.  
The concentration of this hormone in the neonate explained twice as much variability in VDR 
expression compared to concentrations of its precursor (25(OH)D).  Furthermore, if both 
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25(OH)D and 1,25(OH)2D were entered into a model together, 25(OH)D was no longer 
significantly associated with VDR expression.  Of interest, the significant relationship between 
1,25(OH)2D  and VDR expression was evident only in the neonate; maternal 1,25(OH)2D 
concentrations at delivery were unrelated to VDR expression.  In this cohort and other studies of 
pregnant adult women there is a lack of association between neonatal and maternal 1,25(OH)2D 
concentrations at delivery (23;24).  This is because, unlike 25(OH)D, the fetus is capable of 
synthesizing 1,25(OH)2D; animal models show that the 1α-hydroxylase is active in the 
embryonic state, and fetal renal 1α-hydroxylase near term is similar to maternal renal activity 
and significantly higher than non-pregnant adults (25;26).  Studies in lambs have been used to 
demonstrate that fetally derived 1,25(OH)2D regulates fetal Ca homeostasis independently of 
maternal 1,25(OH)2D (27).  The findings from our study in adolescents are significant because 
they indicate that, fetal and not maternal 1,25(OH)2D serves as a signal to regulate placental 
VDR expression.  Calcitriol is a positive regulator of VDR expression in mammalian cells in-
vitro (28).  Analogous regulation has been established in human placental choriocarcinoma cell 
lines (13), confirming a plausible mechanism for the association detected.   
Increased VDR expression may result in increased placental capacity for Ca transport, as 
several genes that play significant roles in placental Ca transport are up-regulated by 
1,25(OH)2D,.  These include the Ca import protein TRPV6 (29;30), and the Ca-chaperone 
proteins, calbindin D9K and D28K (13;31;32).  Furthermore, 1,25(OH)2D treatment of the 
placental syncytiotrophoblast cell line (JEG-3) leads to a dose-dependent increase in Ca uptake 
(33).  Although this syncytiotrophoblast model was initially derived from a choriocarcinoma cell 
line and may undergo different genetic regulation than healthy placental cells in-vivo, these data 
support the idea that increased 1,25(OH)2D / VDR mediated activity may increase placental Ca 
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flux.  It is possible that increased neonatal 1,25(OH)2D may serve as a signal to increase VDR 
expression in the placenta, to increase placental Ca supply to the fetus.  A limitation of our study 
was that we did not relate VDR expression with expression or activity of other genes known to 
be impacted by this receptor.      
If increased VDR expression impacts placental Ca transfer in-utero, this may influence 
Ca accrual in the fetus.  In this cohort, adolescents with higher VDR expression in the placenta 
had more positive fetal femur Z-scores.  To our knowledge, this is the first time VDR expression 
in the placenta has been linked with a functional outcome of neonatal skeletal development.  We 
have previously reported on determinants of fetal femur Z-score in the larger adolescent 
population (Chapter 3).  It is of note that adding VDR to the covariates previously identified 
increases the explained variability in femur length Z-score by 4%.  A limitation of this study is 
the lack of bone mineral content/density assessment in the neonate.        
The critical role that VDR plays in skeletal development is evident by insufficient 
mineralization and short adult stature observed in humans with non-functional vitamin D 
receptor (vitamin D dependent rickets type II, VDDR-II) (34).  Mice with a knockout in the VDR 
exhibit the hallmarks of human VDDR-II (35), and allow for further characterization of 
phenotype in-utero and during pregnancy.  Both homozygous and heterozygous VDR knock out 
pups are smaller at birth, exhibit defective skeletal mineralization and elevated concentrations of 
1,25(OH)2D (14;36), supporting the idea that VDR contributes to optimization of bone 
development in-utero.   
However, the role that VDR plays in placental Ca transfer and fetal skeletal 
mineralization in mice may be redundant, as the characteristic impaired bone formation, 
hypocalcemia and failure to thrive in VDR knockout animals do not become fully evident until 
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weaning (37), and VDR knockout phenotypes in the fetus/newborn pup can be rescued if 
pregnant dams are fed a high-Ca diet (14).  The ability to compare murine data to humans is 
limited by species and dietary differences.  We and others have documented that pregnant 
adolescents often ingest suboptimal Ca intakes in the context of suboptimal vitamin D status 
(Chapter 2 & 3(38).  These current VDR findings suggest that placental VDR expression in teen 
pregnancy may be responsive to circulating 1,25(OH)2D in the neonate and facilitate increased 
fetal Ca supply.  This mechanism may become particularly relevant in human pregnancy in the 
context of maternal skeletal immaturity combined with inadequate maternal Ca intake and/or 
25(OH)D concentrations.  In such a case, such relationships may be undetectable in whole 
genome knockouts and well-nourished animals.    
Epidemiologic studies also suggest that the VDR plays a role in fetal growth by 
demonstrating that fetal (and placental) VDR genotype modifies the association between 
maternal 25(OH)D status and infant birth size (39).  Maternal D deficiency has been linked to 
reduced infant birth weight only in infants with two most functionally active FokI 
polymorphisms (FF or Ff VDR genotype) (39).  Placental VDR expression has also been 
associated with more complex pregnancy complications such as pre-term delivery; placentas 
collected from preterm births exhibit lower VDR expression than placentas from normal, 
uncomplicated deliveries (40).  Future research is warranted to understand the totality of how 
VDR expression impacts fetal outcomes. 
This study is the first to correlate placental VDR expression in the human placenta with 
both neonatal calcitropic hormones and with a fetal measure of bone acquisition.  Higher 
placental VDR expression was evident among neonates with higher 1,25(OH)2D concentrations 
which indicates that placental VDR expression may be “responsive” to fetal 1,25(OH)2D 
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production.  We have also shown that placental VDR expression is associated with a measure of 
fetal bone accrual – fetal femur length Z-score.  These results increase our understanding of the 
“responsive” nature of the placenta, but more research is needed to elucidate the mechanisms by 
which VDR expression impacts placental Ca transfer.  And as ~500 genes are in some way 
regulated by VDR (41) research is warranted to fully detail the impact and role of VDR on 
placental nutrient transport, and fetal growth. 
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ABSTRACT 
Little is known about how placental Ca transport is regulated in-utero, and in-vivo studies in 
humans are lacking.  We utilized a dual stable Ca isotope approach to obtain in-vivo measures of 
maternal-to-fetal Ca transport in pregnant adolescents.  Maternal Ca intake was assessed via 24-
hour recall; and 25(OH)D, PTH, and 1,25(OH)2D were assessed in adolescents at mid-gestation 
and delivery, and in cord blood at birth.  Fetal femur and humerus length Z-scores were 
generated from sonogram data obtained in the third trimester.  Placentas were collected upon 
delivery and vitamin D receptor (VDR) expression assessed via Western blot.  We administered 
44
Ca orally and 
42
Ca intravenously to pregnant adolescents (n = 12) early in labor, and assessed 
enrichment in maternal circulation two hours post-dosing, and in cord blood at delivery.  We 
generated quantitative measures of maternal-to-fetal Ca transport by calculating ratios of 
neonatal to maternal enrichment, controlling for time-to-delivery.  Study variables that were 
significantly related to maternal-fetal Ca transfer were identified.  Relationships between this 
transfer and fetal long bone Z-scores were explored.  Maternal-fetal 
42
Ca transfer did not differ 
from 
44
Ca transfer and neither was associated with Ca intake, PTH, or 1,25(OH)2D.  Maternal 
25(OH)D > 20 ng/mL at mid-gestation and placental VDR expression were significantly 
positively associated with maternal-fetal 
42
Ca transfer.  Time-adjusted measures of maternal-fetal 
42
Ca and 
44
Ca transfer were significant in models of fetal femur and humerus Z-scores, 
respectively.  The findings from this novel study design suggest that maternal vitamin D status 
and placental VDR play a role in the regulation of maternal-fetal Ca transfer, and that this Ca is 
incorporated into the developing fetal skeleton as reflected in measures of long bone length. 
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INTRODUCTION 
 Over the course of gestation ~30 g of calcium (Ca) is actively transferred across the 
placenta to the developing fetus (1).  Placental Ca flux markedly increases in the third trimester, 
when ~80% of net placental Ca transfer occurs to support peak rates of fetal skeletal 
mineralization (2).  Rates of fetal Ca deposition peak at 35 weeks gestation, and are thought to 
approximate 330 mg Ca/day (3).  In the context of adolescent pregnancy, competition for 
nutrients may arise when fetal development occurs in an environment that is already 
physiologically stressed due to the additional Ca demands of adolescent growth.  
In order to meet this additional Ca demand, maternal intestinal Ca absorption increases 
early in pregnancy and remains elevated until term (4).  Biochemical markers of bone resorption 
and formation both increase significantly across gestation, suggesting that mobilization of 
maternal skeletal stores play a role in satisfying fetal Ca demand (5).  When a woman becomes 
pregnant during her adolescent years, the Ca demands of the developing fetus are added to those 
of adolescent growth, and these normal pregnancy-induced physiological adaptations may not be 
adequate to meet the combined maternal and fetal Ca demand.  Additionally, pregnant 
adolescents are likely to have a high prevalence of vitamin D insufficiency (5-8)Chapter 2) and 
to consume low quality diets that do not meet Ca requirements (9;10)Chapter 2).  For all these 
reasons, it may be more difficult for pregnant adolescents to satisfy Ca demands than adult 
pregnant women. 
 Maternal vitamin D status and Ca and milk intake have been linked to a variety of fetal 
bone outcomes such as bone length, mineral content, and density (11-17), as well as bone 
mineral density of offspring later into childhood (18;19).  We have recently shown that maternal 
Ca intake and vitamin D status interact to impact fetal femur and humerus length as well as 
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neonatal birth length in a pregnant adolescent population (Chapter 3).  However, little is known 
about the impact of maternal Ca intake and vitamin D status on placental Ca transport, and the 
degree to which this transport is impacted by suboptimal intake or maternal nutrient status.  To 
date, we have shown that 25(OH)D is associated with placental vitamin D receptor (VDR) 
expression, and that placental VDR expression is in turn associated with fetal femur length 
(Chapter 4).  These findings suggest that local VDR expression and vitamin D activity at the 
level of the placenta may play a role in regulation of placental Ca flux, but at this time such 
mechanisms remain to be proven. 
 Placental Ca transfer is methodologically challenging to measure in humans, as radio-
active approaches are unsafe during pregnancy.  Stable Ca isotopes provide a safe and effective 
way of tracing homeostatic movements of Ca within the human body.  In order to address the 
lack of data regarding in-utero Ca flux to the human fetus, we undertook a dual stable Ca isotope 
study, administering isotopes to pregnant adolescents early in labor, and then assessing Ca 
enrichment in maternal circulation post-dosing, and in cord blood collected at delivery.  The 
purpose of this study was two-fold.  First, we aimed to characterize neonatal enrichment, derive 
measures of placental Ca transfer and assess what variables were associated with these measures.  
Possible associations between maternal vitamin D and calcitropic hormone status and neonatal 
enrichment were also explored.  Secondly, we sought to explore if measures of maternal-to-fetal 
Ca transfer at parturition were related to measures of neonatal skeletal size that were obtained in-
utero and at birth.   
 172 
 
MATERIALS AND METHODS 
Study Participants 
Twelve adolescents participated in this isotope study that took place at delivery.  All 12 
teens were enrolled in a larger prospective cohort study (n = 171) designed to characterize 
longitudinal changes in maternal and fetal bone health across gestation, as previously described 
(Chapter 2, 3, 4).  Adolescents were recruited from the Rochester Adolescent Maternity Program 
(RAMP) clinic in Rochester, NY.  All were between 16 and 18 years of age, primiparous, 
carrying a single fetus and were otherwise healthy.  Exclusion criteria included known medical 
complications or diseases such as HIV infection, diabetes, pre-diagnosed gestational 
hypertension, diagnosed eating disorders, and malabsorption diseases.  Informed written consent 
was obtained from all participants, and all procedures were approved by the Institutional Review 
Boards of the University of Rochester and Cornell University.  The consent form for this study is 
presented in Appendix 10.  Maternal race, ethnicity, pre-pregnancy weight, and smoking history 
were self-reported.  Each adolescent was asked to attend up to three study visits across 
pregnancy.  At each study visit maternal anthropometrics were recorded and a 24-hour dietary 
recall was administered by study personnel utilizing food models to help estimate portion sizes.  
All 24-hour recalls were analyzed by a registered dietician using the Nutrition Data System for 
Research (NDSR: University of Minnesota, Minneapolis, MN, versions 2006, 2008, and 2009) in 
the Clinical Research Center at the University of Rochester (Rochester, NY).   
At each of the three visits, a fetal sonogram was performed, and fetal femur and humerus 
length were recorded by trained sonographers.  Fetal femur length Z-scores were generated from 
previously published equations derived from a large cohort (n = 949) of pregnant adolescents in 
Baltimore, MD (20).  Fetal humerus length Z-scores were calculated from the published curves 
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generated by Chitty et al. (21).  The femur and humerus length Z-sores used in this study were 
generated using the last prenatal sonogram performed (at 34.2 ± 4.3 weeks).  At birth, infant 
weight and length were recorded by clinical staff using standard procedures.  Maternal blood 
volume at delivery was estimated assuming a blood volume of 70.0 ml/kg, (22) and neonatal 
blood volume was estimated from a formula published by Linderkamp et al. based on neonatal 
weight, length, hemoglobin, and hematocrit (23).   
Placental Vitamin D Receptor (VDR) Expression 
Placental tissue was collected within 30 minutes of delivery and placental protein lysates 
were generated as previously described (Chapter 4).  Placental expression of VDR was 
determined via western blot as previously described (Chapter4).   
Biochemical analyses 
Maternal blood (10 mL) was obtained at mid-gestation (~28 weeks) and at delivery.  At 
delivery, a 10 mL sample of cord blood was also collected.  All blood samples were allowed to 
clot, then serum was separated and stored at -80
0
C until analysis.  In each of the serum samples 
collected, serum total Ca concentration was measured using a Modular (P) Chemistry Automated 
System (Roche Diagnostics, Indianapolis, IN) at the University of Rochester, and also using a 
Dimension Xpand Plus (Siemens Healthcare Diagnostics, Deerfield, IL) at Cornell University.  
As the values obtained did not statistically differ, the mean of both of these values was used.  In 
each maternal and cord serum sample collected, 25-hydroxyvitamin D (25(OH)D) was measured 
by Quest Diagnostics Laboratories (Rochester, NY), using the Diasorin RIA (Diasorin Inc, 
Stillwater, MN).  This laboratory participates in the Vitamin D External Quality Assessment 
Scheme (DEQAS) as a means of quality assurance.  Vitamin D insufficiency was defined as 
25(OH)D ≤ 20 ng/mL.  Adolescents who were vitamin D insufficient at mid-gestation were 
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offered daily 400 IU vitamin D3 supplements at their next prenatal appointment, to take daily 
over the remainder of gestation.  Calcitriol (1,25(OH)2D) was measured by Heartland Assays, 
Inc. (Ames, IA) using a competitive RIA procedure as previously published (24).  Intact 
parathyroid hormone (PTH) was measured using a commercially available ELISA (Biomerica 
Inc, Newport Beach, CA).  Elevated PTH was defined as PTH ≥ 46 pg/mL.  Leptin was analyzed 
using a commercially available ELISA from Millipore (Billerica, MA).   
Isotope Preparation & Administration 
Isotopes were obtained from Oakridge National Laboratory (Oakridge, TN) as 
42
Ca 
(87.7% enriched) and 
44
Ca (96.4% enriched).  The isotope solutions were prepared as isotonic 
solutions of Ca-chloride and certified for sterility and pyrogenicity by Anazao Health (Tampa, 
FL).  Single use vials of 
42
Ca for intravenous use contained 5.0 mL of an isotonic saline solution 
at 0.224 mg 
42
Ca/mL, to provide ~1 mg 
42
Ca per vial.  Single use vials of 
44
Ca
 
containing 3.0 mL 
of an isotonic saline solution at 0.970 mg 
44
Ca/mL each provided ~3 mg of 
44
Ca per vial.  The Ca 
isotopic composition of the final solutions was confirmed using a Thermo Scientific Triton TI 
magnetic sector thermal ionization mass spectrometer (TIMS; Thermo Fisher Scientific Inc, 
Bremen, Germany).  The total Ca concentration of the vials was confirmed using atomic 
absorption spectrophotometry (AAS; Perkin Elmer Analyst 800, Perkin Elmer, Norwalk, CT).      
When participants were admitted to the hospital at ≥ 37 weeks gestation, and were 
approximately 3 cm dilated (as assessed by medical staff), the oral and intravenous isotopes were 
administered.  Isotopes were drawn up in a syringe, and weighed to the nearest 0.001 g in the 
Highland Hospital Pharmacy.  The intravenous dose was administered through an in-dwelling 
heparin-lock over the course of five minutes.  A 5 mL normal saline flush was administered 
through the heparin lock after dosing to ensure full delivery of all isotope.  Immediately after the 
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42
Ca dose was administered, the 
44
Ca was mixed in a small volume (~20 mL) of water flavored 
with drink mix (sugar, calorie, and vitamin free; 4C Food Corp., Brooklyn, NY) and 
administered to the adolescent.  Two ~20 mL rinses of the cup were also consumed by the 
participant to ensure all isotope was ingested.  The empty oral and intravenous dosing syringes 
were post-weighed on the same scale as was used for the pre-dosing weight, to obtain an exact 
measure of the isotope dose delivered.  Two hours after the intravenous dosing, a 10 mL venous 
blood sample was obtained from the participant, and cord blood was collected at delivery for 
isotopic analysis.  Blood samples were allowed to clot before serum was removed and frozen at -
80
0
C until analyses.     
Determination of Isotope Content & Ca Absorption  
Calcium was precipitated from serum using ammonium oxalate, as previously described 
(25).  Precipitated Ca was re-suspended in 3% Ultrex Nitric Acid and ~10 uL was loaded onto a 
rhenium filament.  Calcium isotopic ratios were measured by TIMS (Thermo Scientific Triton 
TI, Thermo Fisher Scientific Inc, Bremen, Germany).  The ratio of each administered isotope to 
43
Ca was measured and the degree to which each ratio was increased over the natural abundance 
ratio (NA) was calculated as delta-percent excess (-% excess) as follows:   
-% excess 42Ca = 42/43Ca – NA 42/43Ca       (Eq. 1) 
   NA 
42/43
Ca   
The same equation was used to calculate -% excess of 44Ca in both maternal and cord blood 
samples.  The NA ratios used were: 
42/43
Ca = 4.799290; 
44/43
Ca = 15.457060 and the relative 
standard deviations of natural abundance measures was 0.0135% and 0.0118%, respectively.  
The following abbreviations are used to represent enrichment of 
42
Ca and 
44
Ca detected in the 
maternal and cord blood samples: 
X 100 
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42
Ca (M) = -% excess 
42
Ca
 
detected in maternal blood at two hours post-dosing
 
 
44
Ca (M) = -% excess 
44
Ca
 
detected in maternal blood at two hours post-dosing
 
 
42
Ca (C)  = -% excess 
42
Ca
 
detected in cord blood 
 
 
44
Ca (C) = -% excess 
44
Ca
 
detected in cord blood 
 
 
During pregnancy, the in-vivo dynamics of Ca partitioning are complex.  Figure 5.1 
diagrams the entrances and exits impacting the size of the miscible Ca pool in a pregnant 
woman.  During pregnancy, this pool expands significantly (4) due to increases in rates of bone 
turnover, blood volume expansion and increased intestinal Ca absorption.  The placental/fetal 
unit serves as an additional compartment to which Ca is transferred out of the miscible Ca pool.  
The rates of bone turnover and the size of the miscible Ca pool are also considerably higher on 
both a net mg and a mg/kg basis in children and neonates due to the high rates of skeletal Ca 
accretion occurring in these groups (26).   
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Figure 5.1 Model of Calcium Dynamics that Impact Calcium Balance During Pregnancy   
Rates of entry into and excretion from the miscible Ca pool are altered during pregnancy and 
vary on an individual basis. Calcium enters the miscible Ca pool from absorption of dietary Ca 
intake (VA) and resorption from bone (VO-).  Calcium is lost to endogenous fecal losses (Vendo), 
renal losses in the urine (Vu), bone Ca deposition (VO+), and Ca transfer to the fetoplacental unit 
(VFetal).  In this study 
44
Ca was administered orally (green arrow), and then assessed in maternal 
circulation and neonatal circulation (cord blood).  Intravenous 
42
Ca was administered directly 
into the miscible Ca pool, (purple arrow).  Enrichment of 
42
Ca in maternal circulation is a 
function of the size of the miscible Ca pool and rates of exit from this compartment.  Enrichment 
of 
42
Ca and 
44
Ca in neonatal circulation will provide insight into the degree of Ca transferred 
from maternal to fetal circulation. 
 
 
We are unable to measure neonatal usage of Ca tracer that is transferred to the fetus after 
maternal dosing.  In general, studies in adult populations, neonates, and preterm infants have 
found that after intravenous administration of Ca isotope, Ca enrichment from the miscible Ca 
pool declines in an exponential manner (27).  Because of the rapid Ca clearance rate observed, 
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we undertook this study in full-term pregnant adolescents admitted for delivery of their infant, in 
order to be able to determine isotopic enrichment of cord blood obtained within a matter of hours 
post maternal dosing.  An additional challenge in assessing placental transfer of Ca to the fetus 
relates to variability in the time that elapses between administration of isotope to the pregnant 
teen and delivery of the neonate (and collection of cord blood).  Figure 5.2 shows the clearance 
of 
42
Ca enrichment from serum after intravenous administration non-pregnant adolescent girls 
(28).  Superimposed on this curve of 
42
Ca decay are the time intervals in which we obtained the 
post-dosing maternal blood sample, and the wide time interval in which cord blood samples were 
obtained.   
 
Figure 5.2 Timing of Two-Hour Post-Dosing Maternal and Cord Blood Sample Collection 
Superimposed on a Serum Enrichment Disappearance Curve 
Shown above is a representative serum clearance curve of 
42
Ca in a group of non-pregnant 
adolescent girls after intravenous administration of 
42
Ca, as previously published by Wastney et 
al. (28).  Superimposed on this curve are the time intervals in which the two-hour post-dose 
maternal blood collection, and cord blood collection were obtained in our cohort (n = 12).  
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After dosing, the serum enrichment of the intravenous tracer follows an exponential 
disappearance curve (Figure 5.2) (27-29).  After administration of an oral isotope, the 
enrichment in serum increases as Ca is absorbed from the gut and tends to peak at approximately 
2 h, and then exponentially disappears following a similar disappearance curve as noted for the 
intravenous tracer (28;30).  For this reason, and to avoid sampling once active labor had begun, 
maternal blood was collected at 2 hours post-dosing.  The intravenous tracer is, in essence, 100% 
absorbed and is administered to control for variability in the overall size and rates of loss from 
the miscible Ca pool.  We followed a classic method used in studies that estimate fractional Ca 
absorption by administering an oral and intravenous isotope, and then generating a ratio of the 
oral to intravenous enrichment corrected for dose and natural abundance (25;31).  We used the 
ratio of the enrichment of the oral isotope (
44
Ca) to the enrichment of the intravenous isotope 
(
42
Ca) in maternal circulation at two hours post-dosing, corrected for dose and natural abundance 
of these isotopes, to provide a relative measure of maternal Ca absorption (25), as follows: 
Relative maternal absorption = (
44
Ca NA) x (
44
Ca (M)) x (mg 
42
Ca
 
given)              (Eq. 2) 
                       (
42
Ca NA) x (
42
Ca (M)) x (mg 
44
Ca given) 
 
Modeling Determinants of Neonatal Enrichment and Placental Ca Transfer 
We generated a quantitative estimate of maternal-to-fetal transfer of the 
42
Ca and 
44
Ca 
dose by calculating a ratio of the enrichment of isotope in the neonate at birth relative to the 
enrichment in the adolescent 2 h post-dosing.  This calculation and the abbreviations used are 
shown below: 
Materal-fetal Ca transfer of 
42
Ca =
 42
Ca (C/M) =  
42
Ca (C)      (Eq. 3) 
                                                 
42
Ca (M)  
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Materal-fetal Ca transfer of 
44
Ca =
 44
Ca (C/M) =  
44
Ca (C)      (Eq. 4) 
                                                 
44
Ca (M)  
We then determined which study variables were associated with neonatal enrichment (
42
Ca (C)  
and 
44
Ca (C), Eq. 1) and with the ratio of neonatal to maternal enrichment (
44
Ca(C/M) and 
44
Ca(C/M), 
Eq. 3, 4). 
 Because the time elapsed from isotope administration to cord blood collection is a major 
determinant of cord blood enrichment, we controlled for the variation in this time-elapsed in two 
different ways, depending on whether isotopic measures were being used as outcome or predictor 
variables.  When modeling determinants of neonatal enrichment, 
42
Ca(C) and 
44
Ca(C) were 
outcome variables.  The best fit for a model of time (from dosing to cord blood collection) 
predicting 
42
Ca(C) and 
44
Ca(C) was determined to be log(time) verses enrichment, as shown below 
for 
42
Ca(C)  in Figure 5.3A.  Thus, to control for this time elapsed, potential predictor variables 
were individually entered into a multiple linear regression model as a covariate along with log 
(time from dosing to delivery), to determine if they were associated with enrichment in the 
neonate while controlling for time elapsed from dosing to delivery.  Variables found to be 
significantly related to 
42
Ca(C) or 
44
Ca(C), while controlling for log(time to delivery), were 
considered predictors of neonatal Ca enrichment.  Statistical determinants of maternal-fetal Ca 
transfer (
42
Ca(C/M) and 
44
Ca(C/M); Eq. 3, 4) were also modeled, controlling for time in the exact 
same manner.  
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Figure 5.3  Generation of Time-Adjusted Neonatal Enrichment to Account for Variation in 
Time from Dosing to Time of Cord Blood Collection  
A. Log(Time from dosing to delivery) is inversely related to 
42
Ca enrichment in cord blood 
(
42
Ca(C); p = 0.069, R
2
 = -0.294).  To adjust for time to delivery, all initial enrichment points at t1 
were extrapolated back to where they would fall on the log(time) curve at t0: (the earliest cord 
collection; 4.58 hours), as shown with the circled dark point.  B. The extrapolated 
42
Ca 
enrichments in cord blood at t0 (
42
Ca(Adj: C)) following adjustment for time to delivery are 
normally distributed. 
 
 
Assessment of Relationships between Maternal-to-Fetal Ca Transfer and Neonatal Outcomes  
When testing if maternal-fetal Ca transfer was associated with neonatal bone outcomes, 
42
Ca(C/M) and 
44
Ca(C/M) were used as predictor variables.  In this case, entering log(time) as a 
covariate predictor of neonatal outcomes was inappropriate.  Thus, we needed to adjust the 
measure of 
42
Ca (C/M) and 
44
Ca (C/M) to control for the variation in time elapsed from maternal 
dosing to cord blood collection in order to determine more accurately if maternal-fetal Ca 
transfer was associated with neonatal outcomes.  We generated a measure of Ca transfer that 
accounted for time elapsed from dosing to delivery, and maternal enrichment.  We then used this 
new variable as an independent variable to test for associations with neonatal outcomes. 
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To derive this adjusted measure of Ca transfer we calculated an “adjusted”, 42Ca(C) 
(
42
Ca(Adj: C)) as the enrichment of neonatal circulation at t0 (the time of the earliest delivery), in 
order to control for differences in time from dosing to cord blood collection.  The slope of the 
curve of log(time) vs. enrichment was used to extrapolate back to obtain 
42
Ca(Adj: C) at t0, using 
42
Ca(C) observed at t1 (the time elapsed from dosing to delivery) as initial points.  A diagram of 
this generation of time-adjusted neonatal 
42
Ca enrichment is shown above in Figure 5.3B.  The 
equation derived from the log(time from dosing to delivery) vs. 
42
Ca(C) curve (Figure 5.3A) used 
to calculate this extrapolated 
42
Ca(Adj: C) enrichment was: 
42
Ca(Adj: C) = m x log(t0) + (
42
Ca(C)  – (m x log(t1))     (Eq. 5) 
t0 = time from dosing to the fastest delivery = 4.58 hours 
t1 = time from dosing to delivery 
m = slope of: 
42
Ca(C) vs. log (time from dosing to delivery) = -0.532219 
The same approach was used to extrapolate back to obtain 
44
Ca(C) extrapolated to t0 (
44
Ca(Adj: C)), 
using 
44
Ca(C) and the time from dosing to delivery (t1) as initial points: 
44
Ca(Adj: C) = m x log(t0) + (
44
Ca(C)  – (m x log(t1))     (Eq. 6) 
t0 = time from dosing to the fastest delivery = 4.58 hours 
t1 = time from dosing to delivery 
m = slope of: 
44
Ca(C) vs. log (time from dosing to delivery) = -0.615411 
 
To derive a measure of time-adjusted maternal-fetal Ca transfer that also controlled for maternal 
enrichment, we simply generated a ratio of 
42
Ca(Adj: C) to maternal enrichment at 2 hours 
(
42
Ca(M)).  The equation for this time-adjusted measure of Ca transfer was calculated as follows: 
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 Time-adjusted maternal-fetal Ca transfer of 
42
Ca = 
42
Ca(Adj: C/M) = 
42
Ca(Adj: C) (Eq. 7) 
                                  
42
Ca(M) 
 
Time-adjusted maternal-fetal Ca transfer of 
44
Ca = 
44
Ca(Adj: C/M) = 
44
Ca(Adj: C) (Eq. 8) 
                                 
44
Ca(M) 
 
Simple linear regression was used to determine if 
42
Ca(Adj: C/M) or 
44
Ca(Adj: C/M) was related 
to fetal femur or humerus Z-scores or birth length, and multiple linear regression was used to test 
the relationship while controlling for other known predictors of fetal femur or humerus Z-scores 
previously identified in this population: maternal race, height, weight gain, Ca intake, vitamin D 
status, placental weight and placental VDR expression (Chapter 3, 4). 
Statistical Analyses 
Analyses were performed using SAS V. 9.2 and JMP 8.0 (SAS Institute Inc, Cary, NC).  
Results are reported as mean ± standard deviation (SD) unless otherwise stated.  ANOVA was 
used to determine if categorical variables were related to maternal enrichment, neonatal 
enrichment and maternal-fetal Ca transfer.  Simple linear regression was used to evaluate 
potential linear statistical predictors of estimated maternal Ca utilization, neonatal enrichment 
and maternal-fetal Ca transfer.  Multiple linear regression was used to evaluate predictors of 
neonatal enrichment and Ca(C/M), always including log (time from dosing to delivery) as a 
covariate.  Variables that were significant with log (time) as a covariate were considered 
predictors.  If log (time) was not significant in the model, the p-value for the simple correlation 
was reported. 
 184 
 
When considering maternal-fetal Ca transfer as a predictor of fetal outcomes, simple 
linear regression was used to determine if the time-adjusted measures of maternal-fetal Ca 
transfer (
42
Ca(Adj:C/M) and 
44
Ca(Adj: C/M); Eq. 7, 8) were related to fetal outcomes.  Multiple linear 
regression was also used to control for other predictors of fetal long bone length.  In all 
modeling, variables that were not normally distributed were log transformed as necessary to 
assure normality of models’ residuals.  Normality was assessed using the Shapiro-Wilks test.   
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RESULTS 
Subject Characteristics 
 Characteristics of the participants and their neonates are presented below in Table 5.1.   
   
Table 5.1. Characteristics of Pregnant Adolescents (n = 12)  
Characteristic Mean ± SD 
Maternal Age (years) 17.3 ± 0.7 
African American 
Caucasian 
75% 
25% 
Calcium Intake (mg/day) 694 ± 230 
Pre-Pregnancy BMI (kg/m
2
) 28.44 ± 6.38 
Maternal Height (m) 1.58 ± 0.07 
Weight Gain (lbs) 44.6 ± 23.3 
Gestational Age Delivery (weeks) 39.9 ± 1.3 
Infant Sex (male) 67% 
Birth Weight (g) 3393 ± 426 g 
Fetal Femur Length Z-Score -0.314 ± 1.201 
Fetal Humerus Length Z-Score -0.457 ± 0.972 
 
 
Maternal age at entry into the study ranged from 16.5 to 18.6 years.  Reported Ca intake did not 
differ within subjects at different study visits, and thus the mean of reported Ca intakes was used 
(Chapter 1).  This ranged from 270 to 1110 mg/day, with only 17% meeting the EAR (1100 
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mg/day), and none meeting the RDA (1300 mg/day) (32).  The dietary Ca intake observed in this 
group was non-significantly lower (p = 0.063) than was observed in the larger cohort of pregnant 
adolescents from which these twelve teens were recruited (917 ± 416 mg/day, n = 163).   In this 
smaller group, there was a wide range in both pre-pregnancy BMI (18.8 – 42.1 kg/m2), and 
gestational weight gain (6.0 – 95.0 lbs).  Both pre-pregnancy BMI and gestational weight gain 
were significantly higher than the means observed in the larger pregnant adolescent cohort (24.7 
± 5.5 kg/m
2
, p = 0.019 and 37.1 ± 1.5 lbs, p < 0.0001, respectively).  No other characteristics 
presented in Table 5.1 significantly differed from characteristics of the larger cohort.  Infant 
birth weight ranged from 2503 to 3915 g; all infants were healthy upon delivery and had no 
antenatal complications.  Total serum Ca and calcitropic hormones in study participants and their 
neonates are presented below in Table 5.2.   
  
Table 5.2.  
Total Serum Ca and Calcitropic Hormone Concentrations in Maternal and Cord Blood
1
 
 Mid-Gestation 
(28.4 ± 2.7 weeks) 
Delivery 
(39.9 ± 1.3 weeks) 
Cord 
Blood 
25(OH)D (ng/mL) 17.6 ± 8.5
a
 18.4 ± 8.9
a
 17.5 ± 9.2
a
 
PTH (pg/mL) 17.5 ± 6.4
a
 33.7 ± 14.3
b
 5.8 ± 0.5
c
 
1,25(OH)2D (pg/mL) - 112.8 ± 37.2 - 
Serum Ca (mg/dL) 9.0 ± 0.3
a
 9.0 ± 0.3
a
 10.5 ± 0.7
b
 
1
 All values presented as mean ± SD. 
a, b, c
 Different letter superscripts indicate that values significantly differed in paired 
analysis:  p < 0.008 
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Approximately 75% and 50% of the adolescents were vitamin D insufficient (25(OH)D ≤ 
20 ng/mL) at mid-gestation and delivery, respectively.  Ten of the 12 adolescents were offered 
vitamin D supplements due to insufficient 25(OH)D concentrations observed at mid-gestation.  
Only eight adolescents received supplements, as two failed to return to the clinic after their mid-
gestation blood work was complete.  Only two adolescents self-reported consuming these 
vitamin D supplements on a daily basis over the remainder of gestation.  Concentrations of 
25(OH)D and the prevalence of 25(OH)D insufficiency at delivery did not differ between 
adolescents who were provided vitamin D supplements verses those who were not.  Cord blood 
25(OH)D did not statistically differ from maternal 25(OH)D at mid-gestation or delivery, and 
73% of neonates were vitamin D insufficient.  Adolescents who received vitamin D supplements 
were more likely to deliver neonates with 25(OH)D ≤ 20 ng/mL (p = 0.004).  Serum PTH was 
elevated (PTH > 46 pg/mL) in two of the adolescents (17%) at delivery.  PTH in cord blood was 
unrelated to maternal concentrations at either time point.  
Dosage and Enrichment Obtained 
 The oral and intravenous doses administered are shown in Table 5.3.  The oral dose 
represented ~0.052% of the miscible Ca pool size reported in pregnant women between 35 – 40 
weeks; the intravenous dose represented ~0.021% of the miscible Ca pool size (4).  The average 
time from dosing to the post-dose maternal blood draw was 2.11 ± 0.13 hours.  Time elapsed 
from dosing to cord blood collection was 8.41 ± 6.96 hours (range: 4.58 – 28.17 hours).   
Average enrichments (-% excess) observed in maternal and neonatal samples are presented 
below in Table 5.3, as are the ratio of fetal to maternal enrichments, the adjusted enrichments of 
the neonate at t0, as well as the ratio of the time-adjusted neonatal to maternal enrichments. 
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The estimates of maternal-fetal Ca transfer did not significantly differ between the 
intravenous and oral isotope (
42
Ca(C/M) vs. 
44
Ca (C/M); p = 0.17); nor did the time adjusted 
estimates of maternal-fetal Ca transfer (
42
Ca(Adj:C/M)  vs. 
44
Ca(Adj: C/M); p = 0.95).  
 
Table 5.3.  
Enrichment of Maternal Serum 2h Post-Dosing and of Cord Blood at Delivery
1 
Enrichment Value Abbreviation Eq. 
42
Ca 
44
Ca 
Dose Delivered (mg) -  1.062 ± 0.017
 
2.659 ± 0.050 
Maternal serum 
Enrichment (%) 
Ca (M) 1 4.963 ± 0.987 2.608 ± 1.567 
Neonatal Cord 
Enrichment (%) 
Ca (C) 1 2.807 ± 0.531 1.673 ± 0.832 
Maternal-fetal Ca 
Transfer 
Ca (C/M)  = Ca (C) 
                     Ca (M)   
3, 4 0.570 ± 0.056 0.881 ± 0.780 
Neonatal Enrichment  
at t0 (%) 
Ca (Adj:C) 5, 6 3.174 ± 0.446 2.097 ± 0.762 
Time-Adjusted Maternal-
fetal Ca Transfer 
Ca (Adj: C/M) = Ca(Adj:C) 
                       Ca (M)   
7, 8 0.650 ± 0.083 1.558 ±1.911 
1
 All values presented as mean ± SD. 
 
Predictors of Maternal Enrichment and Ca Absorption 
 Because the miscible Ca pool size is proportional to body size, enrichment of serum after 
dosing is inversely related to body size.  As expected, the enrichment of 
42
Ca in maternal 
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circulation (
42
Ca (M)) was significantly inversely related to pre-pregnancy weight (p = 0.023), 
weight at delivery (p = 0.013), BMI at delivery (p = 0.038), and estimated maternal blood 
volume (p = 0.037).  A trend was present for a negative association between 
42
Ca (M) and 
maternal leptin concentrations at mid-gestation (p = 0.104) and at delivery (p = 0.119).  
Enrichment of 
44
Ca in maternal circulation (
44
Ca (M)) was also significantly inversely related to 
maternal weight at delivery (p = 0.033) and leptin at mid-gestation (p = 0.046), and tended to be 
inversely associated with BMI at delivery (p = 0.094) and leptin at delivery (p = 0.080).  
Maternal Ca intake during pregnancy was significantly negatively associated with 
44
Ca (M) (p = 
0.029).   
Maternal Ca intake was also marginally negatively correlated with the relative measure of 
maternal Ca utilization (Eq. 2; p = 0.066, R
2
 = 0.30).  Maternal utilization of the oral tracer 
tended to be higher in the African American teens compared to the Caucasian participants (p = 
0.091).  Maternal Ca utilization was not related to any measure of maternal body size (pre-
pregnancy weight and BMI, height, weight gain, weight or BMI at delivery, blood volume, etc.), 
or 25(OH)D, PTH, or 1,25(OH)2D at any time point. 
Predictors of Neonatal Enrichment & Maternal-Fetal Ca Transfer  
The log(time from dosing to delivery) was used as a covariate when testing potential 
predictors of neonatal enrichment.  Table 5.4A shows variables found to be significantly related 
to Ca enrichment in the neonate at delivery, controlling for log(time).  As expected, the strongest 
predictor of 
42
Ca (C) was 
42
Ca (M).   The strongest predictor of 
44
Ca (C) was maternal height.  
Maternal Ca intake was significantly inversely related to 
44
Ca (C) (p = 0.040), even though 
44
Ca (C) 
was not related to the estimate of maternal 
44
Ca utilization (p > 0.51).  All of the other predictors 
of 
42
Ca (C) and 
44
Ca (C), were reflective of maternal body size and were inversely related to 
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neonatal enrichment.  No measures of 25(OH)D, PTH, or 1,25(OH)2D in maternal or neonatal 
circulation were related to neonatal enrichment.  Other variables that were unrelated to measures 
of neonatal enrichment included: race, gestational weight gain, season of delivery, vitamin D 
intake, infant size, and serum Ca.   
Statistical predictors of maternal-fetal Ca transfer (Ca(C/M); Eq. 3, 4), controlling for 
log(time to delivery), are shown in Table 5.4B.  Maternal vitamin D intake, maternal 25(OH)D 
sufficiency at mid-gestation, and placental VDR expression were significantly positively 
associated with 
42
Ca (C/M).  Variables not shown in Table 5.4B that were unrelated to either    
42
Ca (C/M) or 
44
Ca (C/M) include: PTH, 1,25(OH)2D, maternal weight, height, weight gain, and BMI, 
season of delivery, infant size, and serum Ca.   
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Table 5.4 
Predictors of Neonatal Enrichment at Birth (
42
Ca (C) and 
44
Ca (C)) and Maternal-Fetal Ca Transfer 
(
42
Ca (C/M) and 
44
Ca (C/M)), Controlling for Time-to-Delivery 
A. 
42
Ca (C)
 44
Ca (C)
 
Predictor p r p r 
Ca Intake (mg/d) 0.8904
2
 NA 0.0399
1
 -0.45 
Maternal Enrichment <0.0001
1
 0.88 0.0755
1
 0.43 
Maternal Leptin at Mid-Gestation 0.0165
1
 -0.67 0.0981
2
 -0.50 
Maternal Leptin at Delivery 0.0276
1
 -0.72 0.1710
2
 -0.42 
Pre-Pregnancy BMI 0.0555
1
 -0.66 0.3922
2
 NA 
Pre-Pregnant Weight 0.0068
1
 -0.67 0.1206
2
 -0.47 
Maternal Height 0.0371
1
 -0.41 0.0044
1
 -0.62 
Maternal Weight at Delivery 0.0027
1
 -0.52 0.1316
2
 -0.46 
Maternal BMI at Delivery 0.0172
1
 -0.67 0.3887
2
 NA 
Estimated Maternal BV at Delivery 0.0045
1
 -0.59 0.0651
1
 -0.46 
B. 
42
Ca (C/M)
 44
Ca (C/M) 
Predictor p r p r 
Vitamin D intake 0.0527
2
 0.57 0.8309
2
 NA 
Sufficient 25(OH)D at Mid-gestation 0.0490
2
 
 
Higher 
42
Ca (C/M) 
0.3067
2
 
 
NA 
Maternal Ca Utilization (Eq. 2) 0.5897
2
 NA 0.0481
2
 -0.60 
Placental VDR Expression 0.0042
2
 0.64 0.6038
2
 NA 
NA = Not applicable: no r value given for p > 0.30; BV = Blood volume 
1
 = p-value given is for parameter estimate when controlling for log(time to delivery)  
2
 = controlling for log(time to delivery) does not change correlation 
 
 
A multiple regression model of 
42
Ca (C/M), was generated that included the variables 
identified above as significant covariates, as well as log(time to delivery), placental weight and 
an interaction between placental weight and VDR expression as initial covariates.  After non-
significant predictors were removed from the model, log(time), placental VDR expression, and 
the interaction between placental weight and VDR expression remained significant covariates in 
the model of 
42
Ca (C/M), and together explained 80.0% of the observed variation in this measure of 
maternal-fetal transfer of 
42
Ca.  A similar approach was taken to model determinants of 
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maternal-fetal transfer of 
44
Ca (
44
Ca (C/M)); estimated maternal Ca utilization (Eq. 2) alone 
remained a significant predictor. 
Associations with Neonatal Bone Outcomes 
To determine if maternal-fetal  Ca transfer was related to fetal and neonatal skeletal 
outcomes, the time-adjusted measures of maternal-fetal Ca transfer (
42
Ca (Adj: C/M)   and 
44
Ca (Adj: 
C/M); Eq. 7, 8) were tested for association with fetal femur Z-score, fetal humerus Z-score, and 
birth length.  There were no significant relationships between either 
42
Ca (Adj: C/M)  or 
44
Ca (Adj: C/M)  
and any of these skeletal outcomes.  However, when models of fetal femur and humerus Z-scores 
were generated that included maternal race, height, weight gain, Ca intake, vitamin D status, 
placental weight and placental VDR expression as covariates, significant relationships between 
42
Ca (Adj: C/M)  and 
44
Ca (Adj: C/M)  and fetal skeletal outcomes became evident.  The best model of 
fetal femur Z-score in this cohort included the variables of maternal weight gain, maternal 
25(OH)D at delivery, placental weight, placental VDR expression, and 
42
Ca (Adj: C/M).  Together 
these variables explained 82.0% of the variation in fetal femur Z-scores (p = 0.013).   The 
addition of 
42
Ca (Adj: C/M) to this model of the model for fetal femur Z-score increased the R
2
 from 
0.58 to 0.82.  The best model of fetal humerus Z-score in this cohort included the variables of 
maternal race, height, weight gain, Ca intake and 25(OH)D at delivery, placental weight, 
placental VDR expression, the interaction between placental weight and VDR expression, and 
44
Ca (Adj: C/M).  Together these variables explained 99.9% of the variation in fetal humerus Z-
scores (p = 0.018).  The addition of 
44
Ca (Adj: C/M) to this model of fetal humerus Z-score increased 
the R
2
 by from 0.46 to 0.99.
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DISCUSSION 
 In this research we utilized a novel approach to obtain in-vivo measures of maternal-to-
fetal Ca transport in human pregnancy.  The data obtained inform our understanding of Ca 
dynamics during pregnancy, and suggest that maternal vitamin D status and placental expression 
of the vitamin D receptor (VDR) may play a role in regulation of Ca transport to the fetus.  
Additionally, the measures of maternal-fetal Ca transfer that we derived were significant in 
models of fetal femur and humerus length Z-scores, suggesting that increases in Ca transport to 
the fetus are incorporated into the developing fetal skeleton, and reflected in long bone length.   
We utilized a novel approach, administering dual-stable Ca isotopes to pregnant 
adolescents early in labor and assessing enrichment in maternal circulation post-dosing, and in 
cord blood at birth.  The main predictor of neonatal 
42
Ca enrichment was maternal 
42
Ca 
enrichment.  When characterizing enrichment of maternal serum post-dosing, the main statistical 
predictors of maternal enrichment were measures of maternal body size and leptin.  These 
measures were also negatively associated with enrichment in cord blood.  Serum leptin is 
reflective of adiposity and may be as a proxy measure of fatness.  However, leptin also has 
physiological properties, plays a role in maintaining energy balance during pregnancy (33), and 
has been shown to increase more-so in pregnant adolescents that are still growing, than in adult 
pregnancies (34).  It is unknown whether the negative association we detected between maternal 
serum leptin and Ca enrichment is simply a reflection of body size, or indicative of an alternate 
physiological role of leptin during pregnancy.   
 We derived estimates of maternal-fetal Ca transfer by generating a ratio of neonatal to 
maternal enrichment (
42
Ca(C/M) and 
44
Ca(C/M)) and these ratio estimates of maternal-fetal Ca 
transport of the oral and intravenous doses did not significantly differ.  This implies that there is 
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not preferential maternal-fetal transfer of Ca derived from a meal over Ca in the miscible Ca pool 
originating from other inputs, such as maternal bone turnover.  We report here that maternal 
vitamin D sufficiency at mid-gestation was positively associated with maternal-fetal 
42
Ca 
transport (
42
Ca(C/M)).  Our findings imply that maternal 25(OH)D sufficiency is associated with 
increased maternal-fetal transport of Ca to the fetus, which provides biological plausibility to the 
body of literature that links maternal 25(OH)D sufficiency with indices of fetal and infant bone 
(35), including fetal femoral development (15), and knee-to-heel length at birth (16).  We also 
report here that placental VDR expression is significant in models of maternal-fetal 
42
Ca 
transport (
42
Ca(C/M)).  This positive relationship is also biologically plausible, as the expression of 
many Ca transporters in the placenta are regulated by VDR-mediated 1,25(OH)2D activity (36).  
Increased VDR expression may increase expression of these transporters impacting net Ca 
transfer.   
In this small sample size, we observed that the time-adjusted estimates of maternal-fetal 
Ca transfer were associated with significantly more positive fetal femur and humerus length Z-
scores in multivariate models.  As Ca is the main mineral component of bone, is necessary for 
skeletal mineralization, and also plays a role in regulation of endochondral bone growth (37-39), 
it follows that increased transport of Ca to the fetus may result in increased long bone length.   
In the larger cohort of pregnant adolescents (from whom these participants were 
recruited) we have shown that placental VDR expression is a significant positive covariate in 
models of fetal femur Z-score (Chapter 4).  In this sub-study we show that placental VDR 
expression may regulate maternal-fetal Ca transport, which impacts fetal femur and humerus 
length.  These finding provide a physiological explanation of the association detected between 
VDR expression and fetal femur Z-score in the larger cohort (Chapter 4).  It is noteworthy that 
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adding our measure of maternal-fetal Ca transfer to models of fetal femur and humerus Z-scores 
resulted in a large increase in the R
2
 of the models.  Our sample size is quite limited and thus the 
modeling in this study is not nearly as powerful as the modeling of fetal femur Z-scores in the 
larger cohort (Chapters 3, 4).  Thus, the model characteristics presented here must be interpreted 
with caution.  However, it is still particularly noteworthy that the addition of this dynamic 
measure of actual in-vivo Ca transport (
42
Ca(Adj: C/M) and 
44
Ca(Adj: C/M)) to the other covariates 
(which are all static measures of maternal or placental characteristics) dramatically improved the 
predictive capacity of these models.  As fetal Ca demand and placental Ca transfer increases late 
in gestation (3), we may have improved our ability to detect differences in Ca transport by 
assessing this measure at term.  Furthermore, the potential competition for nutrients between 
maternal and fetal needs, combined with the low Ca intake and 25(OH)D status observed in this 
group of 12, may have also increased our ability to detect statistical relationships indicative of 
factors regulating placental Ca transport under suboptimal maternal availability.   
The dual isotope approach used in this study allowed us to generate a relative measure of 
maternal utilization of the oral dose.  Because we were only able to assess maternal enrichment 
at a single time-point, we were unable to calculate actual fractional Ca absorption.  However 
comparing the adjusted ratio of 
44
Ca to 
42
Ca in maternal circulation (Eq. 2) provides a relative 
estimate of maternal dietary Ca utilization between participants.  In this group, this relative 
measure of maternal Ca utilization tended to be higher in African American vs. Caucasian 
adolescents (p = 0.091).  Non-pregnant African American girls (age 5 – 16 years) exhibit higher 
rates of fraction and total Ca absorption compared to Caucasian counterparts  (40).  The same 
racial dichotomy may be observed in this study.  Maternal Ca utilization in this group was also 
inversely related to habitual Ca intake.  This relationships is not commonly detected in pregnant 
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populations (41-43), as fractional Ca absorption universally increases during pregnancy (4) even 
if Ca intake increases (41).  However, the inverse relationship between Ca intake and fractional 
Ca absorption is well documented among non-pregnant populations and non-pregnant 
adolescents (40;44).  The wide range in Ca intakes (270 to 1110 mg/day) in this group may have 
increased our ability to detect this association.  However, as our sample size was limited, the 
detection of such novel associations must be interpreted with caution.  Other innate factors in our 
study design that were beyond our control may have added error to our relative measure of 
maternal Ca utilization.  For instance, even though adolescents were not provided food upon 
admittance to the hospital, they arrived in various states of fasting.  Thus the contents of the gut, 
which impacts Ca absorption, cannot be controlled for.  Furthermore, this study was undertaken 
during labor, and it is not known to what degree intestinal Ca absorption is impacted by the 
physiological and hormonal state of parturition. 
This study is novel in its approach to obtain in-vivo measures of placental Ca partitioning 
in human pregnancy.  To our knowledge, this has never been attempted.  However, there were 
several limitations to this methodology that arose from the variable timing and unpredictable 
nature of delivery.  We controlled for time-to-delivery statistically, but were unable to control for 
the stage of labor at which the post-dosing maternal blood collection was obtained.  Undertaking 
this approach in women undergoing planned cesarean sections may allow for more accurate 
control over these variables.  However, planned surgical removal of the fetus introduces different 
stressors on the system that may impact results.  Neither approach is without limitations.  A 
larger sample size would also have increased our power to detect relationships and more 
accurately model determinants of maternal-fetal Ca transfer.   
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Despite these limitations, this study informs our understanding of placental Ca transport 
in humans.  We have shown that maternal 25(OH)D status and placental expression of VDR are 
associated with measures of maternal-fetal Ca transport.  This data suggests that increases in 
transport of Ca are incorporated into the fetal skeleton and reflected in fetal long bone length.   
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CHAPTER 6 
 
SUMMARY AND CONCLUSIONS 
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Summary        
This doctoral research describes and discusses novel findings regarding the impact of Ca 
intake and vitamin D status on calcitropic hormones during pregnancy, on indices of fetal and 
infant skeletal health, and on vitamin D receptor (VDR) expression in the placenta - in the 
context of adolescent pregnancy.  This work also reports findings generated by a novel approach 
to quantify placental Ca transfer in-vivo, and discusses the impact of maternal Ca intake and 
vitamin D status on this process.  There were four specific aims of this dissertation that were 
individually detailed and discussed in chapters two through five.  Below is a brief summary of 
the conclusions from each specific aim, followed by the implications of this research as a whole, 
and suggestions for future research. 
Pregnancy induces a variety of maternal physiological adaptations that occur to 
accommodate the demands of the developing fetus.  In order to increase Ca availability to the 
fetus and accommodate fetal skeletal growth, intestinal Ca absorption and metabolic bone 
activity increase significantly in the pregnant woman.  These physiological adaptations are 
accompanied by changes in the calcitropic hormones: PTH and 1,25(OH)2D.   
The first specific aim was to investigate how maternal Ca intake and 25(OH)D status 
were associated with temporal changes in calcitropic hormone concentrations across pregnancy 
in a cohort of pregnant adolescents.  This age group is at risk for both inadequate Ca intake and 
vitamin D insufficiency and may have an elevated Ca demand due to the combined Ca required 
for both continued maternal growth and fetal skeletal mineralization.  We detected a high 
prevalence of vitamin D insufficiency in these adolescents.  We also reported that PTH increased 
across gestation, and was elevated (≥ 46 pg/mL) in 40% of teens by delivery.  As most studies of 
PTH during pregnancy report that circulating concentrations of this hormone do not change 
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and/or remain low, this finding is novel.  Parathyroid hormone may be increased as a 
compensatory response to ensure adequate Ca supply to the fetus under conditions of a strained 
maternal Ca economy.  Data from markers of bone turnover in this group (presented in Appendix 
11) support this observation; adolescents who exhibited elevated PTH at delivery had 
significantly higher circulating concentrations of a marker of bone resorption when compared to 
adolescents with PTH concentrations within normal ranges.  The inverse relationship detected 
between 25(OH)D and PTH at mid-gestation and delivery suggests that low vitamin D status 
may exacerbate a constrained ability to maintain Ca homeostasis when demands are elevated, 
and also indicates that limited 25(OH)D may be impacting the elevated concentrations of PTH 
observed.  Serum 25(OH)D was also inversely related to 1,25(OH)2D in a time-delayed manner, 
while PTH and Ca intake were not related to 1,25(OH)2D.  Together these findings suggest that 
this cohort exhibits an increased Ca demand during pregnancy, and that maternal concentration 
of the vitamin D prohormone, 25(OH)D, was playing a significant role in these hormonal 
alterations.  The observed changes were not associated with maternal age across the 13-18 year 
age range in this adolescent study population.  Maternal Ca intake seemed to be less involved in 
regulation of these hormones at the relatively high Ca intakes observed (~ 1000 mg/day).  To our 
knowledge this is among the largest published study to date to report on Ca intake and 
1,25(OH)2D concentrations across pregnancy and among neonates at birth.  
Our second aim was to determine if maternal Ca intake and vitamin D status were 
associated with measures of fetal and infant skeletal health, and to determine if there was any 
interaction between these nutrients and fetal bone length.  Both maternal Ca intake and vitamin 
D status were associated with fetal femur and humerus length Z-scores and with neonatal length 
at birth.  Significant improvements in both fetal long bone Z-scores and birth length became 
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evident at a dietary Ca intake of 1050 mg/day.  Adolescents with sufficient 25(OH)D   (> 20 
ng/mL) exhibited more positive fetal femur and humerus Z-scores.  There was a significant 
interaction in the effects of Ca intake and 25(OH)D status that implied a capacity of one nutrient 
to compensate for limited intake/status of the other.  These findings have clinical relevance in 
that they suggest that achieving adequacy in only one nutrient may have a significant impact on 
fetal skeletal growth that is maintained at delivery.  This data underscores the importance of 
encouraging pregnant adolescents to meet dietary Ca intake recommendations and/or to achieve 
sufficient 25(OH)D status in order to ensure optimal fetal skeletal development.   
Our third specific aim was to investigate how maternal Ca intake and vitamin D status 
were related to VDR expression in the placenta, and if variation in VDR expression was related 
to fetal femur Z-scores.  Circulating concentrations of the hormonal form of vitamin D in the 
neonate (1,25(OH)2D) were most strongly linearly associated with placental VDR expression.  
Neonatal 25(OH)D status was significantly inversely related to placental VDR, but the analogous 
relationship with maternal 25(OH)D only approached significance.  Dietary Ca intake was not 
associated with placental VDR expression. These findings may suggest that placental VDR is 
increased as a compensatory response to limited neonatal 25(OH)D status, and is stimulated by 
circulating neonatal concentrations of 1,25(OH)2D.  Maternal 25(OH)D was not significantly 
associated with neonatal 1,25(OH)2D, further strengthening the independent effects of fetal 
signals on placental VDR expression. Functional consequences of placental VDR expression 
were also evident as indicated by the finding that placental VDR expression was a significant 
predictor of fetal femur length Z-scores.  Increased placental VDR expression may facilitate the 
placenta’s capacity for vitamin D – mediated regulation of gene expression, which may impact 
rates of Ca transport to the fetus. 
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Our final specific aim was to obtain in-vivo measures of placental Ca transport and 
determine if maternal Ca intake, vitamin D status, or placental VDR expression was associated 
with Ca enrichment of maternally administered stable Ca isotopes in the neonate at birth.  
Placental VDR expression was found to be a statistically significant predictor of maternal-to-
fetal transfer of intravenous isotope (
42
Ca) to the fetus, but was not associated with maternal-to-
fetal transfer of the maternally ingested isotope (
44
Ca).  The lack of a relationship with maternal-
to-fetal transfer of the oral isotope is likely due to the additional variability in this measure that 
results from individual variation in intestinal Ca absorption– variability to which the intravenous 
dose is not subject.  Maternal 25(OH)D status at mid-gestation (but not at delivery) was also 
associated with higher placental transfer of intravenous tracer to the neonate.  These relationships 
suggest that placental VDR expression facilitates Ca transfer to the fetus in-utero, which 
corroborates the association previously detected between placental VDR expression and fetal 
femur length (Chapter 4).  Finally, the in-vivo measures of maternal-to-fetal Ca transfer 
remained significant when entered into models of fetal femur and humerus length Z-scores 
linking our dynamic measures of placental Ca flux with static measures of fetal long-bone length 
in vivo.  
The relationships detailed in this research are summarized below in Figure 6.1. 
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Figure 6.1 Summary of Relationships Documented In Doctoral Research  
Summary of findings from chapters 2 – 5, indicating the significant relationships observed 
between maternal vitamin D status and maternal Ca intake on calcitropic hormones in the 
pregnant adolescent and neonate, placental expression of VDR, and fetal and neonatal skeletal 
outcomes.  Corresponding p-values for each relationship are indicated.  *The nature of the 
interaction indicated by the purple arrows, suggests that Ca intake is a significant predictor of 
fetal femur and humerus length and birth length only when maternal 25(OH)D ≤ 20 ng/mL.  
Similarly, maternal 25(OH)D sufficiency is a significant predictor of fetal femur and humerus 
length only when maternal Ca intake < 1050 mg/day.    
 
 
 
When the data as a whole is examined in Figure 6.1, the number of arrows originating 
from maternal Ca intake alone vs. maternal 25(OH)D or Ca/vitamin D interactions make it clear 
that maternal vitamin D status is significantly associated with the calcitropic response to 
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pregnancy in these adolescents, more so than Ca intake.  Furthermore, both maternal vitamin D 
status (25(OH)D) and both neonatal 25(OH)D and 1,25(OH)2D impact placental VDR 
expression, which is associated with dynamic measures of maternal-to-fetal Ca transfer and 
gestational-age adjusted measures of fetal femur length in-utero.  The modulation of placental 
VDR may be one mechanism by which maternal vitamin D status impacts fetal long bone Z-
scores and neonatal birth length.  Finally, the observed interaction between maternal Ca intake 
and vitamin D status on fetal and neonatal bone outcomes implies that the impact of vitamin D 
on fetal/neonatal outcomes is most significant when maternal dietary Ca intake is suboptimal and 
vice versa.  This interaction is clinically relevant as it implies that significant improvements in 
fetal and neonatal bone outcomes can be obtained if the cohort of Ca/D insufficient pregnant 
adolescents can achieve either adequate Ca intake (≥ 1050 mg/day) or sufficient 25(OH)D status.  
Placental transport of nutrients and subsequent fetal development is a highly complex 
process that is regulated by both maternal and neonatal factors.  Under conditions of suboptimal 
maternal Ca intake or inadequate vitamin D status, compensatory mechanisms, such as were 
observed in this study, may become active to ensure adequate nutrient supply to the fetus.  The 
large range in Ca intakes observed, the prevalence of inadequate 25(OH)D detected in this 
population, and the skeletal immaturity of this age group likely improved our ability to detect 
many of the relationships noted in Figure 6.1.  An additional strength of the study is the 
prospective longitudinal design, which provided us with an opportunity to address temporal 
trends in relevant calcitropic hormones.  The assessment of maternal nutrient intake, biomarkers 
of nutritional status in the mother and neonate, and assessment of fetal and neonatal bone 
outcomes adds to the overall impact of these data.   
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In this research, the effect sizes observed in relation to fetal and neonatal bone outcomes 
(eg: maternal Ca intake, 25(OH)D sufficiency, and placental VDR expression, etc.) were 
relatively small, explaining on average less than 10% of the variation in outcomes noted.  
However, as fetal skeletal development is known to be a complex process and is regulated by 
both environmental and genetic factors, a model with a large R
2
 was not expected.  It is 
estimated that fully ¾ of bone mass is genetically determined and not modifiable and that 
individual variation in Ca nutrition early in life only explains 5 -10% of peak adult bone mass 
(1).  This fits with the effect sizes described here.  However, it is also known that bone mass 
“tracks” throughout life (1), and as such a 5% difference in bone mass if maintained, may have a 
dramatic impact on subsequent skeletal health.  Existing data have found that even a  5 – 10% 
difference in peak adult bone mass translates into a 25 – 50% difference in hip fracture rate late 
in life (1).  Thus, to identify easily modifiable factors (such as Ca intake and vitamin D status) 
that are significant predictors of fetal bone length at any effect size, is of clinical significance to 
this population. 
The last month has witnessed a dramatic increase in the data available on calcitropic 
hormone and vitamin D status across gestation, and our data contribute to this increase in 
knowledge.  A very large cross-sectional study (n = 1016) was published in July, 2011 by 
Haddow et al. addressing the relationship between 25(OH)D and PTH early in pregnancy (11 – 
13 weeks) (2).   The large sample size and racial diversity (42% African American) of this cohort 
has addressed a well-known gap in existing literature (2).  Furthermore, just two weeks ago, 
Hollis et al. published the results of an NIH-funded,  randomized vitamin D supplementation trial 
during pregnancy (n = 530) (3).  Until this study was published, ours would have been the largest 
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report on 1,25(OH)2D during pregnancy and in the neonate.  It is still the largest to address these 
issues in pregnant adolescents.     
Haddow et al., detected similar findings and a similar racial dichotomy regarding the 
negative relationship between 25(OH)D and PTH as we detected in our pregnant adolescents (2).  
However they did not undertake analyses grouping both races together as a function of 25(OH)D 
status (as we did), to examine if it was the racial or vitamin D status that was driving the 
relationships observed.  In addition, their study was cross-sectional early in gestation at a time 
that fetal skeletal demands are low (11 -13 weeks of gestation), and therefore provides no data on 
PTH concentrations late in pregnancy, when fetal Ca demands are highest (2).  Hollis et al. 
established the safety of large doses of vitamin D and found these to increase 25(OH)D status.  
These data also described relationships between 25(OH)D and both PTH and 1,25(OH)2D across 
pregnancy (3).  A large randomized clinical trial of vitamin D supplementation during pregnancy 
has been widely called for in the literature, but the Hollis et al study suffered fundamental flaws 
in the randomization process (due to IRB regulation) that make interpretation of the intention-to-
treat analyses difficult.  Furthermore, the relationships reported between 25(OH)D and the 
calcitropic hormones were observational in nature, based on an analyses of  all supplementation 
groups combined.  Thus, despite the study being a randomized controlled trial, the inferences 
drawn are not of stronger evidence than our own.  Yet, despite these caveats, this study addresses 
a significant gap and adds to data on maternal calcitropic hormone physiology in adult women.  
Our study population was skeletally immature and vitamin D insufficient throughout pregnancy, 
and thus more likely to exhibit hormonal changes and relationships that are indicative of 
compensatory responses to meet fetal demand; such relationships may not be present or 
detectable in adult women.  Studies that focus only on early gestation may miss these changes, 
 213 
 
and studies that supplement with vitamin D result in improvements in 25(OH)D status that may 
independently impact homeostasis.  Furthermore, our data differ from Hollis and Haddow as we 
took a holistic approach to address all three physiological participants of pregnancy: addressing 
status and outcomes in the mother, the fetus, and at the level of the placenta.  As the placenta 
mediates nutrient transfer between the mother and fetus, our consideration of placental role in the 
maternal/fetal relationships observed increases the interpretation of our findings.  We also 
addressed the impact of vitamin D status on functional skeletal outcome in the fetus and neonate, 
beyond neonatal status only.  Finally, our studies increase knowledge regarding interactions 
between maternal Ca intake and vitamin D status during pregnancy – a point which both of these 
studies neglected to address.   
Our assessment of fetal femur/humerus length and neonatal birth length were important 
study outcomes as it has become increasingly appreciated that nutritional status and growth in-
utero impact the offspring’s subsequent risk of chronic disease in adulthood.  The links between 
maternal nutritional status and the fetal and neonatal skeletal measures described in this research 
contribute to the fetal programming literature, and to our understanding of fetal responses to 
maternal nutrient supply.  Finally, these data are of clinical relevance, as the Ca intakes and 
vitamin D status observed in this cohort are representative of the consumption and status patterns 
of many pregnant women in the United States, and thus these findings have broader relevance to 
adult pregnant women with inadequate Ca intake and/or vitamin D status and highlight the need 
for further research in this area.   
 
Limitations and Considerations 
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This research makes a legitimate contribution to our understanding of calcitropic 
hormone response and fetal programming in adolescent pregnancy.  However, our study had 
several limitations that may be addressed in future research.  As discussed in Chapter 2, there are 
limitations to assessing PTH status from a single blood sample that was not taken in the fasted 
state at a standardized time.  There are also limitations to assessing habitual dietary intake using 
a 24 hour recall and food frequency questionnaire.  Additional measures of maternal and 
neonatal BMC at birth would have strengthened study outcomes but proved too difficult to 
obtain logistically in this age group and clinical setting.  It would have been preferable to have 
recruited only non-smoking teens but recruitment was expanded to maximize study numbers.  
The timing of our study measures was highly variable given compliance issues in this age group.  
In addition, concurrent adult data would have allowed us to more fully distinguish adolescent 
effects from those due to Ca and vitamin D insufficiency, but study funding limitations 
precluded these measures.  Many of our variables were self-reported and may not be accurate in 
this group and there are no good biomarkers for Ca intake.   
While there are many limitations and study design components that could have been 
improved upon, working with a pregnant adolescent population is extremely challenging, as they 
are a vulnerable research population, have limited independence, limited access to transportation 
and/or are not old enough to drive, and this age-group is often unreliable in terms of follow-up 
and self-reported data.  The lack of post-partum follow up data on bone outcomes is a limitation 
to this research, and is called for in this population.  The frequent change in permanent residence, 
and contact information made follow up in this particular cohort impossible.  However, these 
data would inform our understanding of the sustained effects of maternal Ca intake and vitamin 
D status during adolescent pregnancy on subsequent maternal and offspring outcomes.  
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Future Directions 
These data have provided novel insight into the impact of maternal vitamin D and Ca 
status during pregnancy on the calcitropic hormone response to pregnancy, placental expression 
of VDR, transfer of Ca to the fetus, and fetal bone growth.  These findings have also generated 
new questions.  Additional research on the impact of elevated PTH and low 25(OH)D on 
maternal bone mass across pregnancy are needed in this pediatric population.  Given the 
significant interactions observed between dietary Ca and vitamin D status, additional studies 
assessing dietary interventions with controlled intakes of both nutrients should be explored.  
Studies are also warranted to determine if the fetal bone deficits observed in-utero and the birth 
length deficits observed at birth are maintained or if these deficits are influenced by subsequent 
diet or adaptations that occur in early growth.  Studies assessing net skeletal accretion in the 
neonate at birth are also called for, as these assessments were not possible in this cohort.   
This research has also identified novel relationships between neonatal vitamin D status 
and placental expression of VDR.  Mechanistic studies are needed to examine the possible 
additional effects of increased VDR expression on other VDRE-containing genes in the placenta.  
Similarly, additional work is needed to fully explore 1,25(OH)2D / VDR action in the placenta, 
given the known and varied endocrine, paracrine, and intracrine effects of this hormone in 
various tissues.  Animal models may be particularly useful in investigating how the placental 
responds to fetal endocrine signals.  Fetal calcitriol production can be up-regulated by altering 
the fetal genome and placental gene expression and Ca transport can be monitored in response to 
targeted manipulations of the system.  Additional studies documenting the effect of maternal diet 
on the outcomes studied would also improve our understanding of the placental role in nutrient 
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partitioning and the mechanisms in place to regulate partitioning between the adolescent and 
fetus.  
Finally, these results also call for more qualitative studies to understand the roots of the 
poor supplement adherence, unhealthy dietary patterns and extremes of gestational weight gain 
observed in these adolescents.  Results from such work are necessary in order to design age-
appropriate interventions that target at-risk teens early in pregnancy and provide adequate 
nutrition and education to ensure achievement of optimal nutrient status by term.  Such research 
can improve maternal and birth outcomes in this vulnerable age group and ensure adequate 
neonatal endowment of key nutrients, which will result in immediate and possible long-term 
health gains. 
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ABSTRACT         
Osteoprotegerin (OPG) is involved in the regulation of bone turnover but little is known about 
this protein during pregnancy or among neonates.  We undertook a prospective longitudinal 
study to identify relationships between OPG, markers of bone turnover, and birth outcomes in 
155 pregnant adolescents (13-18 y) and their newborns. Maternal blood samples were collected 
at mid-gestation and at delivery.  Cord blood was obtained at delivery.  Serum OPG, estradiol, 
and markers of bone formation (osteocalcin) and resorption (N-telopeptide) were assessed in all 
samples.  Placental OPG expression was assessed in placental tissue obtained at delivery.  Bone 
markers and OPG increased significantly from mid-gestation (26.0 ± 3.4 weeks) to delivery (39.3 
± 2.6 weeks).  Neonatal OPG was significantly lower, but bone turnover markers significantly 
higher than maternal values at mid-gestation and at parturition (p<0.001).  African American 
adolescents had higher concentrations of OPG than Caucasian adolescents at mid-gestation (p = 
0.01) and delivery (p = 0.04).  Gestational age and estradiol were also predictors of maternal 
OPG at mid-gestation and delivery.  OPG concentrations in cord blood were correlated with 
maternal OPG concentrations and were negatively associated with infant birth weight Z-score (p 
= 0.02) and ponderal index (p = 0.02).  In conclusion, maternal OPG concentrations increased 
across gestation and were significantly higher than neonatal OPG concentrations.  Maternal and 
neonatal OPG concentrations were not associated with markers of bone turnover or placental 
OPG expression, but neonatal OPG was inversely associated with neonatal anthropometric 
measures.  Additional research is needed to identify roles of OPG during pregnancy. 
KEY WORDS      
Adolescent Pregnancy, osteoprotegerin, Birth Weight, Bone 
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INTRODUCTION   
Adolescent pregnancy is a significant public health problem in the United States.  
Approximately 410,000 adolescents gave birth in 2009.
1
  When childbearing occurs prior to 
attainment of peak skeletal mass, there is a potential competition for nutrients between the 
adolescent and her developing fetus.  Pregnant adolescents also have a greater risk for adverse 
birth outcomes including premature birth, low birth weight, and higher neonatal mortality when 
compared to adult women.2 
Pregnancy is a state of high bone turnover as maternal calcium physiology responds to 
the calcium demands required to mineralize the fetal skeleton.  Several studies have noted that 
markers of bone turnover increase throughout gestation.3-6  Osteocalcin (OC) is the major non-
collagenous protein found in bone and is commonly used as an index of bone formation.  N-
telopeptide (NTX) is a collagen cross-linking domain that is released into the circulation when 
bone is resorbed.  Although overall bone metabolic activity increases during pregnancy, many 
reports have documented a net loss of maternal trabecular bone following gestation.
3,4,7
  This 
pregnancy induced bone loss is greater in pregnant adolescents than among pregnant adults.
8,9
  
 In 1997, the Receptor Activator of Nuclear factor Kappa-β (RANK) / RANK-ligand 
(RANKL) / Osteoprotegerin (OPG) system was identified as a major regulator of the coordinated 
activity of osteoclasts and osteoblasts.
10
  Interactions between RANK and RANK-L stimulate 
osteoclastogenesis and bone resorption.  Osteoprotegerin (OPG) is a soluble decoy receptor for 
RANKL and may protect bone mass by limiting RANK / RANK-L interactions.
11
  At present, 
few studies have investigated OPG concentrations during pregnancy.  Existing data are limited, 
and comprised of a few relatively small, cross-sectional studies,
12-14
  that suggest that OPG 
concentrations increase from early pregnancy (15-18 weeks) to term.
12-14
  It is known that the in-
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utero environment plays a role in programming offspring’s risk for chronic disease in adult 
life.
15,16
  Several studies have linked infant size at birth with adult BMC and risk of 
osteoporosis.
17,18
  Currently, the possible impact of variation in circulating OPG during 
pregnancy and in the fetus on bone turnover makers or other maternal or neonatal characteristics 
remains unexplored.   
The objective of this research was to characterize the longitudinal changes and 
determinants of circulating OPG concentrations across gestation in a large cohort of pregnant 
adolescents and their neonates.  We aimed to determine if OPG concentrations in neonatal and 
maternal circulation were significantly related, and if they were associated with other variables 
including bone turnover markers and placental OPG expression.  We also investigated whether 
maternal or neonatal OPG concentrations were associated with infant birth weight Z-score and 
ponderal index.    
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 METHODS 
Study Participants: 
A cohort of 155 pregnant adolescents (≤ 18 y) was recruited to participate in a 
prospective, longitudinal study of calcium and bone homeostasis. Adolescents were recruited 
from the Rochester Adolescent Maternity Program (RAMP) in Rochester, NY.  Pregnant 
adolescents were between 12 - 30 weeks of gestation at entry into the study, were otherwise 
healthy, and were carrying a single fetus.  Exclusion criteria included known medical 
complications or diseases such as HIV infection, diabetes, gestational hypertension and 
diagnosed eating disorders or malabsorption diseases.  Informed written consent was obtained 
from all participants, and study procedures were approved by the Institutional Review Boards of 
the University of Rochester and Cornell University.  Maternal race, ethnicity (Hispanic or non-
Hispanic), and smoking history were self-reported.  Infant race was classified as African 
American if the mother reported both herself and the father as African American; as Caucasian if 
the mother reported both herself and the father as Caucasian; or as biracial if the infant’s 
maternal and paternal reported race differed.  Infant ethnicity was classified similarly as either: 
Hispanic, non-Hispanic, or multi-ethnic.  Age at menarche was self-reported, and gynecological 
age was calculated as the number of years elapsed from menarche to conception.  At birth, infant 
weight and length were recorded by clinical staff using standard procedures and neonatal 
ponderal index (kg/m
3
) was calculated using the length and weight measures.  Birth weight Z-
scores were generated using published curves specific to infant sex and gestational age at birth.
19
  
Upon delivery, the placenta was collected and weighed to the nearest 0.1 g.   
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Blood Sample Collection and Analyses: 
A maternal blood sample (10 mL) was collected at mid-gestation by clinical staff during 
a routine prenatal visit.  Because most visits occurred mid-day, participants were not counseled 
to fast before blood collection.  At delivery, a second, non-fasting maternal blood sample and a 
10 mL cord blood sample were collected.  All samples were allowed to clot at room temperature 
before serum was separated and stored at -80
0 
C until analysis.  All biochemical analyses were 
obtained using these serum samples.   
Maternal and cord blood NTX concentrations were measured in serum by ELISA (Ostex 
International, Seattle, WA) at the University of Rochester CLIA certified laboratory.  
Osteocalcin was measured at Yale University in the laboratory of Dr. Caren Gundberg using a 
radioimmunoassay that recognizes both the intact and major proteolytic product, as previously 
published
20
 (intra-assay and inter-assay coefficient of variation (CV) were 3.8% and 7.1%, 
respectively).  Serum OPG was measured using a commercially available ELISA (DY805: R&D 
Systems, Minneapolis, MN; inter- and intra-assay CV were 5.5% and 6.5%, respectively) and 
estradiol was analyzed using a commercially available ELISA from Alpco Diagnostics (Salem, 
NH; inter- and intra-assay CV were 4.2% and 10.1%, respectively).  Leptin was measured using 
a commercially available ELISA from Millipore (Billerica, MA; inter- and intra-assay CV were 
4.5% and 8.3%, respectively).  
Placental Collection and Western Blot: 
Five, one-square-inch placental tissue samples were collected from various locations 
throughout the entire placenta in order to obtain as representative a sampling as possible.  
Maternal and fetal membranes were removed and tissue samples were pooled, homogenized, and 
frozen at -80
0 
C until analysis.  Protein lysates were generated using a Polytron PT3100 tissue 
 261 
 
homogenizer (Kinematica, Inc., Lucerne, Switzerland) at 5,000 rpm in a hypertonic lysis buffer 
containing protease inhibitor.  Homogenized tissue was centrifuged at 13,000 rpm for 20 minutes 
at 4
0 
C.  Protein concentrations in the supernatant were determined with the Bio-Rad assay (Bio-
Rad, Hercules, CA).  Lysates were frozen at -80
0 
C in SDS sample buffer until analysis. 
Relative placental OPG expression was determined via Western blot.  Lysates were 
separated on a 10% SDS-PAGE gel and transferred to a PVDF membrane (Millipore, Billerica, 
MA).  Membranes were blocked in Odyssey Blocking Buffer (Li-Cor BioSciences, Lincoln, NB) 
for 1-h at room temperature and then probed with Goat-anti-OPG (AF805: R&D Systems, 
Minneapolis, MN) at a concentration of 0.3 µg/mL and Rabbit-anti-β-actin (AbCam, Cambridge, 
MA) at 6.7 ng/mL overnight at 4
0 
C.  Fluorescent secondary antibodies were used: Donkey-anti-
Goat 800 at a concentration of 0.17 µg/mL (Li-Cor BioSciences), and Chicken-anti-Rabbit 647 
at 0.13 µg/mL (Invitrogen, Carlsbad, CA).  All antibodies were made in a solution of Odyssey 
blocking buffer diluted 1:1 in a phospho-buffered saline (PBS) solution.  The OPG and β-actin 
bands were quantified using the Odyssey infrared imaging system (Li-Cor Biosciences), and the 
ratio of OPG to β-actin calculated.  Intra-membrane variation was controlled for by normalizing 
the OPG: β-actin ratio of individual placentas to a standard control placental sample that was run 
on every gel.  This standard placental control lysate was prepared as described above using tissue 
collected from a healthy adult woman delivering at term. 
Statistical Analyses: 
Statistical analyses were undertaken using SAS 9.2 and JMP 8.0 (SAS Institute Inc, Cary, 
NC).  Results are reported as the mean ± standard deviation (SD) unless otherwise noted.  Paired 
t-tests or non-parametric tests were used to assess changes in biochemical markers within 
subjects from mid-gestation to delivery.  Independent t-tests or ANOVA were used to determine 
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if normally distributed variables differed by race, and the Wilcoxon Rank sum test was utilized 
for nonparametric data.  The Shapiro Wilks test was used to assess normality of variables.  
Simple and multiple linear regression were used to assess statistical determinants of OPG at mid-
gestation and delivery.  Non-normally distributed variables were log transformed as necessary to 
ensure normality of models’ residuals.  In multiple linear regressions, interaction terms were 
evaluated, but none were significant and thus are not reported.  When modeling determinants of 
mid-gestation OPG concentrations, one participant’s data were excluded because her OPG value 
was an outlier (over four standard deviations from the mean).  Study findings were not impacted 
if this data point was included or excluded.  Simple and multiple linear regression analyses were 
used to assess the relationships between OPG and infant outcomes.  Sample size calculations 
were undertaken to determine the sample size necessary to appropriately characterize mean OPG 
concentrations and yield a minimal detectable difference equivalent to 25% of the previously 
reported standard deviation in OPG concentrations in pregnant women at term.  Using these 
parameters, we required a sample size of 120 to yield a power of 80% at an alpha of 0.05.
14
  The 
sample size we achieved in this study also provided us with 80% power (α = 0.05) to detect a 
minimal detectable difference of 0.24 in birth weight Z-score and 0.10 kg/m
3
 in ponderal 
index.
19,21
  Data were considered significant if P values were <0.05.  P values between 0.05 and 
0.10 were considered trends. 
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RESULTS 
Subject Characteristics 
Characteristics of the study population as a whole, and among the group when stratified 
by race are presented in Table 1.  Of those enrolled; 65% were African American and 35% were 
Caucasian.  Two teens identified their race as American Indian.   In order to collapse maternal 
race into a bivariate category and avoid loss of data from the two American Indian adolescents, 
these two adolescents were included within the African American cohort.  None of the race-
specific analyses differed if data were analyzed with these two adolescents combined with either 
the African American or Caucasian cohorts, and all study results remained significant if these 
two subjects were excluded.  Maternal age at enrollment into the study ranged from 13.6 to 18.7 
years and birth weight Z-score ranged from -2.58 to 2.09.  Approximately 8.6% of teens 
delivered prematurely (<37 weeks); 12.0% delivered a low birth weight (LBW) infant (<2500 g), 
and 6.7% delivered a large for gestational age (LGA) infant (>4500 g).  A significantly higher 
percentage of Caucasian participants self identified as Hispanic (55.6%) than did African 
American participants (6.9%; p<0.01).  There were no differences in length of gestation, birth 
weight, birth weight Z-score, ponderal index, rate of preterm, LBW, or LGA by infant sex, or 
maternal race (Table 1).  
Estradiol increased by 127% (3077 ± 1674 vs. 5802 ± 2880 pg/ml) over the 13.1 ± 4.3 
week interval that elapsed from the mid-gestation to delivery blood collection.  The observed 
gestational increase in estradiol did not differ by race or maternal age across the 13-18 y age 
range studied. 
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Relationships between circulating maternal OPG and markers of bone turnover  
Mean maternal concentrations of OPG, NTX, and OC all increased significantly from 
mid-gestation to delivery (p<0.001) (Fig 1) and mid-gestation values were significantly 
correlated with those at delivery (p<0.001 for all; n = 111, R
2
 = 0.55; n = 114, R
2
 = 0.10; n = 
120, R
2
 = 0.27, respectively).  Serum OC and NTX were highly correlated with each other at 
mid-gestation (26.0 ± 3.4 weeks: p<0.001, n = 137, R
2
 = 0.08) and at delivery (39.3 ± 2.6 weeks: 
p<0.001, n = 113, R
2
 = 0.26).  Furthermore, the rate of increase in OC from mid-gestation to 
delivery (change in OC (ng/mL)/weeks elapsed) was highly correlated with rate of increase in 
NTX (p = 0.002, n = 84, R
2
 = 0.11).  While correlated, the relative percent increase in NTX was 
significantly greater than the increase observed for OC (63% vs. 38%; p<0.001, n = 105).  OPG 
was not significantly associated with NTX or OC at any time point measured.  The relative 
increase in OPG (54%) did not significantly differ from that observed for NTX or OC.  Neither 
maternal age (range: 13.6 – 18.7 y), nor gynecological age (range: 1.2 – 10.7 y) were associated 
with markers of bone turnover or OPG at any time point measured.  Osteocalcin was higher in 
Caucasian adolescents at delivery than in African American adolescents (p = 0.023), although 
the difference between the observed means was minimal (0.7 ng/mL) and the relative increase in 
OC from mid-gestation to delivery did not differ as a function of race.  In contrast, no significant 
differences in NTX were evident between racial groups when examined as either absolute values 
or as percent change across gestation.   
Variables associated with circulating maternal OPG 
At mid-gestation, none of the following variables were related to circulating OPG 
concentrations: maternal weight, weight gain, leptin, chronological age, gynecological age, 
maternal height, pre-pregnancy weight or BMI.  At mid-gestation, both estradiol (p = 0.001, n = 
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136, R
2
 = 0.08) and gestational age at sampling (p = 0.010, n = 139, R
2
 = 0.05) were significantly 
positively associated with OPG.  Furthermore, OPG in African American adolescents was on 
average 506 pg/mL higher than the mean observed in Caucasian adolescents (p = 0.007, n = 
139).  When NTX, estradiol, race, and gestational age were all entered into a model of mid-
gestation OPG, gestational age was no longer significant. The best model identified (using 
maternal mid-gestation NTX, estradiol and race as predictors) accounted for 20% of the 
variability (p<0.001) in mid-gestation OPG. 
 At delivery, circulating OPG concentrations were not significantly related to maternal 
weight, weight gain, delivery leptin concentrations, height, pre-pregnancy weight, chronological 
age, or gynecological age.   Similar to observations evident at mid-gestation, delivery OPG 
concentrations were significantly and positively related to gestational age (p = 0.013, n = 123, R
2
 
= 0.05) and were also positively associated with pre-pregnancy BMI (p = 0.036, n = 123, R
2
 = 
0.04).  The racial difference in OPG persisted, and was of similar magnitude (444 pg/mL, p = 
0.044) to that observed at mid-gestation.  The relationship between estradiol and OPG at delivery 
approached significance (p = 0.053, n = 122, R
2
 = 0.03), and was thus included as a covariate in 
the initial model of maternal OPG at delivery.  The best model identified to predict OPG at 
delivery included estradiol, gestational age, and race (p = 0.010), but this model predicted only 
7% of the variation in maternal OPG.    
Neonatal OPG, OC, and NTX  
NTX and OC were significantly higher in cord blood than in maternal blood at delivery 
(p<0.001).  In contrast, OPG was significantly lower in cord vs. maternal blood at delivery 
(p<0.001) (Fig 1).  Cord blood OC tended to correlate with maternal OC at mid-gestation (p = 
0.05, n = 100, R
2
 = 0.04), but not at delivery.  NTX in cord blood was not associated with 
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maternal levels at any time point or with cord OC or OPG concentrations.  In contrast, cord OPG 
concentrations were highly correlated with maternal OPG concentrations at mid-gestation 
(p<0.010, n = 99, R
2
 = 0.07) and at delivery (p = 0.001, n = 106, R
2
 = 0.06).  Neonatal OPG was 
not associated with maternal or infant race, infant sex, estradiol, pre-pregnancy BMI, gestational 
age at delivery, or any other study variable collected. 
Relationships between neonatal OPG concentrations and infant anthropometrics at birth 
Neonatal OPG was significantly inversely correlated with both birth weight Z-score (p = 
0.029; Fig 2A) and ponderal index (kg/m
3
) (p = 0.014; Fig 2B).  As expected, gestational age 
explained 37% of the variation in birth weight.  Neonatal OPG alone was not significantly 
associated with infant birth weight (p = 0.18).  However, when neonatal OPG was added as a 
covariate along with gestational age, OPG became a significant predictor of birth weight 
(parameter estimate p = 0.020, n = 113), and explained an additional 3% of the variation in birth 
weight.  Similarly, gestational age at delivery explained 6% of the variability in ponderal index 
at birth.  When neonatal OPG was added as a covariate to the model for ponderal index, the 
parameter estimate for OPG remained significant (p = 0.006) and explained an additional 2% of 
the variation in infant ponderal index.   
The difference in average birth weight Z-score between the highest and lowest quartiles 
of cord blood OPG was 0.347.  This difference represents a 192 g higher mean birth weight 
between the lowest vs. highest quartile of neonatal OPG.  The difference in ponderal index 
between the lowest and highest quartiles of neonatal OPG was 1.72 kg/m
3
.  Overall, the mean 
ponderal index of infants in the highest quartile of neonatal OPG was significantly lower 
(p<0.001) than the average ponderal index previously published from a large cohort (n = 1,040) 
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of term infants.
21
  The observed relationships between OPG and ponderal index and between 
OPG and birth weight Z-scores were independent of maternal and neonatal race.   
Placental OPG 
Placental OPG expression (via western blot) was assessed in 68 placental samples; a 
representative blot is shown in Fig 3.  Neither placental weight nor placental expression of OPG 
was significantly associated with maternal OPG at mid-gestation or at delivery or with any of the 
other study measures obtained. 
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DISCUSSION  
In this group of pregnant adolescents and their neonates, we found that maternal serum 
OPG concentrations across gestation and at birth were not significantly associated with maternal 
or neonatal bone turnover markers.  Significant differences in maternal OPG concentration as a 
function of race were evident at both mid-gestation and at parturition.  Of interest, neonatal 
concentrations of OPG were significantly correlated with, but lower than maternal concentrations 
and were negatively associated with neonatal anthropometric variables.   
Expression of OPG has previously been characterized in the human placenta, amnion, 
and choriodecidual tissue.
10,13,22
  Because maternal circulating OPG concentrations have been 
found to decrease by 38% within 4 days post-partum,
14
 it has been postulated that the placenta 
contributes to circulating OPG during pregnancy.
13
  However, while we were able to detect 
placental expression of OPG, we found no significant associations between placental OPG 
expression and OPG concentrations in maternal circulation at mid-gestation or delivery, or in 
neonatal blood at term.  In contrast, maternal and neonatal OPG concentrations were highly 
correlated.  Because little is known about the transfer of this protein across the placenta, the 
relative contribution of maternal or placental OPG to fetal concentrations remains unknown.    
A significant negative relationship was noted between neonatal umbilical cord OPG 
concentrations and both birth weight Z-score and ponderal index.  This is the first time, to our 
knowledge, that such a relationship has been reported.  Neither the observed relationships nor 
infant characteristics were significantly influenced by maternal or infant race.  A study by Briana 
et al. found no significant association between cord OPG concentrations and birth weight, and no 
difference in OPG between appropriate for gestational age (AGA; n = 20) and IUGR (n = 20) 
infants,
23
 but their relatively small sample size may have limited their ability to detect 
 269 
 
associations.  Our observed association between cord OPG concentrations and neonatal birth 
weight Z-score may hint at a role for OPG in neonatal accrual of body stores of fat, bone, or 
muscle.  In a study of lean and obese children (ages 5 – 16 y), OPG was negatively associated 
with total and truncal body fat mass when correcting for pubertal stage and gender.
24
  However, 
in our study, OPG in cord blood was not related to cord blood or maternal leptin concentrations.  
The lack of a relationship between neonatal OPG and other indices of maternal nutritional status 
(BMI, weight gain, etc.), suggests that the association between neonatal OPG and neonatal size 
at birth is independent of maternal BMI during pregnancy.   
The in-utero environment (nutritional and environmental) is known to impact fetal 
skeletal development and mineralization,
17,25-27
 and changes evident at birth may be sustained 
into childhood and adulthood.
28,29
  Maternal under-nutrition or “constraint” in-utero may impact 
offspring’s adult risk of osteoporosis as studies have linked size at birth with adult bone mass,17 
and shown that the in-utero environment mediates the impact of genetics on adult BMC and 
BMD.
30,31
  We report a significant negative relationship between cord OPG and both birth 
weight Z-score and ponderal index.  Elevated OPG concentrations were observed among 
neonates that were smaller at birth.  Because OPG plays a well-characterized role in the 
coordinated balance of osteoblast/osteoclast activity;
10,11
 the elevated neonatal OPG may 
potentially play a programming role in subsequent bone growth and mineralization.  A limitation 
of this study was that post-natal neonatal DXA measures were not obtained.  These were 
originally planned but lack of compliance with the scheduled appointments following pregnancy 
precluded these measures.   
Possible associations between OPG concentrations and concurrent changes in bone 
metabolic activity were explored.  While significant increases in bone turnover markers occurred 
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across pregnancy, no significant relationships were evident between serum OPG and either OC 
or NTX in these adolescents.  These findings are consistent with earlier data in pregnant adult 
women.
13,14
  The lack of association between OPG and markers of bone turnover may indicate 
that OPG is playing additional roles aside from regulation of bone turnover during pregnancy.   
In this group of pregnant adolescents, maternal OPG concentrations were significantly 
associated with gestational age over the time interval in which the mid-gestation blood samples 
were obtained (week 20 to week 37).  Additionally, in the cohort as a whole, and in paired 
analyses, OPG concentrations significantly increased from the mid-gestation measure to the 
measure obtained at delivery.  Other studies have shown that OPG increases throughout  
pregnancy.
13,14
  Previous data from adult women have reported that OPG increases from 38% to 
86% in the third trimester.
4,14
  Our finding of a 54.2% increase in OPG from 26.0 ± 3.4 weeks 
gestation to delivery (39.3 ± 2.6 weeks gestation) is consistent with these prior data.  While 
relative changes in OPG across gestation are variable, the absolute value we observed in these 
pregnant adolescents is significantly higher than previously reported for pregnant adults; in 
which values ranged from 863 pg/mL at 36 weeks,4 to between 132 pg/mL,
12
 to 1400 pg/mL at 
delivery.
14
  Currently, no standard reference materials for OPG exist, thus we cannot rule out 
methodological differences as the source of the elevated OPG concentrations evident in our 
adolescent population.  Elevated OPG concentrations have previously been reported among other 
groups known to have alterations in bone turnover, namely osteoporotic and anorexic women.
32-
34
  In these groups, the elevated OPG has been attributed to OPG’s compensatory bone sparing 
properties.
32-34
  While the OPG concentrations in this adolescent cohort were higher than 
typically reported among adult women, OPG concentrations were not significantly related to  
either chronological nor gynecological age of the adolescent.  
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Maternal race and circulating estradiol were significant predictors of maternal OPG at 
mid-gestation and at delivery. Previous data have shown that estradiol induces OPG expression 
in osteoblastic cells in-vitro,
35,36
 but an earlier in-vivo study failed to detect a relationship 
between estradiol and OPG in serum during pregnancy.
4
  The much larger sample size of our 
population and the increased bone turnover that occurs in pregnant adolescents may have 
influenced our ability to detect the observed associations.  In this group of pregnant adolescents, 
African American teens exhibited significantly higher OPG concentrations compared to the 
Caucasian adolescents.  This is the first time to our knowledge that a racial difference in OPG 
has been reported in a pregnant or non-pregnant population.  Significantly higher bone mass is 
known to be evident among African American vs. non-Hispanic Caucasian women.
37
  Our 
observed differences in OPG are consistent with these racial differences in bone mass.   
The role of OPG during pregnancy remains poorly understood.  Despite the significant 
associations observed in our study, we were able to capture only a small percentage of the 
variability in OPG (20% at mid-gestation and 7% at delivery) using the available study 
measures.  In addition to classically-described roles, OPG also serves as a decoy receptor for the 
apoptosis-inducing ligand (TRAIL),
38
 and binds both TRAIL and RANKL with similar 
affinity.
39
  During pregnancy, placental OPG expression may protect placental membranes from 
the actions of TRAIL to maintain membrane integrity until parturition.
22
  In addition, OPG may 
also play a role in modulating inflammation as OPG expression has been found to be upregulated 
by inflammatory cytokines including IL-1 and TNF-α40 as well as by lipopolysaccharide (LPS) 
in choriodecidua,
22
 but down-regulated by TRAIL.
41
  OPG’s potential role in the inflammatory 
response to pregnancy may be a partial source of the racial differences in OPG detected in these 
adolescents.  Differences in pro and anti-inflammatory cytokines have been found between 
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African American and Caucasian women during pregnancy and at parturition,
42,43
  but we did not 
measure inflammatory cytokines in our study.  These alternate and yet undiscovered roles of 
OPG may account for the some of the unexplained variability in the OPG concentrations we 
observed.  
In conclusion, in pregnant adolescents OPG concentrations increased across gestation but 
were unrelated to concurrent changes in markers of bone turnover.  African American 
adolescents had significantly higher circulating concentrations of OPG compared to Caucasian 
adolescents, in spite of similar concentrations of bone turnover markers.  Neonatal OPG was 
lower than, but highly correlated with maternal OPG concentrations, and was significantly 
inversely associated with birth weight Z-score and ponderal index.  Further research is needed to 
elucidate the mechanisms driving these relationships, and fully clarify the roles of OPG on fetal 
physiology and possible associations with neonatal bone health and subsequent risk of 
osteoporosis. 
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Table 1: Characteristics of the Pregnant Adolescents and their Neonates at Birth
1
  
Subject 
Characteristics 
All Subjects 
 
African American 
Adolescents 
Caucasian 
Adolescents 
Total Recruitment 155 65.2% (101) 34.8% (54) 
Age at Enrollment (y)                   
(weeks gestation) 
17.1 ± 1.1 years (155) 
21.7 ± 5.5 weeks (155) 
17.1 ± 1.2 (101) 
22.0 ± 5.5 (101) 
17.2 ± 0.9 (54) 
21.1 ± 5.6 (54) 
Hispanic 
Non-Hispanic 
23.8 %  (37) 
76.1%  (118) 
6.9 % (7)
2
 
93.1% (94) 
55.6 % (30) 
44.4 % (24) 
Pre-Pregnancy BMI 24.7 ± 5.3 kg/m
2
 (153) 24.5 ± 5.2 (99) 25.1 ± 5.6 (54) 
Multiparous (Parity ≥ 1) 9.0% (155) 9.9% (101) 7.4% (54) 
Gestational Age at Mid-
gestation Blood 
Collection 
26.0 ± 3.4 weeks (152) 26.1 ± 3.3 (99) 25.9 ± 3.5 (53) 
Gestational Age at 
Delivery 
39.3 ± 2.6 weeks (149) 39.1 ± 2.9 (97) 39.6 ± 1.9 (52) 
Birth Weight 3202 ± 583 g  (147) 3151 ± 588  (95) 3294 ± 567 (52) 
Infant Sex 55.3% Male (83) 56.1% (55) 53.8% (28) 
Birth Weight Z-score -0.392 ± 0.904 (147) -0.463 ± 0.884 (95) -0.260 ± 0.933 (52) 
Infant Ponderal Index 24.52 ± 2.10 kg/m
3
 (141) 24.25 ± 3.00 (91) 25.00 ± 3.26 (50) 
OPG at Mid-Gestation 1949 ± 740 pg/mL (138) 2129 ± 764 (89)
3
 1623 ± 571 (49) 
OPG at delivery 2812 ± 1215 pg/mL (123) 2975 ± 1295 (78)
4
 2530 ± 1016 (45) 
1
Data are reported as the Mean ± SD, or percentage, with the sample size in parentheses.  
2
Significantly different than Caucasians: p<0.01.   
3
Significantly different than Caucasians: p<0.001.   
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4
Significantly different than Caucasians: p<0.05.   
Figure 1:  
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Figure 2: 
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Figure 3:  
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FIGURE LEGENDS 
Figure 1: 
Serum concentrations of osteoprotegerin (OPG), N-telopeptide (NTX), and osteocalcin (OC) 
were measured in a group of 155 pregnant adolescents at mid-gestation (26.1 ± 3.3 weeks) and at 
delivery (39.3 ± 2.6 weeks), and in cord blood obtained from neonates at birth.  Different 
superscripts indicate group means significantly differed from each other (p<0.0001).  In paired 
analyses, maternal concentrations of OPG (p<0.0001), NTX (p<0.0001), and OC (p<0.0001) 
were significantly higher at delivery compared to mid-gestation.  Both NTX (p<0.0001) and OC 
(p<0.0001) were significantly higher in the neonate at birth compared to maternal concentrations 
at mid-gestation and delivery.  In contrast OPG values in cord blood were significantly lower 
than those observed among pregnant adolescents at mid-gestation and delivery (p<0.0001). 
Figure 2: 
Neonatal serum OPG concentrations were measured in cord blood collected at delivery from a 
group of 113 pregnant adolescents.  Neonatal OPG was significantly inversely related to birth 
weight Z-score (p = 0.029, n = 113, R
2
 = 0.05) and infant ponderal index, calculated as kg/m
3
 at 
delivery (p = 0.014, n = 112, R
2
 = 0.05).  The average birth weight in these neonates was 3261 ± 
481 g.   
Figure 3: 
Protein lysates were generated from homogenized placental tissue samples collected from 68 
pregnant adolescents at delivery, and OPG expression was analyzed via western blot. Placental 
OPG expression was not related to maternal OPG at mid-gestation (p = 0.98, n = 59) or at 
delivery (p = 0.15, n = 62).  Shown is a representative western blot with individual placental 
lysate samples in lanes 1 - 7.    
